

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |                          |   |                          |    |            |                          |    |            |                        |    |            |                          |    |  |
|---|--------------------------|---|--------------------------|----|------------|--------------------------|----|------------|------------------------|----|------------|--------------------------|----|--|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C07H 21/04, C12N 9/18, 15/31, 15/55</b>  | <b>A1</b>                | <b>(11) International Publication Number:</b> <b>WO 98/42728</b><br><b>(43) International Publication Date:</b> 1 October 1998 (01.10.98) |                          |    |            |                          |    |            |                        |    |            |                          |    |  |
| <b>(21) International Application Number:</b> PCT/US98/05814<br><b>(22) International Filing Date:</b> 25 March 1998 (25.03.98)<br><br><b>(30) Priority Data:</b> <table border="0"><tr><td>60/041,666</td><td>25 March 1997 (25.03.97)</td><td>US</td></tr><tr><td>60/045,211</td><td>30 April 1997 (30.04.97)</td><td>US</td></tr><tr><td>60/046,256</td><td>12 May 1997 (12.05.97)</td><td>US</td></tr><tr><td>08/905,359</td><td>4 August 1997 (04.08.97)</td><td>US</td></tr></table><br><b>(71) Applicant (for all designated States except US):</b> CALIFORNIA INSTITUTE OF TECHNOLOGY [US/US]; 1201 E. California Boulevard, Pasadena, CA 91125 (US).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> ARNOLD, Frances, H. [US/US]; 629 S. Grand Avenue, Pasadena, CA 91106 (US). SHAO, Zhixin [CN/CN]; 110 S. Michigan Avenue, #7, Pasadena, CA 91106 (US). AFFHOLTER, Joseph, A. [US/US]; 823 E. Sanford Road, Midland, MI 48642 (US). ZHAO, Huimin [CN/CN]; 1324 Cordova Street, Pasadena, CA 91106 (US). GIVER, Lorraine, J. [US/US]; 140 S. Catalina Avenue #4, Pasadena, CA 91106 (US). |                          | 60/041,666  | 25 March 1997 (25.03.97) | US | 60/045,211 | 30 April 1997 (30.04.97) | US | 60/046,256 | 12 May 1997 (12.05.97) | US | 08/905,359 | 4 August 1997 (04.08.97) | US | <b>(74) Agents:</b> OLDENKAMP, David, J. et al.; Oppenheimer Wolff & Donnelly LLP, Suite 3800, 2029 Century Park East, Los Angeles, CA 90067 (US).<br><br><b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| 60/041,666  | 25 March 1997 (25.03.97) | US  |                          |    |            |                          |    |            |                        |    |            |                          |    |  |
| 60/045,211  | 30 April 1997 (30.04.97) | US  |                          |    |            |                          |    |            |                        |    |            |                          |    |  |
| 60/046,256  | 12 May 1997 (12.05.97)   | US  |                          |    |            |                          |    |            |                        |    |            |                          |    |  |
| 08/905,359  | 4 August 1997 (04.08.97) | US  |                          |    |            |                          |    |            |                        |    |            |                          |    |  |
| <b>(54) Title:</b> RECOMBINATION OF POLYNUCLEOTIDE SEQUENCES USING RANDOM OR DEFINED PRIMERS<br><br><b>(57) Abstract</b><br><br>A method for <i>in vitro</i> mutagenesis and recombination of polynucleotide sequences based on polymerase-catalyzed extension of primer oligonucleotides is disclosed. The method involves priming template polynucleotide(s) with random-sequences or defined-sequence primers to generate a pool of short DNA fragments with a low level of point mutations. The DNA fragments are subjected to denaturation followed by annealing and further enzyme-catalyzed DNA polymerization. This procedure is repeated a sufficient number of times to produce full-length genes which comprise mutants of the original template polynucleotides. These genes can be further amplified by the polymerase chain reaction and cloned into a vector for expression of the encoded proteins.   |                          |   |                          |    |            |                          |    |            |                        |    |            |                          |    |  |

ATTORNEY DOCKET NUMBER: 10424-003-999  
SERIAL NUMBER: 09/920,118  
REFERENCE: B12

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |                          |   |                          |    |            |                          |    |            |                        |    |            |                          |    |  |
|---|--------------------------|---|--------------------------|----|------------|--------------------------|----|------------|------------------------|----|------------|--------------------------|----|--|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C07H 21/04, C12N 9/18, 15/31, 15/55</b>  | <b>A1</b>                | <b>(11) International Publication Number:</b> <b>WO 98/42728</b><br><b>(43) International Publication Date:</b> 1 October 1998 (01.10.98) |                          |    |            |                          |    |            |                        |    |            |                          |    |  |
| <b>(21) International Application Number:</b> PCT/US98/05814<br><b>(22) International Filing Date:</b> 25 March 1998 (25.03.98)<br><br><b>(30) Priority Data:</b> <table border="0"><tr><td>60/041,666</td><td>25 March 1997 (25.03.97)</td><td>US</td></tr><tr><td>60/045,211</td><td>30 April 1997 (30.04.97)</td><td>US</td></tr><tr><td>60/046,256</td><td>12 May 1997 (12.05.97)</td><td>US</td></tr><tr><td>08/905,359</td><td>4 August 1997 (04.08.97)</td><td>US</td></tr></table><br><b>(71) Applicant (for all designated States except US):</b> CALIFORNIA INSTITUTE OF TECHNOLOGY [US/US]; 1201 E. California Boulevard, Pasadena, CA 91125 (US).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> ARNOLD, Frances, H. [US/US]; 629 S. Grand Avenue, Pasadena, CA 91106 (US). SHAO, Zhixin [CN/CN]; 110 S. Michigan Avenue, #7, Pasadena, CA 91106 (US). AFFHOLTER, Joseph, A. [US/US]; 823 E. Sanford Road, Midland, MI 48642 (US). ZHAO, Huimin [CN/CN]; 1324 Cordova Street, Pasadena, CA 91106 (US). GIVER, Lorraine, J. [US/US]; 140 S. Catalina Avenue #4, Pasadena, CA 91106 (US). |                          | 60/041,666  | 25 March 1997 (25.03.97) | US | 60/045,211 | 30 April 1997 (30.04.97) | US | 60/046,256 | 12 May 1997 (12.05.97) | US | 08/905,359 | 4 August 1997 (04.08.97) | US | <b>(74) Agents:</b> OLDENKAMP, David, J. et al.; Oppenheimer Wolff & Donnelly LLP, Suite 3800, 2029 Century Park East, Los Angeles, CA 90067 (US).<br><br><b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| 60/041,666  | 25 March 1997 (25.03.97) | US  |                          |    |            |                          |    |            |                        |    |            |                          |    |  |
| 60/045,211  | 30 April 1997 (30.04.97) | US  |                          |    |            |                          |    |            |                        |    |            |                          |    |  |
| 60/046,256  | 12 May 1997 (12.05.97)   | US  |                          |    |            |                          |    |            |                        |    |            |                          |    |  |
| 08/905,359  | 4 August 1997 (04.08.97) | US  |                          |    |            |                          |    |            |                        |    |            |                          |    |  |
| <b>(54) Title:</b> RECOMBINATION OF POLYNUCLEOTIDE SEQUENCES USING RANDOM OR DEFINED PRIMERS<br><br><b>(57) Abstract</b><br><br>A method for <i>in vitro</i> mutagenesis and recombination of polynucleotide sequences based on polymerase-catalyzed extension of primer oligonucleotides is disclosed. The method involves priming template polynucleotide(s) with random-sequences or defined-sequence primers to generate a pool of short DNA fragments with a low level of point mutations. The DNA fragments are subjected to denaturization followed by annealing and further enzyme-catalyzed DNA polymerization. This procedure is repeated a sufficient number of times to produce full-length genes which comprise mutants of the original template polynucleotides. These genes can be further amplified by the polymerase chain reaction and cloned into a vector for expression of the encoded proteins.   |                          |   |                          |    |            |                          |    |            |                        |    |            |                          |    |  |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

## RECOMBINATION OF POLYNUCLEOTIDE SEQUENCES USING RANDOM OR DEFINED PRIMERS

The U.S. Government has certain rights in this invention pursuant to Grant No. DE-FG02-93-CH10578 awarded by the Department of Energy and Grant No. N00014-96-1-0340 awarded by the Office of Naval Research.

5

### BACKGROUND OF THE INVENTION

This application is a continuation-in-part of pending U.S. patent applications, Serial numbers 60/041,666, filed March 25, 1997; 60/045,211, filed April 30, 1997; 60/046,256, filed May 12, 1997; and 08/905,359, filed August 4, 1997.

10

#### 1. Field of the Invention

The present invention relates generally to *in vitro* methods for mutagenesis and recombination of polynucleotide sequences. More particularly, the present invention involves a simple and efficient method for *in vitro* mutagenesis and recombination of polynucleotide sequences based on polymerase-catalyzed extension of primer oligonucleotides, followed by gene assembly and optional gene amplification.

15

#### 2. Description of Related Art

20

The publications and other reference materials referred to herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference. For convenience, the reference materials are numerically referenced and grouped in the appended bibliography.

25

30

Proteins are engineered with the goal of improving their performance for practical applications. Desirable properties depend on the application of interest and may include tighter binding to a receptor, high catalytic activity, high stability, the ability to accept a wider (or narrower) range of substrates, or the ability to function in nonnatural environments such as organic solvents. A variety of approaches, including 'rational' design and random mutagenesis methods, have been successfully used to optimize protein functions (1). The choice of approach for a given optimization problem will depend upon the degree of understanding of the relationships between sequence, structure and function. The rational redesign of an enzyme catalytic site, for example, often

requires extensive knowledge of the enzyme structure, the structures of its complexes with various ligands and analogs of reaction intermediates and details of the catalytic mechanism. Such information is available only for a very few well-studied systems; little is known about the vast majority of potentially interesting enzymes. Identifying the amino acids responsible for existing protein functions and those which might give rise to new functions remains an often-overwhelming challenge. This, together with the growing appreciation that many protein functions are not confined to a small number of amino acids, but are affected by residues far from active sites, has prompted a growing number of groups to turn to random mutagenesis, or 'directed' evolution, to engineer novel proteins (1).

Various optimization procedures such as genetic algorithms (2,3) and evolutionary strategies (4,5) have been inspired by natural evolution. These procedures employ mutation, which makes small random changes in members of the population, as well as crossover, which combines properties of different individuals, to achieve a specific optimization goal. There also exist strong interplays between mutation and crossover, as shown by computer simulations of different optimization problems (6-9). Developing efficient and practical experimental techniques to mimic these key processes is a scientific challenge. The application of such techniques should allow one, for example, to explore and optimize the functions of biological molecules such as proteins and nucleic acids, *in vivo* or even completely free from the constraints of a living system (10,11).

Directed evolution, inspired by natural evolution, involves the generation and selection or screening of a pool of mutated molecules which has sufficient diversity for a molecule encoding a protein with altered or enhanced function to be present therein. It generally begins with creation of a library of mutated genes. Gene products which show improvement with respect to the desired property or set of properties are identified by selection or screening. The gene(s) encoding those products can be subjected to further cycles of the process in order to accumulate beneficial mutations. This evolution can involve few or many generations, depending on how far one wishes to progress and the effects of mutations typically observed in each generation. Such approaches have been used to create novel functional nucleic acids (12), peptides and other small molecules (12), antibodies (12), as well as enzymes and other proteins (13,14,16). Directed evolution requires little specific knowledge about the product itself, only a means to evaluate the

function to be optimized. These procedures are even fairly tolerant to inaccuracies and noise in the function evaluation (15).

The diversity of genes for directed evolution can be created by introducing new point mutations using a variety of methods, including mutagenic PCR (15) or combinatorial cassette mutagenesis (16). The ability to recombine genes, however, can add an important dimension to the evolutionary process, as evidenced by its key role in natural evolution. Homologous recombination is an important natural process in which organisms exchange genetic information between related genes, increasing the accessible genetic diversity within a species. While introducing potentially powerful adaptive and diversification competencies into their hosts, such pathways also operate at very low efficiencies, often eliciting insignificant changes in pathway structure or function, even after tens of generations. Thus, while such mechanisms prove beneficial to host organisms/species over geological time spans, *in vivo* recombination methods represent cumbersome, if not unusable, combinatorial processes for tailoring the performance of enzymes or other proteins not strongly linked to the organism's intermediary metabolism and survival.

Several groups have recognized the utility of gene recombination in directed evolution. Methods for *in vivo* recombination of genes are disclosed, for example, in published PCT application WO 97/07205 and US Pat. No. 5,093,257. As discussed above, these *in vivo* methods are cumbersome and poorly optimized for rapid evolution of function. Stemmer has disclosed a method for *in vitro* recombination of related DNA sequences in which the parental sequences are cut into fragments, generally using an enzyme such as DNase I, and are reassembled (17,18,19). The non-random DNA fragmentation associated with DNase I and other endonucleases, however, introduces bias into the recombination and limits the recombination diversity.

Furthermore, this method is limited to recombination of double-stranded polynucleotides and cannot be used on single-stranded templates. Further, this method does not work well with certain combinations of genes and primers. It is not efficient for recombination of short sequences (less than 200 nucleotides (nts)), for example. Finally, it is quite laborious, requiring several steps. Alternative, convenient methods for creating novel genes by point mutagenesis and recombination *in vitro* are needed.

### SUMMARY OF THE INVENTION

The present invention provides a new and significantly improved approach to creating novel polynucleotide sequences by point mutation and recombination *in vitro* of a set of parental sequences (the templates). The novel polynucleotide sequences can be useful in themselves (for example, for DNA-based computing), or they can be expressed in recombinant organisms for directed evolution of the gene products. One embodiment of the invention involves priming the template gene(s) with random-sequence oligonucleotides to generate a pool of short DNA fragments. Under appropriate reaction conditions, these short DNA fragments can prime one another based on complementarity and thus can be reassembled to form full-length genes by repeated thermocycling in the presence of thermostable DNA polymerase. These reassembled genes, which contain point mutations as well as novel combinations of sequences from different parental genes, can be further amplified by conventional PCR and cloned into a proper vector for expression of the encoded proteins. Screening or selection of the gene products leads to new variants with improved or even novel functions. These variants can be used as they are, or they can serve as new starting points for further cycles of mutagenesis and recombination.

A second embodiment of the invention involves priming the template gene(s) with a set of primer oligonucleotides of defined sequence or defined sequence exhibiting limited randomness to generate a pool of short DNA fragments, which are then reassembled as described above into full length genes.

A third embodiment of the invention involves a novel process we term the 'staggered extension' process, or StEP. Instead of reassembling the pool of fragments created by the extended primers, full-length genes are assembled directly in the presence of the template(s). The StEP consists of repeated cycles of denaturation followed by extremely abbreviated annealing/extension steps. In each cycle the extended fragments can anneal to different templates based on complementarity and extend a little further to create "recombinant cassettes." Due to this template switching, most of the polynucleotides contain sequences from different parental genes (i.e. are novel recombinants). This process is repeated until full-length genes form. It can be followed by an optional gene amplification step.

The different embodiments of the invention provide features and advantages for different applications. In the most preferred embodiment, one or more defined primers or defined primers exhibiting limited randomness



which correspond to or flank the 5' and 3' ends of the template polynucleotides are used with StEP to generate gene fragments which grow into the novel full-length sequences. This simple method requires no knowledge of the template sequence(s).

5 In another preferred embodiment, multiple defined primers or defined primers exhibiting limited randomness are used to generate short gene fragments which are reassembled into full-length genes. Using multiple defined primers allows the user to bias *in vitro* recombination frequency. If sequence information is available, primers can be designed to generate  
10 overlapping recombination cassettes which increase the frequency of recombination at particular locations. Among other features, this method introduces the flexibility to take advantage of available structural and functional information as well as information accumulated through previous generations of mutagenesis and selection (or screening).

15 In addition to recombination, the different embodiments of the primer-based recombination process will generate point mutations. It is desirable to know and be able to control this point mutation rate, which can be done by manipulating the conditions of DNA synthesis and gene reassembly. Using the defined-primer approach, specific point mutations can also be directed to  
20 specific positions in the sequence through the use of mutagenic primers.

The various primer-based recombination methods in accordance with this invention have been shown to enhance the activity of *Actinoplanes utahensis* ECB deacylase over a broad range of pH values and in the presence of organic solvent and to improve the thermostability of *Bacillus subtilis*  
25 subtilisin E. DNA sequencing confirms the role of point mutation and recombination in the generation of novel sequences. These protocols have been found to be both simple and reliable.

The above discussed and many other features and attendant advantages will become better understood by reference to the following  
30 detailed description when taken in conjunction with the accompanying drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts recombination in accordance with the present invention  
35 using random-sequence primers and gene reassembly. The steps shown are:  
a) Synthesis of single-stranded DNA fragments using mesophilic or thermophilic polymerase with random-sequence oligonucleotides as primers (primers not shown); b) Removal of templates; c) Reassembly with



thermophilic DNA polymerase; d) Amplification with thermostable polymerase(s); e) Cloning and Screening (optional); and f) Repeat the process with selected gene(s) (optional).

5           FIG. 2 depicts recombination in accordance with the present invention using defined primers. The method is illustrated for the recombination of two genes, where x = mutation. The steps diagrammed are: a) The genes are primed with defined primers in PCR reactions that can be done separately (2 primers per reaction) or combined (multiple primers per reaction); c) Initial products are formed until defined primers are exhausted. Template is removed (optional); d) Initial fragments prime and extend themselves in further cycles of PCR with no addition of external primers. Assembly continues until full-length genes are formed; e) (optional) Full-length genes are amplified in a PCR reaction with external primers; f) (optional) Repeat the process with selected gene(s).

20           FIG. 3 depicts recombination in accordance with the present invention using two defined flanking primers and StEP. Only one primer and two single strands from two templates are shown here to illustrate the recombination process. The outlined steps are: a) After denaturation, template genes are primed with one defined primer; b) Short fragments are produced by primer extension for a short time; c) In the next cycle of StEP, fragments are randomly primed to the templates and extended further; d) Denaturation and annealing/extension is repeated until full-length genes are made (visible on an agarose gel); e) Full-length genes are purified, or amplified in a PCR reaction with external primers (optional); f) (optional) Repeat the process with selected gene(s).

30           FIG. 4 is a diagrammatic representation of the results of the recombination of two genes using two flanking primers and staggered extension in accordance with the present invention. DNA sequences of five genes chosen from the recombined library are indicated, where x is a mutation present in the parental genes, and the triangle represents a new point mutation.

35           FIG. 5 is a diagrammatic representation of the sequences of the pNB esterase genes described in Example 3. Template genes 2-13 and 5-B12 were recombined using the defined primer approach. The positions of the primers

are indicated by arrows, and the positions where the parental sequences differ from one another are indicated by x's. New point mutations are indicated by triangles. Mutations identified in these recombined genes are listed (only positions which differ in the parental sequences are listed). Both 6E6 and 6H1 are recombination products of the template genes.

FIG. 6 shows the positions and sequences of the four defined internal primers used to generate recombined genes from template genes R1 and R2 by interspersed primer-based recombination. Primer P50F contains a mutation (A→T at base position 598) which simultaneously eliminates a HindIII restriction site and adds a new unique NheI site. Gene R2 also contains a mutation A→G at the same base position, which eliminates the HindIII site.

FIG. 7 is an electrophoresis gel which shows the results of the restriction-digestion analysis of plasmids from the 40 clones.

FIG. 8 shows the results of sequencing ten genes from the defined primer-based recombination library. Lines represent 986-bp of subtilisin E gene including 45 nt of its prosequence, the entire mature sequence and 113 nt after the stop codon. Crosses indicate positions of mutations from parent gene R1 and R2, while triangles indicate positions of new point mutations introduced during the recombination procedure. Circles represent the mutation introduced by the mutagenic primer P50F.

FIG. 9 depicts the results of applying the random-sequence primer recombination method to the gene for *Actinoplanes utahensis* ECB deacylase. (a) The 2.4 kb ECB deacylase gene was purified from an agarose gel. (b) The size of the random priming products ranged from 100 to 500 bases. (c) Fragments shorter than 300 bases were isolated. (d) The purified fragments were used to reassemble the full-length gene with a smear background. (e) A single PCR product of the same size as the ECB deacylase gene was obtained after conventional PCR with the two primers located at the start and stop regions of this gene. (f) After digestion with *Xho*I and *Psh*AI, the PCR product was cloned into a modified pIJ702 vector to form a mutant library. (g) Introducing this library into *Streptomyces lividans* TK23 resulted in approximately 71% clones producing the active ECB deacylase.

FIG. 10 shows the specific activity of the wild-type ECB deacylase and mutant M16 obtained in accordance with the present invention.

FIG. 11 shows pH profiles of activity of the wild-type ECB deacylase and mutant M16 obtained in accordance with the present invention.

FIG.12 shows the DNA sequence analysis of 10 clones randomly chosen from the library/Klenow. Lines represent 986-bp of subtilisin E gene including 45 nt of its prosequence, the entire mature sequence and 113 nt after the stop codon. Crosses indicate positions of mutations from R1 and R2, while triangles indicate positions of new point mutations introduced during the random-priming recombination process.

FIG.13 Thermostability index profiles of the screened clones from the five libraries produced using different polymerases: a) library/Klenow, b) library/T4, c) library/Sequenase, d) library/Stoffel and e) library/Pfu. Normalized residual activity ( $A_r/A_i$ ) after incubation at 65°C was used as an index of the enzyme thermostability. Data were sorted and plotted in descending order.

#### DETAILED DESCRIPTION OF THE INVENTION

In one preferred embodiment of the present invention, a set of primers with all possible nucleotide sequence combinations ( $(dp(N))_L$  where  $L$  = primer length) is used for the primer-based recombination. It has been known for years that oligodeoxynucleotides of different lengths can serve as primers for initiation of DNA synthesis on single-stranded templates by the Klenow fragment of *E.coli* polymerase I (21). Although they are smaller than the size of a normal PCR primer (i.e. less than 13 bases), oligomers as short as hexanucleotides can adequately prime the reaction and are frequently used in labeling reactions (22). The use of random primers to create a pool of gene fragments followed by gene reassembly in accordance with the invention is shown in FIG. 1. The steps include generation of diverse "breeding blocks" from the single-stranded polynucleotide templates through random priming, reassembly of the full-length DNA from the generated short, nascent DNA fragments by thermocycling in the presence of DNA polymerase and nucleotides, and amplification of the desired genes from the reassembled

products by conventional PCR for further cloning and screening. This procedure introduces new mutations mainly at the priming step but also during other steps. These new mutations and the mutations already present in the template sequences are recombined during reassembly to create a library of novel DNA sequences. The process can be repeated on the selected sequences, if desired.

To carry out the random priming procedure, the template(s) can be single- or denatured double-stranded polynucleotide(s) in linear or closed circular form. The templates can be mixed in equimolar amounts, or in amounts weighted, for example, by their functional attributes. Since, at least in some cases, the template genes are cloned in vectors into which no additional mutations should be introduced, they are usually first cleaved with restriction endonuclease(s) and purified from the vectors. The resulting linear DNA molecules are denatured by boiling, annealed to random-sequence oligodeoxynucleotides and incubated with DNA polymerase in the presence of an appropriate amount of dNTPs. Hexanucleotide primers are preferred, although longer random primers (up to 24 bases) may also be used, depending on the DNA polymerase and conditioning used during random priming synthesis. Thus the oligonucleotides prime the DNA of interest at various positions along the entire target region and are extended to generate short DNA fragments complementary to each strand of the template DNA. Due to events such as base mis-incorporations and mispriming, these short DNA fragments also contain point mutations. Under routinely established reaction conditions, the short DNA fragments can prime one another based on homology and be reassembled into full-length genes by repeated thermocycling in the presence of thermostable DNA polymerase. The resulting full-length genes will have diverse sequences, most of which, however, still resemble that of the original template DNA. These sequences can be further amplified by a conventional PCR and cloned into a vector for expression. Screening or selection of the expressed mutants should lead to variants with improved or even new specific functions. These variants can be immediately used as partial solutions to a practical problem, or they can serve as new starting points for further cycles of directed evolution.

Compared to other techniques used for protein optimization, such as combinatorial cassette and oligonucleotide-directed mutagenesis (24,25,26), error-prone PCR (27, 28), or DNA shuffling (17,18,19), some of the advantages of the random-primer based procedure for *in vitro* protein evolution are summarized as follows:

1. The template(s) used for random priming synthesis may be either single- or double-stranded polynucleotides. In contrast, error-prone PCR and the DNA shuffling method for recombination (17,18,19) necessarily employ only double-stranded polynucleotides. Using the technique described here, mutations and/or crossovers can be introduced at the DNA level by using different DNA-dependent DNA polymerases, or even directly from mRNA by using different RNA-dependent DNA polymerases. Recombination can be performed using single-stranded DNA templates.

2. In contrast to the DNA shuffling procedure, which requires fragmentation of the double-stranded DNA template (generally done with DNase I) to generate random fragments, the technique described here employs random priming synthesis to obtain DNA fragments of controllable size as "breeding blocks" for further reassembly (FIG. 1). One immediate advantage is that two sources of nuclease activity (DNase I and 5'-3' exonuclease) are eliminated, and this allows easier control over the size of the final reassembly and amplification gene fragments.

3. Since the random primers are a population of synthetic oligonucleotides that contain all four bases in every position, they are uniform in their length and lack a sequence bias. The sequence heterogeneity allows them to form hybrids with the template DNA strands at many positions, so that every nucleotide of the template (except, perhaps, those at the extreme 5' terminus) should be copied at a similar frequency into products. In this way, both mutations and crossover may happen more randomly than, for example, with error-prone PCR or DNA shuffling.

4. The random-primed DNA synthesis is based on the hybridization of a mixture of hexanucleotides to the DNA templates, and the complementary strands are synthesized from the 3'-OH termini at the random hexanucleotide primer using polymerase and the four deoxynucleotide triphosphates. Thus the reaction is independent of the length of the DNA template. DNA fragments of 200 bases length can be primed equally well as linearized plasmid or  $\lambda$  DNA (29). This is particularly useful for engineering peptides, for example.

5. Since DNase I is an endonuclease that hydrolyzes double-stranded DNA preferentially at sites adjacent to pyrimidine nucleotides, its use in DNA shuffling may result in bias (particularly for genes with high G+C or high A+T content) at the step of template gene digestion. Effects of this potential bias on the overall mutation rate and recombination frequency may be avoided by using the random-priming approach. Bias in random priming

due to preferential hybridization to GC-rich regions of the template DNA could be overcome by increasing the A and T content in the random oligonucleotide library.

5 An important part of practicing the present invention is controlling the average size of the nascent, single-strand DNA synthesized during the random priming process. This step has been studied in detail by others. Hodgson and Fisk (30) found that the average size of the synthesized single-strand DNA is an inverse function of primer concentration:  $\text{length} = k / \sqrt{\ln P_c}$ , where  $P_c$  is the primer concentration. The inverse relationship between primer concentration and output DNA fragment size may be due to steric hindrance. Based on this guideline, proper conditions for random-priming synthesis can be readily set for individual genes of different lengths.

10 Since dozens of polymerases are currently available, synthesis of the short, nascent DNA fragments can be achieved in a variety of fashions. For example, bacteriophage T4 DNA polymerase (23) or T7 sequenase version 2.0 DNA polymerase (31,32) can be used for the random priming synthesis.

For single-stranded polynucleotide templates (particularly for RNA templates), a reverse transcriptase is preferred for random-priming synthesis. Since this enzyme lacks 3'→5' exonuclease activity, it is rather prone to error.

20 In the presence of high concentrations of dNTPs and  $\text{Mn}^{2+}$ , about 1 base in every 500 is misincorporated (29).

By modifying the reaction conditions, the PCR can be adjusted for the random priming synthesis using thermostable polymerase for the short, nascent DNA fragments. An important consideration is to identify by routine experimentation the reaction conditions which ensure that the short random primers can anneal to the templates and give sufficient DNA amplification at higher temperatures. We have found that random primers as short as  $\text{dp(N)}_{12}$  can be used with PCR to generate the extended primers. Adapting the PCR to the random priming synthesis provides a convenient method to make short, nascent DNA fragments and makes this random priming recombination technique very robust.

25

30

In many evolution scenarios, recombination should be conducted between oligonucleotide sequences for which sequence information is available for at least some of the template sequences. In such scenarios, it is often possible to define and synthesize a series of primers which are interspersed between the various mutations. When defined primers are used, they can be

35



between 6 and 100 bases long. In accordance with the present invention, it was discovered that by allowing these defined primers to initiate a series of overlapping primer extension reactions (which may be facilitated by thermocycling), it is possible to generate recombination cassettes each containing one or more of the accumulated mutations, allelic or isotypic differences between templates. Using the defined primers in such a way that overlapping extension products are generated in the DNA polymerization reactions, exhaustion of available primer leads to the progressive cross-hybridization of primer extended products until complete gene products are generated. The repeated rounds of annealing, extension and denaturation assure recombination of each overlapping cassette with every other.

A preferred embodiment of the present invention involves methods in which a set of defined oligonucleotide primers is used to prime DNA synthesis. FIG. 2 illustrates an exemplary version of the present invention in which defined primers are used. Careful design and positioning of oligonucleotide primers facilitates the generation of non-random extended recombination primers and is used to determine the major recombination (co-segregation) events along the length of homologous templates.

Another embodiment of the present invention is an alternative approach to primer-based gene assembly and recombination in the presence of template. Thus, as illustrated in FIG. 3, the present invention includes recombination in which enzyme-catalyzed DNA polymerization is allowed to proceed only briefly (by limiting the time and lowering the temperature of the extension step) prior to denaturation. Denaturation is followed by random annealing of the extended fragments to template sequences and continued partial extension. This process is repeated multiple times, depending on the concentration of primer and template, until full length sequences are made. This process is called staggered extension, or StEP. Although random primers can also be used for StEP, gene synthesis is not nearly as efficient as with defined primers. Thus defined primers are preferred.

In this method, a brief annealing/extension step(s) is used to generate the partially extended primer. A typical annealing/extension step is done under conditions which allow high fidelity primer annealing ( $T_{\text{annealing}}$  greater than  $T_m - 25$ ), but limit the polymerization/extension to no more than a few seconds (or an average extension to less than 300 nts). Minimum extensions are preferably on the order of 20-50 nts. It has been demonstrated that thermostable DNA polymerases typically exhibit maximal polymerization rates



of 100-150 nucleotides/second/enzyme molecule at optimal temperatures, but follow approximate Arrhenius kinetics at temperatures approaching the optimum temperature ( $T_{opt}$ ). Thus, at a temperature of 55°C, a thermostable polymerase exhibits only 20-25% of the steady state polymerization rate that it exhibits at 72°C ( $T_{opt}$ ), or 24 nts/second (40). At 37°C and 22°C, *Taq* polymerase is reported to have extension activities of 1.5 and 0.25 nts/second, respectively (24). Both time and temperature can be routinely altered based on the desired recombination events and knowledge of basic polymerase kinetics and biochemistry.

The progress of the staggered extension process is monitored by removing aliquots from the reaction tube at various time points in the primer extension and separating DNA fragments by agarose gel electrophoresis. Evidence of effective primer extension is seen from the appearance of a low molecular weight 'smear' early in the process which increases in molecular weight with increasing cycle number.

Unlike the gene amplification process (which generates new DNA exponentially), StEP generates new DNA fragments in an additive manner in its early cycles which contain DNA segments corresponding to the different template genes. Under non-amplifying conditions, 20 cycles of StEP generates a maximal molar yield of DNA of approximately 40 times the initial template concentration. In comparison, the idealized polymerase chain reaction process for gene amplification is multiplicative throughout, giving a maximal molar yield of approximately  $1 \times 10^6$ -fold through the same number of steps. In practice, the difference between the two processes can be observed by PCR, giving a clear 'band' after only a few (less than 10) cycles when starting with template at concentrations of less than 1 ng/ul and primers at 10-500-fold excess (vs.  $10^6$ -fold excess typical of gene amplification). Under similar reaction conditions, the StEP would be expected to give a less visible 'smear', which increases in molecular weight with increasing number of cycles. When significant numbers of primer extended DNA molecules begin to reach sizes of greater than 1/2 the length of the full length gene, a rapid jump in molecular weight occurs, as half-extended forward and reverse strands begin to cross-hybridize to generate fragments nearly 2 times the size of those encountered to that point in the process. At this point, consolidation of the smear into a discrete band of the appropriate molecular weight can occur rapidly by either

continuing to subject the DNA to StEP, or altering the thermocycle to allow complete extension of the primed DNA to drive exponential gene amplification.

Following gene assembly (and, if necessary, conversion to double stranded form) recombined genes are amplified (optional), digested with  
5 suitable restriction enzymes and ligated into expression vectors for screening of the expressed gene products. The process can be repeated if desired, in order to accumulate sequence changes leading to the evolution of desired functions.

The staggered extension and homologous gene assembly process (StEP)  
10 represents a powerful, flexible method for recombining similar genes in a random or biased fashion. The process can be used to concentrate recombination within or away from specific regions of a known series of sequences by controlling placement of primers and the time allowed for annealing/extension steps. It can also be used to recombine specific cassettes  
15 of homologous genetic information generated separately or within a single reaction. The method is also applicable to recombining genes for which no sequence information is available but for which functional 5' and 3' amplification primers can be prepared. Unlike other recombination methods, the staggered extension process can be run in a single tube using  
20 conventional procedures without complex separation or purification steps.

Some of the advantages of the defined-primer embodiments of the present invention are summarized as follows:

1. The StEP method does not require separation of parent molecules from assembled products.
- 25 2. Defined primers can be used to bias the location of recombination events.
3. StEP allows the recombination frequency to be adjusted by varying extension times.
4. The recombination process can be carried out in a single tube.
- 30 5. The process can be carried out on single-stranded or double-stranded polynucleotides.
6. The process avoids the bias introduced by DNase I or other endonucleases.
7. Universal primers can be used.
- 35 8. Defined primers exhibiting limited randomness can be used to increase the frequency of mutation at selected areas of the gene.

As will be appreciated by those skilled in the art, several embodiments of the present invention are possible. Exemplary embodiments include:

1. Recombination and point mutation of related genes using only defined flanking primers and staggered extension.
2. Recombination and mutation of related genes using flanking primers and a series of internal primers at low enough concentration that exhaustion of the primers will occur over the course of the thermocycling, forcing the overlapping gene fragments to cross-hybridize and extend until recombined synthetic genes are formed.
3. Recombination and mutation of genes using random-sequence primers at high concentration to generate a pool of short DNA fragments which are reassembled to form new genes.
4. Recombination and mutation of genes using a set of defined primers to generate a pool of DNA fragments which are reassembled to form new genes.
5. Recombination and mutation of single-stranded polynucleotides using one or more defined primers and staggered extension to form new genes.
6. Recombination using defined primers with limited randomness at more than 30% or more than 60% of the nucleotide positions within the primer.

Examples of practice showing use of the primer-based recombination method are as follows.

#### EXAMPLE 1

##### **Use of defined flanking primers and staggered extension to recombine and enhance the thermostability of subtilisin E**

This example shows how the defined primer recombination method can be used to enhance the thermostability of subtilisin E by recombination of two genes known to encode subtilisin E variants with thermostabilities exceeding that of wild-type subtilisin E. This example demonstrates the general method outlined in FIG. 3 utilizing only two primers corresponding to the 5' and 3' ends of the templates.

As outlined in FIG. 3, extended recombination primers are first generated by the staggered extension process (StEP), which consists of repeated cycles of denaturation followed by extremely abbreviated annealing/extension step(s). The extended fragments are reassembled into full-length genes by thermocycling-assisted homologous gene assembly in the

presence of a DNA polymerase, followed by an optional gene amplification step.

Two thermostable subtilisin E mutants R1 and R2 were used to test the defined primer based recombination technique using staggered extension.

5 The positions at which these two genes differ from one another are shown in Table 1. Among the ten nucleotide positions that differ in R1 and R2, only those mutations leading to amino acid substitutions Asn 181-Asp (N181D) and Asn 218-Ser (N218S) confer thermostability. The remaining mutations are neutral with respect to their effects on thermostability (33). The half-lives at  
10 65°C of the single variants N181D and N218S are approximately 3-fold and 2-fold greater than that of wild type subtilisin E, respectively, and their melting temperatures,  $T_m$ , are 3.7°C and 3.2°C higher than that of wild type enzyme, respectively. Random recombination events that yield sequences containing both these functional mutations will give rise to enzymes whose half lives at  
15 65°C are approximately 8-fold greater than that of wild type subtilisin E, provided no new deleterious mutations are introduced into these genes during the recombination process. Furthermore, the overall point mutagenesis rate associated with the recombination process can be estimated from the catalytic activity profile of a small sampling of the recombined variant library. If the  
20 point mutagenesis rate is zero, 25% of the population should exhibit wild type-like activity, 25% of the population should have double mutant (N181D+N218S)-like activity and the remaining 50% should have single mutant (N181D or N218S)-like activity. Finite point mutagenesis increases the fraction of the library that encodes enzymes with wild-type like (or lower)  
25 activity. This fraction can be used to estimate the point mutagenesis rate.

**TABLE 1**  
**DNA and amino acid substitutions in thermostable**  
**subtilisin E mutants R1 and R2.**

| Gene | Base | Base Substitution | Position in codon | Amino acid | Amino acid substitution |
|------|------|-------------------|-------------------|------------|-------------------------|
| R1   | 780  | A → G             | 2                 | 109        | Asn→Ser                 |
|      | 1107 | A → G             | 2                 | 218        | Asn→Ser                 |
|      | 1141 | A → T             | 3                 | 229        | synonymous              |
|      | 1153 | A → G             | 3                 | 233        | synonymous              |
| R2   | 484  | A → G             | 3                 | 10         | synonymous              |
|      | 520  | A → T             | 3                 | 22         | synonymous              |
|      | 598  | A → G             | 3                 | 48         | synonymous              |
|      | 731  | G → A             | 1                 | 93         | Val→Ile                 |
|      | 745  | T → C             | 3                 | 97         | synonymous              |
|      | 780  | A → G             | 2                 | 109        | Asn→Ser                 |
|      | 995  | A → G             | 1                 | 181        | Asn→Asp                 |
|      | 1189 | A → G             | 3                 | 245        | synonymous              |

Mutations listed are relative to wild type subtilisin E with base substitution at 780 in common.

5

#### Materials and Methods

*Procedure for defined primer based recombination using two flanking primers.*

Two defined primers, P5N (5'-CCGAG CGTTG CATAT GTGGA AG-3' (SEQ. ID. NO: 1), underlined sequence is NdeI restriction site) and P3B (5'-CGACT CTAGA GGATC CGATT C-3' (SEQ. ID. NO: 2), underlined sequence is BamHI restriction site), corresponding to 5' and 3' flanking primers, respectively, were used for recombination. Conditions (100 ul final volume): 0.15 pmol plasmid DNA containing genes R1 and R2 (mixed at 1:1) were used as template, 15 pmol of each flanking primer, 1 times *Taq* buffer, 0.2 mM of each dNTP, 1.5 mM MgCl<sub>2</sub> and 0.25 U *Taq* polymerase. Program: 5 minutes of 95°C, 80 cycles of 30 seconds 94°C, 5 seconds 55°C. The product of correct size (approximately 1kb) was cut from an 0.8% agarose gel after electrophoresis and purified using QIAEX II gel extraction kit. This purified product was digested with NdeI and BamHI and subcloned into pBE3 shuttle vector. This gene library was amplified in *E. coli* HB101 and transferred into *B. subtilis* DB428 competent cells for expression and screening, as described elsewhere (35).

25

#### DNA sequencing

Genes were purified using QIAprep spin plasmid miniprep kit to obtain sequencing quality DNA. Sequencing was done on an ABI 373 DNA

Sequencing System using the Dye Terminator Cycle Sequencing kit (Perkin-Elmer, Branchburg, NJ).

## Results

5           The progress of the staggered extension was monitored by removing aliquots (10 ul) from the reaction tube at various time points in the primer extension process and separating DNA fragments by agarose gel electrophoresis. Gel electrophoresis of primer extension reactions revealed that annealing/extension reactions of 5 seconds at 55°C resulted in the  
10           occurrence of a smear approaching 100 bp (after 20 cycles), 400 bp (after 40 cycles), 800 bp (after 60 cycles) and finally a strong approximately 1 kb band within this smear. This band (mixture of reassembled products) was gel purified, digested with restriction enzyme *Bam*HI and *Nde*I, and ligated with vector generated by *Bam*HI-*Nde*I digestion of the *E. coli* / *B. subtilis* pBE3  
15           shuttle vector. This gene library was amplified in *E. coli* HB101 and transferred into *B. subtilis* DB428 competent cells for expression and screening (35).

          The thermostability of enzyme variants was determined in the 96-well plate format described previously (33). About 200 clones were screened, and  
20           approximately 25% retained subtilisin activity. Among these active clones, the frequency of the double mutant-like phenotype (high thermostability) was approximately 23%, the single mutant-like phenotype was approximately 42%, and wild type-like phenotype was approximately 34%. This distribution is very close to the values expected when the two thermostable mutations N218S  
25           and N181D can recombine with each other completely freely.

          Twenty clones were randomly picked from *E. coli* HB101 gene library. Their plasmid DNAs were isolated and digested with *Nde*I and *Bam*HI. Nine out of 20 (45%) had the inserts of correct size (approximately 1 kb). Thus, approximately 55% of the above library had no activity due to lack of the  
30           correct subtilisin E gene. These clones are not members of the subtilisin library and should be removed from our calculations. Taking into account this factor, we find that 55% of the library (25% active clones/45% clones with correct size insert) retained subtilisin activity. This activity profile indicates a point mutagenesis rate of less than 2 mutations per gene (36). Five clones with  
35           inserts of the correct size were sequenced. The results are summarized in FIG. 4. All five genes are recombination products with minimum crossovers

varying from 1 to 4. Only one new point mutation was found in these five genes.

### EXAMPLE 2

#### 5                    **Use of defined flanking primers and staggered extension                          to recombine pNB esterase mutants**

10                    The two-primer recombination method used here for pNB esterase is analogous to that described in Example 1 for subtilisin E. Two template pNB esterase mutant genes that differ at 14 bases are used. Both templates (61C7 and 4G4) are used in the plasmid form. Both target genes are present in the extension reaction at a concentration of 1 ng/ul. Flanking primers (RM1A and RM2A, Table 2) are added at a final concentration of 2 ng/ul (approximately 200-fold molar excess over template).

15                    **TABLE 2**

**Primers used in the recombination of the pNB esterase genes**

| Primer | Sequence                                     |
|--------|--|
| RM1A   | GAG CAC ATC AGA TCT ATT AAC (SEQ. ID. NO: 3) |
| RM2A   | GGA GTG GCT CAC AGT CGG TGG (SEQ. ID. NO: 4) |

20                    Clone 61C7 was isolated based on its activity in organic solvent and contains 13 DNA mutations vs. the wild-type sequence. Clone 4G4 was isolated for thermostability and contains 17 DNA mutations when compared with wild-type. Eight mutations are shared between them, due to common ancestry. The gene product from 4G4 is significantly more thermostable than the gene product from 61C7. Thus, one measure of recombination between the genes is the co-segregation of the high solvent activity and high thermostability or the loss of both properties in the recombined genes. In addition, recombination frequency and mutagenic rate can be ascertained by sequencing random clones.

25                    For the pNB esterase gene, primer extension proceeds through 90 rounds of extension with a thermocycle consisting of 30 seconds at 94°C followed by 15 seconds at 55°C. Aliquots (10 µl) are removed following cycle 20, 40, 60, 70, 80 and 90. Agarose gel electrophoresis reveals the formation of a low molecular weight 'smear' by cycle 20, which increases in average size and overall intensity at each successive sample point. By cycle 90, a



pronounced smear is evident extending from 0.5 kb to 4 kb, and exhibiting maximal signal intensity at a size of approximately 2 kb (the length of the full length genes). The jump from half-length to full length genes appears to occur between cycles 60 and 70.

5           The intense smear is amplified through 6 cycles of polymerase chain reaction to more clearly define the full length recombined gene population. A minus-primer control is also amplified with flanking primers to determine the background due to residual template in the reaction mix. Band intensity from the primer extended gene population exceeds that of the control by greater  
10           than 10-fold, indicating that amplified, non-recombined template comprise only a small fraction of the amplified gene population.

          The amplified recombined gene pool is digested with restriction enzymes XbaI and BamHI and ligated into the pNB106R expression vector described by Zock et al. (35). Transformation of ligated DNA into E. coli strain  
15           TG1 is done using the well characterized calcium chloride transformation procedure. Transformed colonies are selected on LB/agar plates containing 20 µg/ml tetracycline.

          The mutagenic rate of the process is determined by measuring the percent of clones expressing an active esterase (20). In addition, colonies  
20           picked at random are sequenced and used to define the mutagenic frequency of the method and the efficiency of recombination.

### **EXAMPLE 3**

#### **Recombination of pNB esterase genes using interspersed 25           internal defined primers and staggered extension**

          This example demonstrates that the interspersed defined primer recombination technique can produce novel sequences through point mutagenesis and recombination of mutations present in the parent sequences.

#### **30           Experimental design and background information**

          Two pNB esterase genes (2-13 and 5-B12) were recombined using the defined primer recombination technique. Gene products from both 2-13 and 5-B12 are measurably more thermostable than wild-type. Gene 2-13 contains 9 mutations not originally present in, the wild-type sequence, while gene 5-  
35           B12 contains 14. The positions at which these two genes differ from one another are shown in FIG. 5.

Table 3 shows the sequences of the eight primers used in this example. Location (at the 5' end of the template gene) of oligo annealing to the template genes is indicated in the table, as is primer orientation (F indicates a forward primer, R indicates reverse). These primers are shown as arrows along gene 2-13 in FIG. 5.

TABLE 3

## Sequences of primers used in this example

| name | orientation | location | sequence                                 |
|------|-------------|----------|--|
| RM1A | F           | -76      | GAGCACATCAGATCTATTAAC (SEQ. ID. NO: 3)   |
| RM2A | R           | +454     | GGAGTGGCTCACAGTCGGTGG (SEQ. ID. NO: 4)   |
| S2   | F           | 400      | TTGAACTATCGGCTGGGGCGG (SEQ. ID. NO: 5)   |
| S5   | F           | 1000     | TTACTAGGGAAGCCGCTGGCA (SEQ. ID. NO: 6)   |
| S7   | F           | 1400     | TCAGAGATTACGATCGAAAAC (SEQ. ID. NO: 7)   |
| S8   | R           | 1280     | GGATTGTATCGTGTGAGAAAG (SEQ. ID. NO: 8)   |
| S10  | R           | 880      | AATGCCGGAAGCAGCCCCTTC (SEQ. ID. NO: 9)   |
| S13  | R           | 280      | CACGACAGGAAGATTTTGA CT (SEQ. ID. NO: 10) |

## Materials and Methods

*Defined-primer based recombination*

1. Preparation of genes to be recombined. Plasmids containing the genes to be recombined were purified from transformed TG1 cells using the Qiaprep kit (Qiagen, Chatsworth, CA). Plasmids were quantitated by UV absorption and mixed 1:1 for a final concentration of 50 ng/ul.

2. Staggered extension PCR and reassembly. 4  $\mu$ l of the plasmid mixture was used as template in a 100  $\mu$ l standard reaction (1.5 mM MgCl<sub>2</sub>, 50 mM KCl, 10 mM Tris-HCl pH 9.0, 0.1% Triton X-100, 0.2 mM dNTPs, 0.25 U *Taq* polymerase (Promega, Madison, WI)) which also contained 12.5 ng of each of the 8 primers. A control reaction which contained no primers was also assembled. Reactions were thermocycled through 100 cycles of 94°C, 30 seconds; 55°C, 15 seconds. Checking an aliquot of the reaction on an agarose gel at this point showed the product to be a large smear (with no visible product in the no primer control).

3. *DpnI* digestion of the templates. 1  $\mu$ l from the assembly reactions was then digested with *DpnI* to remove the template plasmid. The 10  $\mu$ l *DpnI* digest contained 1 x NEBuffer 4 and 5 U *DpnI* (both obtained from

New England Biolabs, Beverly, MA) and was incubated at 37°C for 45 minutes, followed by incubation at 70°C for 10 minutes to heat kill the enzyme.

4. PCR amplification of the reassembled products. The 10 µl digest was then added to 90 µl of a standard PCR reaction (as described in step 2) containing 0.4 µM primers 5b (ACTTAATCTAGAGGGTATTA) (SEQ. ID. NO: 11) and 3b (AGCCTCGCGGGATCCCCGGG) (SEQ. ID. NO: 12) specific for the ends of the gene. After 20 cycles of standard PCR (94°C, 30 seconds; 48°C, 30 seconds, 72°C, 1 minute) a strong band of the correct size (2 kb) was visible when the reaction was checked on an agarose gel, while only a very faint band was visible in the lane from the no-primer control. The product band was purified and cloned back into the expression plasmid pNB106R and transformed by electroporation into TG1 cells.

#### Results

Four 96 well plates of colonies resulting from this transformation were assayed for pNB esterase initial activity and thermostability. Approximately 60% of the clones exhibited initial activity and thermostability within 20% of the parental gene values. Very few (10%) of the clones were inactive (less than 10% of parent initial activity values). These results suggest a low rate of mutagenesis. Four mutants with the highest thermostability values were sequenced. Two clones (6E6 and 6H1) were the result of recombination between the parental genes (FIG. 5). One of the remaining two clones contained a novel point mutation, and one showed no difference from parent 5B12. The combination of mutations T99C and C204T in mutant 6E6 is evidence for a recombination event between these two sites. In addition, mutant 6H1 shows the loss of mutation A1072G (but the retention of mutations C1038T and T1310C), which is evidence for two recombination events (one between sites 1028 and 1072, and another between 1072 and 1310). A total of five new point mutations were found in the four genes sequenced.

#### EXAMPLE 4

##### **Recombination of two thermostable subtilisin E variants using internal defined primers and staggered extension**

This example demonstrates that the defined primer recombination technique can produce novel sequences containing new combinations of mutations present in the parent sequences. It further demonstrates the utility of the defined primer recombination technique to obtain further improvements

in enzyme performance (here, thermostability). This example further shows that the defined primers can bias the recombination so that recombination appears most often in the portion of the sequence defined by the primers (inside the primers). Furthermore, this example shows that specific mutations can be introduced into the recombined sequences by using the appropriate defined primer sequence(s) containing the desired mutation(s).

Genes encoding two thermostable subtilisin E variants of Example 1 (R1 and R2) were recombined using the defined primer recombination procedure with internal primers. FIG. 6 shows the four defined internal primers used to generate recombined progeny genes from template genes R1 and R2 in this example. Primer P50F contains a mutation (A→T at base position 598) which eliminates a HindIII restriction site and simultaneously adds a new unique NheI site. This primer is used to demonstrate that specific mutations can also be introduced into the population of recombined sequences by specific design of the defined primer. Gene R2 also contains a mutation A→G at the same base position, which eliminates the HindIII site. Thus restriction analysis (cutting by NheI and HindIII) of random clones sampled from the recombined library will indicate the efficiency of recombination and of the introduction of a specific mutation via the mutagenic primer. Sequence analysis of randomly-picked (unscreened) clones provides further information on the recombination and mutagenesis events occurring during defined primer-based recombination.

### **Materials and Methods**

#### *Defined-primer based recombination*

A version of the defined primer based recombination illustrated in FIG. 2 was carried out with the addition of StEP.

1. Preparation of genes to be recombined. About 10 ug of plasmids containing R1 and R2 gene were digested at 37°C for 1 hour with *NdeI* and *BamHI* (30 U each) in 50 µl of 1x buffer B (Boehringer Mannheim, Indianapolis, IN). Inserts of approximately 1 kb were purified from 0.8% preparative agarose gels using QIAEX II gel extraction kit. The DNA inserts were dissolved in 10 mM Tris-HCl (pH 7.4). The DNA concentrations were estimated, and the inserts were mixed 1:1 for a concentration of 50 ng/ul.

2. Staggered extension PCR and reassembly. Conditions (100 ul final volume): about 100 ng inserts were used as template, 50 ng of each of 4 internal primers, 1x Taq buffer, 0.2 mM of each dNTP, 1.5 mM MgCl<sub>2</sub> and .25 U Taq polymerase. Program: 7 cycles of 30 seconds at 94°C, 15 seconds at

55°C, followed by another 10 cycles of 30 seconds at 94°C, 15 seconds at 55°C, 5 seconds at 72°C (staggered extension), followed by 53 cycles of 30 seconds at 94°C, 15 seconds at 55°C, 1 minute at 72°C (gene assembly).

3. *DpnI* digestion of the templates. 1 µl of this reaction was diluted up to 9.5 µl with dH<sub>2</sub>O and 0.5 µl of *DpnI* restriction enzyme was added to digest the DNA template for 45 minutes, followed by incubation at 70°C for 10 minutes and then this 10 µl was used as template in a 10-cycle PCR reaction.

4. PCR amplification of reassembled products. PCR conditions (100 µl final volume): 30 pmol of each outside primer P5N and P3B, 1x Taq buffer, 0.2 mM of each dNTP and 2.5 U of *Taq* polymerase. PCR program: 10 cycles of 30 seconds at 94°C, 30 seconds at 55°C, 1 minute at 72°C. This program gave a single band at the correct size. The product was purified and subcloned into pBE3 shuttle vector. This gene library was amplified in *E. coli* HB101 and transferred into *B. subtilis* DB428 competent cells for expression and screening, as described elsewhere (35). Thermostability of enzyme variants was determined in the 96-well plate format described previously (33).

#### DNA sequencing

Ten *E. coli* HB101 transformants were chosen for sequencing. Genes were purified using QIAprep spin plasmid miniprep kit to obtain sequencing quality DNA. Sequencing was done on an ABI 373 DNA Sequencing System using the Dye Terminator Cycle Sequencing kit (Perkin-Elmer, Branchburg, NJ).

#### Results

##### 1) restriction analysis:

Forty clones randomly picked from the recombined library were digested with restriction enzymes *NheI* and *BamHI*. In a separate experiment the same forty plasmids were digested with *HindIII* and *BamHI*. These reaction products were analyzed by gel electrophoresis. As shown in FIG. 7, eight out of 40 clones (approximately 20%) contain the newly introduced *NheI* restriction site, demonstrating that the mutagenic primer has indeed been able to introduce the specified mutation into the population.

##### 2) DNA sequence analysis

The first ten randomly picked clones were subjected to sequence analysis, and the results are summarized in FIG. 8. A minimum of 6 out of the 10 genes have undergone recombination. Among these 6 genes, the minimal crossover events (recombination) between genes R1 and R2 vary from

1 to 4. All visible crossovers occurred within the region defined by the four primers. Mutations outside this region are rarely, if ever, recombined, as shown by the fact that there is no recombination between the two mutations at base positions 484 and 520. These results show that the defined primers can bias recombination so that it appears most often in the portion of the sequence defined by the primers (inside the primers). Mutations very close together also tend to remain together (for example, base substitutions 731 and 745 and base substitutions 1141 and 1153 always remain as a pair). However, the sequence of clone 7 shows that two mutations as close as 33 bases apart can be recombined (base position at 1107 and 1141).

Twenty-three new point mutations were introduced in the ten genes during the process. This error rate of 0.23% corresponds to 2-3 new point mutations per gene, which is a rate that has been determined optimal for generating mutant libraries for directed enzyme evolution (15). The mutation types are listed in Table 4. Mutations are mainly transitions and are evenly distributed along the gene.

TABLE 4

## New point mutations identified in ten recombined genes

| Transition | Frequency | Transversion | Frequency |
|------------|-----------|--------------|-----------|
| G → A      | 4         | A → T        | 1         |
| A → G      | 4         | A → C        | 1         |
| C → T      | 3         | C → A        | 1         |
| T → C      | 5         | C → G        | 0         |
|            |           | G → C        | 1         |
|            |           | G → T        | 0         |
|            |           | T → A        | 3         |
|            |           | T → G        | 0         |

A total of 9860 bases were sequenced. The mutation rate was 0.23%

## 4) Phenotypic analysis

Approximately 450 *B. subtilis* DB428 clones were picked and grown in SG medium supplemented with 20 ug/ml kanamycin in 96-well plates. Approximately 56% of the clones expressed active enzymes. From previous experience, we know that this level of inactivation indicates a mutation rate on the order of 2-3 mutations per gene (35). Approximately 5% clones showed

double mutant (N181D+N218S)-like phenotypes (which is below the expected 25% value for random recombination alone due primarily to point mutagenesis). (DNA sequencing showed that two clones, 7 and 8, from the ten randomly picked clones contain both N218S and N181D mutations.)

5

#### EXAMPLE 5

##### **Optimization of the *Actinoplanes utahensis* ECB deacylase by the random-priming recombination method**

10 In this example, the method is used to generate short DNA fragments from denatured, linear, double-stranded DNA (e.g., restriction fragments purified by gel electrophoresis; 22). The purified DNA, mixed with a molar excess of primers, is denatured by boiling, and synthesis is then carried out using the Klenow fragment of *E. coli* DNA polymerase I. This enzyme lacks 5'→3' exonuclease activity, so that the random priming product is synthesized  
15 exclusively by primer extension and is not degraded by exonuclease. The reaction is carried out at pH 6.6, where the 3'→5' exonuclease activity of the enzyme is much reduced (36). These conditions favor random initiation of synthesis.

The procedure involves the following steps:

20 1. Cleave the DNA of interest with appropriate restriction endonuclease(s) and purify the DNA fragment of interest by gel electrophoresis using Wizard PCR Prep Kit (Promega, Madison, WI). As an example, the *Actinoplanes utahensis* ECB deacylase gene was cleaved as a 2.4 kb-long *Xho*I-*Psh*AI fragment from the recombinant plasmid pSHP100. It was essential to  
25 linearize the DNA for the subsequent denaturation step. The fragment was purified by agarose gel electrophoresis using the Wizard PCR Prep Kit (Promega, Madison, WI) (FIG.9, step (a)). Gel purification was also essential in order to remove the restriction endonuclease buffer from the DNA, since the  $Mg^{2+}$  ions make it difficult to denature the DNA in the next step.

30 2. 400 ng (about 0.51 pmol) of the double-stranded DNA dissolved in  $H_2O$  was mixed with 2.75  $\mu g$  (about 1.39 nmol) of dp(N)<sub>6</sub> random primers. After immersion in boiling water for 3 minutes, the mixture was placed immediately in an ice/ethanol bath.

35 The size of the random priming products is an inverse function of the concentration of primer (33). The presence of high concentrations of primer is thought to lead to steric hindrance. Under the reaction conditions described



here the random priming products are approximately 200-400 bp, as determined by electrophoresis through an alkaline agarose gel (FIG. 9 step b).

3. Ten  $\mu$ l of 10 x reaction buffer [10X buffer: 900 mM HEPES, pH 6.6; 0.1 M magnesium chloride, 10 mM dithiothreitol, and 5 mM each dATP, dCTP, dGTP and dTTP) was added to the denatured sample, and the total volume of the reaction mixture was brought up to 95  $\mu$ l with H<sub>2</sub>O.

4. Ten units (about 5  $\mu$ l) of the Klenow fragment of *E.coli* DNA polymerase I was added. All the components were mixed by gently tapping the outside of the tube and were centrifuged at 12,000 g for 1-2 seconds in a microfuge to move all the liquid to the bottom. The reaction was carried out at 22°C for 35 minutes.

The rate of the extension depends upon the concentrations of the template and the four nucleotide precursors. Because the reaction was carried out under conditions that minimize exonucleolytic digestion, the newly synthesized products were not degraded to a detectable extent.

5. After 35 minutes at 22°C, the reaction was terminated by cooling the sample to 0°C on ice. 100  $\mu$ l of ice-cold H<sub>2</sub>O was added to the reaction mixture.

6. The random primed products were purified by passing the whole reaction mixture through Centricon-100 (to remove the template and proteins) and Centricon-10 filters (to remove the primers and fragments less than 50 bases), successively. Centricon filters are available from Amicon Inc (Beverly, MA). The retentate fraction (about 85  $\mu$ l in volume) was recovered from Centricon-10. This fraction contained the desired random priming products (FIG. 9, step c) and was used for whole gene reassembly.

Reassembly of the whole gene was accomplished by the following steps:

1. For reassembly by PCR, 5  $\mu$ l of the random-primed DNA fragments from Centricon-10, 20  $\mu$ l of 2x PCR pre-mix (5-fold diluted cloned *Pfu* buffer, 0.5 mM each dNTP, 0.1U/ $\mu$ l cloned *Pfu* polymerase (Stratagene, La Jolla, CA)), 8  $\mu$ l of 30% (v/v) glycerol and 7  $\mu$ l of H<sub>2</sub>O were mixed on ice. Since the concentration of the random-primed DNA fragments used for reassembly is the most important variable, it is useful to set up several separate reactions with different concentrations to establish the preferred concentration.

2. After incubation at 96°C for 6 minutes, 40 thermocycles were performed, each with 1.5 minutes at 95°C, 1.0 minutes at 55°C and 1.5 minutes + 5 second/cycle at 72°C, with the extension step of the last cycle

proceeding at 72°C for 10 minutes, in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA) apparatus without adding any mineral oil.

3. 3 µl aliquots at cycles 20, 30 and 40 were removed from the reaction mixture and analyzed by agarose gel electrophoresis. The reassembled PCR product at 40 cycles contained the correct size product in a smear of larger and smaller sizes (see FIG. 9, step d).

The correctly reassembled product of this first PCR was further amplified in a second PCR reaction which contained the PCR primers complementary to the ends of the template DNA. The amplification procedure was as follows:

1. 2.0 µl of the PCR reassembly aliquots were used as template in 100-µl standard PCR reactions, which contained 0.2 mM each primers of *xhoF28* (5' GGTAAGAGCGAGTCTCGAGGGGGAGATGC3') (SEQ. ID. NO: 13) and *pshR22* (5' AGCCGGCGTGACGTGGGTCAGC 3') (SEQ. ID. NO: 14), 1.5 mM MgCl<sub>2</sub>, 10 mM Tris-HCl [pH 9.0], 50 mM KCl, 200 µM each of the four dNTPs, 6% (v/v) glycerol, 2.5 U of *Taq* polymerase (Promega, Madison, WI) and 2.5 U of *Pfu* polymerase (Stratagene, La Jolla, CA).

2. After incubation at 96°C for 5 minutes, 15 thermocycles were performed, each with 1.5 minutes at 95°C, 1.0 minutes at 55°C and 1.5 minutes at 72°C, followed by additional 15 thermocycles of 1.5 minutes at 95°C, 1.0 minutes at 55°C and 1.5 minutes + 5 second/cycle at 72°C with the extension step of the last cycle proceeding at 72°C for 10 minutes, in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA) apparatus without adding any mineral oil.

3. The amplification resulted in a large amount of PCR product with the correct size of the ECB deacylase whole gene (FIG. 9, step e).

Cloning was accomplished as follows:

1. The PCR product of ECB deacylase gene was digested with *Xho* I and *Psh* AI restriction enzymes, and cloned into a modified pIJ702 vector.

2. *S. lividans* TK23 protoplasts were transformed with the above ligation mixture to form a mutant library.

#### In situ screening the ECB deacylase mutants

Each transformant within the *S. lividans* TK23 library obtained as described above was screened for deacylase activity with an *in situ* plate assay

method using ECB as substrate. Transformed protoplasts were allowed to regenerate on R2YE agar plates by incubation at 30°C for 24 hours and to develop in the presence of thiostrepton for further 48-72 hours. When the colonies grew to proper size, 6 ml of 45°C purified-agarose (Sigma) solution containing 0.5 mg/ml ECB in 0.1 M sodium acetate buffer (pH 5.5) was poured on top of each R2YE-agar plate and allowed to further develop for 18-24 hours at 37°C. Colonies surrounded by a clearing zone larger than that of a control colony containing wild-type recombinant plasmid pSHP150-2 were indicative of more efficient ECB hydrolysis resulting from improved enzyme properties or improved enzyme expression and secretion level, and were chosen as potential positive mutants. These colonies were picked for subsequent preservation and manipulation.

#### HPLC assay of the ECB deacylase mutants

Single positive transformants were inoculated into 20 ml fermentation medium containing 5 µg/ml thiostrepton and allowed to grow at 30°C for 48 hours. At this step, all cultures were subjected to HPLC assay using ECB as substrate. 100 µl of whole broth was used for an HPLC reaction at 30°C for 30 minutes in the presence of 0.1 M NaAc (pH 5.5), 10% (v/v) MeOH and 200 µg/ml of ECB substrate. 20 µl of each reaction mixture was loaded onto a PolyLC polyhydroxyethyl aspartamide column (4.6 x 100 mm) and eluted by acetonitrile gradient at a flow rate of 2.2 ml/min. The ECB-nucleus was detected at 225 nm.

#### Purification of the ECB deacylase mutants

After the HPLC assay, 2.0 ml pre-cultures of all potential positive mutants were then used to inoculate 50-ml fermentation medium and allowed to grow at 30°C, 280 rpm for 96 hours. These 50-ml cultures were then centrifuged at 7,000 g for 10 minutes. The supernatants were re-centrifuged at 16,000 g for 20 minutes. The supernatants containing the ECB deacylase mutant enzymes were stored at -20°C.

The supernatants from the positive mutants were further concentrated to 1/30 their original volume with an Amicon filtration unit with molecular weight cutoff of 10 kD. The resulting enzyme samples were diluted with an equal volume of 50 mM KH<sub>2</sub>PO<sub>4</sub> (pH 6.0) buffer and 1.0 ml was applied to Hi-Trap ion exchange column. The binding buffer was 50 mM KH<sub>2</sub>PO<sub>4</sub> (pH 6.0), and the elution buffer was 50 mM KH<sub>2</sub>PO<sub>4</sub> (pH 6.0) and 1.0 M NaCl. A linear

gradient from 0 to 1.0 M NaCl was applied in 8 column volumes with a flow rate of 2.7 ml/min. The ECB deacylase mutant fraction eluted at 0.3 M NaCl and was concentrated and buffer exchanged into 50 mM KH<sub>2</sub>PO<sub>4</sub> (pH 6.0) in Amicon Centricon-10 units. Enzyme purity was verified by SDS-PAGE, and the concentration was determined using the Bio-Rad Protein Assay.

#### Specific activity assay of the ECB deacylase mutants

4.0 µg of each purified ECB deacylase mutant was used for the activity assay at 30°C for 0-60 minutes in the presence of 0.1 M NaAc (pH 5.5), 10% (v/v) MeOH and 200 µg/ml of ECB substrate. 20 µl of each reaction mixture was loaded onto a PolyLC polyhydroxyethyl aspartamide column (4.6 x 100 mm) and eluted with an acetonitrile gradient at a flow rate of 2.2 ml/min. The reaction products were monitored at 225 nm and recorded on an IBM PC data acquisition system. The ECB nucleus peak was numerically integrated and used to calculate the specific activity of each mutant.

As shown in FIG. 10, after only one round of applying this random-priming based technique on the wild-type ECB deacylase gene, one mutant (M16) from 2,012 original transformants was found to possess 2.4 times the specific activity of the wild-type enzyme. FIG 11 shows that the activity of M16 has been increased relative to that of the wild-type enzyme over a broad pH range.

The nucleotide sequence which encodes the M16 mutant gene is set forth in SEQ. ID. NO: 26. The nucleotide sequence for the wild-type ECB deacylase gene is set forth in SEQ. ID. NO: 31.

Other mutant genes which were isolated utilizing the above method include mutant M2#7, M2#14, M15 and M20. The nucleotide sequences for these mutant genes are set forth in SEQ. ID. NOS: 27, 28, 29 and 30, respectively. The amino acid sequences for the ECB deacylases encoded by the mutant genes are set forth in SEQ. ID. NOS: 32 (M16); 33 (M2#7); 34 (M2#14); 35 (M15); and 36 (M20).

The above-identified mutant genes may be ligated into a suitable expression vector and incorporated into a host cell or organism for expression.

The resulting ECB deacylase enzyme which is expressed by the transformed host cell or organism may be isolated, purified and used as an enzyme in a wild variety of synthetic protocols which require the ECB deacylase enzyme. Alternatively, the transformed host cell or organism may be incorporated

directly into suitable production broths where the ECB deacylase enzyme is generated *in situ* by the transformant.

#### EXAMPLE 6

5                   **Improving the thermostability *Bacillus subtilis* subtilisin E  
                  using the random-sequence primer recombination method**

This example demonstrates the use of various DNA polymerases for primer-based recombination. It further demonstrates the stabilization of subtilisin E by recombination.

10                  Genes R1 and R2 encoding the two thermostable subtilisin E variants described in Example 1 were chosen as the templates for recombination.

(1) *Target gene preparation*

15                  Subtilisin E thermostable mutant genes R1 and R2 (FIG.11) were subjected to random primed DNA synthesis. The 986-bp fragment including 45 nt of subtilisin E prosequence, the entire mature sequence and 113 nt after the stop codon were obtained by double digestion of plasmid pBE3 with *Bam* HI and *Nde* I and purified from a 0.8% agarose gel using the Wizard PCR Prep Kit (Promega, Madison, WI). It was essential to linearize the DNA for the  
20                  subsequent denaturation step. Gel purification was also essential in order to remove the restriction endonuclease buffer from the DNA, since the  $Mg^{2+}$  ions make it difficult to denature the DNA in the next step.

(2) *Random primed DNA synthesis*

25                  Random primed DNA synthesis used to generate short DNA fragments from denatured, linear, double-stranded DNA. The purified *B. subtilis* subtilisin E mutant genes, mixed with a molar excess of primers, were denatured by boiling, and synthesis was then carried out using one of the following DNA polymerases: the Klenow fragment of *E. coli* DNA polymerase I,  
30                  bacteriophage T4 DNA polymerase and T7 sequenase version 2.0 DNA polymerase.

                  Under its optimal performance conditions (29), bacteriophage T4 DNA polymerase gives similar synthesis results as the Klenow fragment does. When T7 sequenase version 2.0 DNA polymerase (31, 32) is used, the lengths of the  
35                  synthesized DNA fragments are usually larger. Some amount of  $MnCl_2$  has to be included during the synthesis in order to control the lengths of the synthesized fragments within 50-400 bases.

Short, nascent DNA fragments can also be generated with PCR using the Stoffel fragment of *Taq* DNA polymerase or *Pfu* DNA polymerase. An important consideration is to identify by routine experimentation the reaction conditions which ensure that the short random primers can anneal to the templates and give sufficient DNA amplification at higher temperatures. We have found that random primers as short as  $\text{dp(N)}_{12}$  can be used with PCR to generate fragments.

#### 2.1 Random primed DNA synthesis with the Klenow fragment

The Klenow fragment of *E. coli* DNA polymerase I lacks 5'→3' exonuclease activity, so that the random priming product is synthesized exclusively by primer extension and is not degraded by exonuclease. The reaction was carried out at pH 6.6, where the 3'→5' exonuclease activity of the enzyme is much reduced (36). These conditions favor random initiation of synthesis.

1. 200 ng (about 0.7 pmol) of R1 DNA and equal amount of R2 DNA dissolved in H<sub>2</sub>O was mixed with 13.25 µg (about 6.7 nmol) of  $\text{dp(N)}_6$  random primers. After immersion in boiling water for 5 minutes, the mixture was placed immediately in an ice/ethanol bath.

The size of the random priming products is an inverse function of the concentration of primer (30). The presence of high concentrations of primer is thought to lead to steric hindrance. Under the reaction conditions described here the random priming products are approximately 50-500 bp, as determined by agarose gel electrophoresis.

2. Ten µl of 10 x reaction buffer [10x buffer: 900 mM HEPES, pH 6.6; 0.1 M magnesium chloride, 20 mM dithiothreitol, and 5 mM each dATP, dCTP, dGTP and dTTP) was added to the denatured sample, and the total volume of the reaction mixture was brought up to 95 µl with H<sub>2</sub>O.

3. Ten units (about 5 µl) of the Klenow fragment of *E. coli* DNA polymerase I (Boehringer Mannheim, Indianapolis, IN) was added. All the components were mixed by gently tapping the outside of the tube and were centrifuged at 12,000 g for 1-2 seconds in a microfuge to move all the liquid to the bottom. The reaction was carried out at 22°C for 3 hours.

The rate of the extension depends upon the concentrations of the template and the four nucleotide precursors. Because the reaction was carried out under conditions that minimize exonucleolytic digestion, the newly synthesized products were not degraded to a detectable extent.



4. After 3 hours at 22°C, the reaction was terminated by cooling the sample to 0°C on ice. 100 µl of ice-cold H<sub>2</sub>O was added to the reaction mixture.

5. The random primed products were purified by passing the whole reaction mixture through Microcon-100 (Amicon, Beverly MA) (to remove the template and proteins) and Microcon-10 filters (to remove the primers and fragments less than 40 bases), successively. The retentate fraction (about 65 µl in volume) was recovered from the Microcon-10. This fraction containing the desired random priming products was buffer-exchanged against PCR reaction buffer with the new Microcon-10 further use in whole gene reassembly.

## 2.2 Random primed DNA synthesis with bacteriophage T4 DNA polymerase

Bacteriophage T4 DNA polymerase and the Klenow fragment of *E. coli* DNA polymerase I are similar in that each possesses a 5'-3' polymerase activity and a 3'-5' exonuclease activity. The exonuclease activity of bacteriophage T4 DNA polymerase is more than 200 times that of the Klenow fragment. Since it does not displace the short oligonucleotide primers from single-stranded DNA templates (23), the efficiency of mutagenesis is different from the Klenow fragment.

1. 200 ng (about 0.7 pmol) of R1 DNA and equal amount of R2 DNA dissolved in H<sub>2</sub>O was mixed with 13.25 µg (about 6.7 nmol) of dp(N)<sub>6</sub> random primers. After immersion in boiling water for 5 minutes, the mixture was placed immediately in an ice/ethanol bath. The presence of high concentrations of primer is thought to lead to steric hindrance.

2. Ten µl of 10 x reaction buffer [10x buffer: 500 mM Tris-HCl, pH 8.8; 150 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>; 70 mM magnesium chloride, 100 mM 2-mercaptoethanol, 0.2 mg/ml bovine serum albumin and 2 mM each dATP, dCTP, dGTP and dTTP) was added to the denatured sample, and the total volume of the reaction mixture was brought up to 90 µl with H<sub>2</sub>O.

3. Ten units (about 10 µl) of the T4 DNA polymerase I (Boehringer Mannheim, Indianapolis, IN) was added. All the components were mixed by gently tapping the outside of the tube and were centrifuged at 12,000 g for 1-2 seconds in a microfuge to move all the liquid to the bottom. The reaction was carried out at 37°C for 30 minutes. Under the reaction conditions described here the random priming products are approximately 50-500 bp.



4. After 30 minutes at 37°C, the reaction was terminated by cooling the sample to 0°C on ice. 100 µl of ice-cold H<sub>2</sub>O was added to the reaction mixture.

5. The random primed products were purified by passing the whole reaction mixture through Microcon-100 (to remove the template and proteins) and Microcon-10 filters (to remove the primers and fragments less than 40 bases), successively. The retentate fraction (about 65 µl in volume) was recovered from the Microcon-10. This fraction containing the desired random priming products was buffer-exchanged against PCR reaction buffer with the new Microcon-10 further use in whole gene reassembly.

### 2.3 Random primed DNA synthesis with the T7 sequenase v2.0 DNA polymerase

Since the T7 sequenase v2.0 DNA polymerase lacks exonuclease activity and is highly processive, the average length of DNA synthesized is greater than that of DNAs synthesized by the Klenow fragment or T4 DNA polymerase. But in the presence of proper amount of MnCl<sub>2</sub> in the reaction, the size of the synthesized fragments can be controlled to less than 400 bps.

1. 200 ng (about 0.7 pmol) of R1 DNA and equal amount of R2 DNA dissolved in H<sub>2</sub>O was mixed with 13.25 µg (about 6.7 nmol) of dp(N)<sub>6</sub> random primers. After immersion in boiling water for 5 minutes, the mixture was placed immediately in an ice/ethanol bath. The presence of high concentrations of primer is thought to lead to steric hindrance.

2. Ten µl of 10 x reaction buffer [10X buffer: 400 mM Tris-HCl, pH 7.5; 200 mM magnesium chloride, 500 mM NaCl, 3 mM MnCl<sub>2</sub>, and 3 mM each dATP, dCTP, dGTP and dTTP) was added to the denatured sample, and the total volume of the reaction mixture was brought up to 99.2 µl with H<sub>2</sub>O.

3. Ten units (about 0.8 µl) of the T7 Sequenase v2.0 (Amersham Life Science, Cleveland, Ohio) was added. All the components were mixed by gently tapping the outside of the tube and were centrifuged at 12,000 g for 1-2 seconds in a microfuge to move all the liquid to the bottom. The reaction was carried out at 22°C for 15 minutes. Under the reaction conditions described here the random priming products are approximately 50-400 bps.

4. After 15 minutes at 22°C, the reaction was terminated by cooling the sample to 0°C on ice. 100 µl of ice-cold H<sub>2</sub>O was added to the reaction mixture.

5. The random primed products were purified by passing the whole reaction mixture through Microcon-100 (to remove the template and proteins) and Microcon-10 filters (to remove the primers and fragments less than 40 bases), successively. The retentate fraction (about 65  $\mu$ l in volume) was recovered from the Microcon-10. This fraction containing the desired random priming products was buffer-exchanged against PCR reaction buffer with the new Microcon-10 further use in whole gene reassembly.

#### 2.4 Random primed DNA synthesis with PCR using the Stoffel fragment of *Taq* DNA polymerase

Similar to the Klenow fragment of *E. coli* DNA polymerase I, the Stoffel fragment of *Taq* DNA polymerase lacks 5' to 3' exonuclease activity. It is also more thermostable than *Taq* DNA polymerase. The Stoffel fragment has low processivity, extending a primer an average of only 5-10 nucleotides before it dissociates. As a result of its lower processivity, it may also have improved fidelity.

1. 50 ng (about 0.175 pmol) of R1 DNA and equal amount of R2 DNA dissolved in H<sub>2</sub>O was mixed with 6.13  $\mu$ g (about 1.7 nmol) of dp(N)<sub>12</sub> random primers.

2. Ten  $\mu$ l of 10x reaction pre-mix [10x reaction pre-mix: 100 mM Tris-HCl, pH 8.3; 30 mM magnesium chloride, 100 mM KCl, and 2 mM each dATP, dCTP, dGTP and dTTP) was added, and the total volume of the reaction mixture was brought up to 99.0  $\mu$ l with H<sub>2</sub>O.

3. After incubation at 96°C for 5 minutes, 2.5 units (about 1.0  $\mu$ l) of the Stoffel fragment of *Taq* DNA polymerase (Perkin-Elmer Corp., Norwalk, CT) was added. Thirty-five thermocycles were performed, each with 60 seconds at 95°C, 60 seconds at 55°C and 50 seconds at 72°C, without the extension step of the last cycle, in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA) apparatus. Under the reaction conditions described here the random priming products are approximately 50-500 bp.

4. The reaction was terminated by cooling the sample to 0°C on ice. 100  $\mu$ l of ice-cold H<sub>2</sub>O was added to the reaction mixture.

5. The random primed products were purified by passing the whole reaction mixture through Microcon-100 (to remove the template and proteins) and Microcon-10 filters (to remove the primers and fragments less than 40 bases), successively. The retentate fraction (about 65  $\mu$ l in volume) was recovered from the Microcon-10. This fraction containing the desired random

priming products was buffer-exchanged against PCR reaction buffer with the new Microcon-10 further use in whole gene reassembly.

## 2.5 Random primed DNA synthesis with PCR using *Pfu* DNA polymerase

*Pfu* DNA polymerase is extremely thermostable, and the enzyme possesses an inherent 3' to 5' exonuclease activity but does not possess a 5'→3' exonuclease activity. Its base substitution fidelity has been estimated to be  $2 \times 10^{-6}$ .

1. 50 ng (about 0.175 pmol) of R1 DNA and equal amount of R2 DNA dissolved in H<sub>2</sub>O was mixed with 6.13mg (about 1.7 nmol) of dp(N)<sub>12</sub> random primers.

2. Fifty µl of 2 x reaction pre-mix [2 x reaction pre-mix: 5-fold diluted cloned *Pfu* buffer (Stratagene, La Jolla, CA), 0.4 mM each dNTP], was added, and the total volume of the reaction mixture was brought up to 99.0 µl with H<sub>2</sub>O.

3. After incubation at 96°C for 5 minutes, 2.5 units (about 1.0 µl) of *Pfu* DNA polymerase (Stratagene, La Jolla, CA) was added. Thirty-five thermocycles were performed, each with 60 seconds at 95°C, 60 seconds at 55°C and 50 seconds at 72°C, without the extension step of the last cycle, in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA) apparatus. Under the reaction conditions described here the major random priming products are approximately 50-500 bp.

4. The reaction was terminated by cooling the sample to 0°C on ice. 100 µl of ice-cold H<sub>2</sub>O was added to the reaction mixture.

5. The random primed products were purified by passing the whole reaction mixture through Microcon-100 (to remove the template and proteins) and Microcon-10 filters (to remove the primers and fragments less than 40 bases), successively. The retentate fraction (about 65 µl in volume) was recovered from the Microcon-10. This fraction containing the desired random priming products was buffer-exchanged against PCR reaction buffer with the new Microcon-10 further use in whole gene reassembly.

### (3) Reassembly of the whole gene

1. For reassembly by PCR, 10 µl of the random-primed DNA fragments from Microcon-10, 20 µl of 2 X PCR pre-mix (5-fold diluted cloned

*Pfu* buffer, 0.5 mM each dNTP, 0.1U/ $\mu$ l cloned *Pfu* polymerase (Stratagene, La Jolla, CA)), 15  $\mu$ l of H<sub>2</sub>O were mixed on ice.

2. After incubation at 96°C for 3 minutes, 40 thermocycles were performed, each with 1.0 minute at 95°C, 1.0 minute at 55°C and 1.0 minute + 5 second/cycle at 72°C, with the extension step of the last cycle proceeding at 72°C for 10 minutes, in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA) apparatus without adding any mineral oil.

3. 3  $\mu$ l aliquots at cycles 20, 30 and 40 were removed from the reaction mixture and analyzed by agarose gel electrophoresis. The reassembled PCR product at 40 cycles contained the correct size product in a smear of larger and smaller sizes.

#### (4) Amplification

The correctly reassembled product of this first PCR was further amplified in a second PCR reaction which contained the PCR primers complementary to the ends of the template DNA.

1. 2.0  $\mu$ l of the PCR reassembly aliquots were used as template in 100- $\mu$ l standard PCR reactions, which contained 0.3 mM each primers of P1 (5' CCGAGCGTTGC ATATGTGGAAG 3') (SEQ. ID. NO: 15) and P2 (5' CGACTCTAGAGGATCCGATTC 3') (SEQ. ID. NO: 16), 1.5 mM MgCl<sub>2</sub>, 10 mM Tris-HCl [pH 9.0], 50 mM KCl, 200 mM each of the four dNTPs, 2.5 U of *Taq* polymerase (Promega, Madison, WI, USA) and 2.5 U of *Pfu* polymerase (Stratagene, La Jolla, CA).

2. After incubation at 96°C for 3 minutes, 15 thermocycles were performed, each with 60 seconds at 95°C, 60 seconds at 55°C and 50 seconds at 72°C, followed by additional 15 thermocycles of 60 seconds at 95°C, 60 seconds at 55°C and 50 seconds (+ 5 second/cycle) at 72°C with the extension step of the last cycle proceeding at 72°C for 10 minutes, in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA) apparatus without adding any mineral oil.

3. The amplification resulted in a large amount of PCR product with the correct size of the subtilisin E whole gene.

#### (5) Cloning

Since the short DNA fragments were generated with five different DNA polymerases, there were five pools of final PCR amplified reassembled

products. Each of the DNA pool was used for constructing the corresponding subtilisin E mutant library.

1. The PCR amplified reassembled product was purified by Wizard DNA-CleanUp kit (Promega, Madison, WI), digested with *Bam* HI and *Nde* I, electrophoresed in a 0.8% agarose gel. The 986-bp product was cut from the gel and purified by Wizard PCR Prep kit (Promega, Madison, WI). Products were ligated with vector generated by *Bam* HI-*Nde* I digestion of the pBE3 shuttle vector.

2. *E. coli* HB101 competent cells were transformed with the above ligation mixture to form a mutant library. About 4,000 transformants from this library were pooled, and recombinant plasmid mixture was isolated from this pool.

3. *B. subtilis* DB428 competent cells were transformed with the above isolated plasmid mixture to form another library of the subtilisin E variants.

4. Based on the DNA polymerase used for random priming the short, nascent DNA fragments, the five libraries constructed here were named: library/Klenow, library/T4, library/Sequenase, library/Stoffel and library/Pfu. About 400 transformants from each library were randomly picked and subjected to screening for thermostability [see Step (7)].

#### (6) Random clone sequencing

Ten random clones from the *B. subtilis* DB428 library/Klenow was chosen for DNA sequence analysis. Recombinant plasmids were individually purified from *B. subtilis* DB428 using a QIAprep spin plasmid miniprep kit (QIAGEN) with the modification that 2 mg/ml lysozyme was added to P1 buffer and the cells were incubated for 5 minutes at 37°C, retransformed into competent *E. coli* HB 101 and then purified again using QIAprep spin plasmid miniprep kit to obtain sequencing quality DNA. Sequencing was done on an ABI 373 DNA Sequencing System using the Dye Terminator Cycle Sequencing kit (Perkin-Elmer Corp., Norwalk, CT).

#### (7) Screening for thermostability

About 400 transformants from each of the five libraries described at Step (4) were subjected to screening. Screening was based on the assay described previously (33, 35), using succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (SEQ. ID. NO: 25) as substrate. *B. subtilis* DB428 containing the plasmid

library were grown on LB/kanamycin (20 µg/ml) plates. After 18 hours at 37°C single colonies were picked into 96-well plates containing 100 µl SG/kanamycin medium per well. These plates were shaken and incubated at 37°C for 24 hours to let the cells to grow to saturation. The cells were spun down, and the supernatants were sampled for the thermostability assay. Three replica 96-well assay plates were duplicated for each growth plate, with each well containing 10 ml of supernatant. The subtilisin activities were then measured by adding 100 µl of activity assay solution (0.2 mM succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (SEQ. ID. NO: 25), 100 mM Tris-HCl, 10 mM CaCl<sub>2</sub>, pH 8.0, 37 °C). Reaction velocities were measured at 405 nm over 1.0 min. in a ThermoMax microplate reader (Molecular Devices, Sunnyvale CA). Activity measured at room temperature was used to calculate the fraction of active clones (clones with activity less than 10% of that of wild type were scored as inactive). Initial activity (A<sub>i</sub>) was measured after incubating one assay plate at 65°C for 10 minutes by immediately adding 100 µl of prewarmed (37°C) assay solution (0.2mM succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (SEQ. ID. NO: 25), 100 mM Tris-HCl, pH 8.0, 10 mM CaCl<sub>2</sub>) into each well. Residual activity (A<sub>r</sub>) was measured after 40 minute incubation.

#### (8) Sequence Analysis

After screening, one clone that showed the highest thermostability within the 400 transformants from the library/Klenow was re-streaked on LB/kanamycin agar plate, and single colonies derived from this plate were inoculated into tube cultures, for glycerol stock and plasmid preparation. The recombinant plasmid was purified using a QIAprep spin plasmid miniprep kit (QIAGEN) with the modification that 2 mg/ml lysozyme was added to P1 buffer and the cells were incubated for 5 minutes at 37°C, retransformed into competent *E. coli* HB 101 and then purified again using QIAprep spin plasmid miniprep kit to obtain sequencing quality DNA. Sequencing was done on an ABI 373 DNA Sequencing System using the Dye Terminator Cycle Sequencing kit (Perkin-Elmer Corp., Norwalk, CT).

#### Results

##### 1. Recombination frequency and efficiency associated with the random-sequence recombination.

The random primed process was carried out as described above. The process is illustrated in FIG. 1. Ten clones from the mutant library/Klenow were selected at random and sequenced. As summarized in FIG. 12 and Table

5, all clones were different from the parent genes. The frequency of occurrence of a particular point mutation from parent R1 or R2 in the recombined genes ranged from 40% to 70%, fluctuating around the expected value of 50%. This indicates that the two parent genes have been nearly randomly recombined with the random primer technique. FIG. 12 also shows that all ten mutations can be recombined or dissected, even those that are only 12 bp apart.

We then estimated the rates of subtilisin thermoinactivation at 65°C by analyzing the 400 random clones from each of the five libraries constructed at Step (5). The thermostabilities obtained from one 96-well plate are shown in FIG.13, plotted in descending order. Approximately 21% of the clones exhibited thermostability comparable to the mutant with the N181D and N218S double mutations. This indicates that the N181D mutation from RC2 and the N218S mutation from RC1 have been randomly recombined. Sequence analysis of the clone exhibiting the highest thermostability among the screened 400 transformants from the library/Klenow showed the mutation N181D and N218S did exist.

2. Frequency of newly introduced mutations during the random priming process.

Approximately 400 transformants from each of the five *B.subtilis* DB428 libraries [see Step (5)] were picked, grown in SG medium supplemented with 20 ug/ml kanamycin in 96-well plates and subjected to subtilisin E activity screening. Approximately 77-84% of the clones expressed active enzymes, while 16-23% of the transformants were inactive, presumably as a result of newly introduced mutations. From previous experience, we know that this rate of inactivation indicates a mutation rate on the order of 1 to 2 mutations per gene (35).

As shown in FIG. 12, 18 new point mutations were introduced in the process. This error rate of 0.18% corresponds to 1-2 new point mutations per gene, which is a rate that has been determined from the inactivation curve. Mutations are nearly randomly distributed along the gene.



TABLE 5

**DNA and amino acid residue substitutions in the ten random clones from Library/Klenow**

| Clone # | Position | Base Substitution | Substitution Type | Amino Acid Substitution | Substitution Type |
|---------|----------|-------------------|-------------------|-------------------------|-------------------|
| C#1     | 839      | A→C               | transversion      | Gly→Gly                 | synonymous        |
| C#2     | 722      | A→G               | transition        | Ser→Ser                 | synonymous        |
| C#2     | 902      | T→C               | transition        | Val→Val                 | synonymous        |
| C#2     | 1117     | C→G               | transversion      | Ser→Ser                 | synonymous        |
| C#4     | 809      | T→C               | transition        | Asn→Asn                 | synonymous        |
| C#4     | 1098     | G→C               | transversion      | Gly→Ala                 | non-synonymous    |
| C#4     | 1102     | T→C               | transition        | Ala→Ala                 | synonymous        |
| C#6     | 653      | C→A               | transversion      | His→Ile                 | non-synonymous    |
| C#6     | 654      | A→T               | transversion      | His→Ile                 | non-synonymous    |
| C#6     | 657      | T→C               | transition        | Val→Ala                 | non-synonymous    |
| C#6     | 658      | A→C               | transversion      | Val→Ala                 | non-synonymous    |
| C#6     | 1144     | A→G               | transition        | Ala→Ala                 | synonymous        |
| C#6     | 1147     | A→G               | transition        | Ala→Ala                 | synonymous        |
| C#7     | 478      | T→C               | transition        | Ile→Ile                 | synonymous        |
| C#9     | 731      | A→G               | transition        | Ala→Ala                 | synonymous        |
| C#9     | 994      | A→G               | transition        | Val→Val                 | synonymous        |
| C#10    | 1111     | A→G               | transition        | Gly→Gly                 | synonymous        |
| C#10    | 1112     | A→T               | transversion      | Thr→Ser                 | non-synonymous    |

5           The mutation types are listed in TABLE 5. The direction of mutation is clearly nonrandom. For example, A changes more often to G than to either T or C. All transitions, and in particular T-C and A-G, occur more often than transversion. Some nucleotides are more mutable than others. One G→C, one C→G and one C→A transversions were found within the 10 sequenced clones.

10       These mutations were generated very rarely during the error-prone PCR mutagenesis of subtilisin (37). Random-priming process may allow access to a greater range of amino acid substitutions than PCR-based point mutagenesis.

15           It is interesting to note that a short stretch of 5' C GGT ACG CAT GTA GCC GGT ACG 3' (SEQ. ID. NO: 16) at the position 646-667 in parents R1 and R2 was mutated to 5' C GGT ACG ATT GCC GCC GGT ACG 3' (SEQ. ID. NO: 17) in random clone C#6. Since the stretch contains two short repeats at the both ends, the newly introduced mutations may result from a slipped-strand mispairing process instead of point-mutation only process. Since there is no frame-shift, this kind of slippage may be useful for domain conversion.

3. Comparison of different DNA polymerase fidelity in the random-priming process.

During random-priming recombination, homologous DNA sequences are nearly randomly recombined and new point mutations are also introduced. Though these point mutations may provide useful diversity for some *in vitro* evolution applications, they are problematic recombination of beneficial mutations already identified previously, especially when the mutation rate is this high. Controlling error rate during random priming process is particularly important for successfully applying this technique to solve *in vitro* evolution problems. By choosing different DNA polymerase and modifying the reaction conditions, the random priming molecular breeding technique can be adjusted to generate mutant libraries with different error rates.

The Klenow fragment of *E.coli* DNA polymerase I, bacteriophage T4 DNA polymerase, T7 sequenase version 2.0 DNA polymerase, the Stoffel fragment of *Taq* polymerase and *Pfu* polymerase have been tested for the nascent DNA fragment synthesis. The activity profiles of the resulting five populations [see Step (5)] are shown in FIG. 13. To generate these profiles, activities of the individual clones measured in the 96-well plate screening assay are plotted in descending order. The Library/Stoffel and Library/Klenow contain higher percentage of wild-type or inactive subtilisin E clones than that of the Library/*Pfu*. In all five populations, percentage of the wild-type and inactive clones ranges from 17-30%.

**EXAMPLE 7**

**Use of defined flanking primers and staggered extension  
to recombine single stranded DNA**

This example demonstrates the use of the defined primer recombination with staggered extension in the recombination of single stranded DNA.

**Method Description**

Single-stranded DNA can be prepared by a variety of methods, most easily from plasmids using helper phage. Many vectors in current use are derived from filamentous phages, such as M13mp derivatives. After transformation into cells, these vectors can give rise both to new double-stranded circles and to single-stranded circles derived from one of the two strands of the vector. Single-stranded circles are packaged into phage particles, secreted from cells and can be easily purified from the culture supernatant.

Two defined primers (for example, hybridizing to 5' and 3' ends of the templates) are used here to recombine single stranded genes. Only one of the primers is needed before the final PCR amplification. Extended recombination primers are first generated by the staggered extension process (StEP), which consists of repeating cycles of denaturation followed by extremely abbreviated annealing/extension step(s). The extended fragments are then reassembled into full-length genes by thermocycling-assisted homologous gene assembly in the presence of a DNA polymerase, followed by a gene amplification step.

The progress of the staggered extension process is monitored by removing aliquots (10 ul) from the reaction tube (100 ul starting volume) at various time points in the primer extension and separating DNA fragments by agarose gel electrophoresis. Evidence of effective primer extension is seen as appearance of a low molecular weight 'smear' early in the process which increases in molecular weight with increasing cycle number. Initial reaction conditions are set to allow template denaturation (for example, 94°C-30 second denaturation) followed by very brief annealing/extension step(s) (e.g. 55°C-1 to 15 seconds) repeated through 5-20 cycle increments prior to reaction sampling. Typically, 20-200 cycles of staggered extension are required to generate single stranded DNA 'smears' corresponding to sizes greater than the length of the complete gene.

The experimental design is as in Example 1. Two thermostable subtilisin E mutants R1 and R2 gene are subcloned into vector M13mp18 by restriction digestion with EcoRI and BamHI. Single stranded DNA is prepared as described (39).

#### *Two flanking primer based recombination*

Two defined primers, P5N (5'-CCGAG CGTTG CATAT GTGGA AG-3' (SEQ. ID. NO: 18), underlined sequence is NdeI restriction site) and P3B (5'-CGACT CTAGA GGATC CGATT C-3' (SEQ. ID. NO: 19), underlined sequence is BamHI restriction site), corresponding to 5' and 3' flanking primers, respectively, are used for recombination. Conditions (100 ul final volume): 0.15 pmol single-stranded DNA containing R1 and R2 gene (mixed at 1:1) are used as template, 15 pmol of one flanking primer (either P5N or P3B), 1x *Taq* buffer, 0.2 mM of each dNTP, 1.5 mM MgCl<sub>2</sub> and 0.25 U *Taq* polymerase. Program: 5 minutes of 95°C, 80-200 cycles of 30 seconds at 94°C, 5 seconds at 55°C. The single-stranded DNA products of correct size (approximately 1kb) are cut from 0.8% agarose gel after electrophoresis and purified using

QIAEX II gel extraction kit. This purified product is amplified by a conventional PCR. Condition (100 ul final volume): 1-10 ng of template, 30 pmol of each flanking primer, 1x *Taq* buffer, 0.2 mM of each dNTP, 1.5 mM  $MgCl_2$  and 0.25 U *Taq* polymerase. Program: 5 minutes at 95°C, 20 cycles of 30 seconds at 94°C, 30 seconds at 55°C, 1 minute at 72°C. The PCR product is purified, digested with *Nde*I and *Bam*HI and subcloned into pBE3 shuttle vector. This gene library is amplified in *E. coli* HB101 and transferred into *B. subtilis* DB428 competent cells for expression and screening, as described elsewhere (35). Thermostability of enzyme variants is determined in the 96-well plate format described previously (33).

This protocol results in the generation of novel sequences containing novel combinations of mutations from the parental sequences as well as novel point mutations. Screening allows the identification of enzyme variants that are more thermostable than the parent enzymes, as in Example 1.

As is apparent from the above examples, primer-based recombination may be used to explore the vast space of potentially useful catalysts for their optimal performance in a wide range of applications as well as to develop or evolve new enzymes for basic structure-function studies.

While the present specification describes using DNA-dependent DNA polymerase and single-stranded DNA as templates, alternative protocols are also feasible for using single-stranded RNA as a template. By using specific protein mRNA as the template and RNA-dependent DNA polymerase (reverse transcriptase) as the catalyst, the methods described herein may be modified to introduce mutations and crossovers into cDNA clones and to create molecular diversity directly from the mRNA level to achieve the goal of optimizing protein functions. This would greatly simplify the ETS (expression-tagged strategy) for novel catalyst discovery.

In addition to the above, the present invention is also useful to probe proteins from obligate intracellular pathogens or other systems where cells of interest cannot be propagated (38).

Having thus described exemplary embodiments of the present invention, it should be noted by those skilled in the art that the within disclosures are exemplary only and that various other alternatives, adaptations, and modifications may be made within the scope of the present invention. Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is only limited by the following claims.

BIBLIOGRAPHY

1. Shao, Z. and Arnold F. H. 1996. Engineering new functions and altering existing functions. *Curr. Opin. Struct. Biol.* 6: 513-518.
2. Holland, J. H. 1975. *Adaption in natural and artificial systems*. The University Press, Ann Arbor.
3. Goldberg, D. E. 1989. *Genetic algorithms in search, optimization and machine learning*. Addison-Wesley. Reading.
4. Eigen, M. 1971. Self-organization of matter and the evolution of biological macromolecules. *Naturwissenschaften* 58: 465-523.
5. Rechenberg, I. 1973. *Evolutionstrategie: Optimierung technischer Systeme nach Prinzipien der biologischen Evolution*. Frommann-Holzboog, Stuttgart.
6. Brady, R. M. 1985. Optimization strategies gleaned from biological evolution. *Nature* 317: 804-806.
7. Muhlenbein, H. 1991. The parallel genetic algorithm as function optimizer. *Parallel Computing* 17:619-632.
8. Pál, K. F. 1993. Genetic algorithms for the traveling salesman problem-based on a heuristic crossover operation. *Bio. Cybern.* 69: 539-546.
9. Pál, K. F. 1995. Genetic algorithm with local optimization. *Bio.Cybern.* 73, 335-341.
10. Joyce, G. F. 1992. Directed molecular evolution. *Scientific American*, 267:90-97.
11. Arnold, F. H. 1996. Directed evolution - creating biocatalysts for the future. *Chem. Eng. Sci.* 51:5091-5102.
12. Abelson JN, Ed. 1996. *Combinatorial chemistry. Methods in Enzymology*, 267. Academic Press, Inc., San Diego.
13. Warren MS, Benkovic SJ. 1997. Combinatorial manipulation of three key active site residues in glycinamide ribonucleotide transformylase. *Protein Engineering* 10:63-68.
14. Wang C-I, Yang Q, Craik CS. 1996. Phage display of proteases and macromolecular inhibitors. *Methods in Enzymology* 267:52-68.
15. Moore, J. C. and Arnold, F. H. 1996. Directed evolution of a para-nitrobenzyl esterase for aqueous-organic solvents. *Nature Biotech.* 14: 458-467.
16. Reidhaar-Olson, J. F. and Sauer, R. T. 1988. Combinatorial cassette mutagenesis as a probe of the informational content of protein sequences. *Science* 241: 53-57.
17. Stemmer, W. P. C. 1994a. Rapid evolution of a protein in vitro by DNA shuffling. *Nature*, 370: 389-391.

18. Stemmer, W. P. C. 1994b. DNA shuffling by random fragmentation and reassembly -*in vitro* recombination for molecular evolution. Proc. Natl. Acad. Sci., USA, 91:10747-10751.
19. U.S. Patent No. 5,605,793.
20. Moore, J. C., H.-M. Jin, O. Kuchner and F. H. Arnold. 1997. Strategies for the *in vitro* Evolution of Protein Function: Enzyme Evolution by Random combination of Improved Sequences, J. Molecular Biology, in press.
21. Klenow, H. and I. Henningsen. 1970. Selective elimination of the exonuclease activity of the deoxyribonucleic acid polymerase from *Escherichia coli* B by limited proteolysis. Proc. Natl. Acad. Sci. 65:168
22. Feinberg, A. P. and Vogelstein, B. 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132: 6-13.
23. Nossal, N.G. 1974. DNA synthesis on a double-stranded DNA template by the T4 bacteriophage DNA polymerase and the T4 gene 32 DNA unwinding protein. J. Biol. Chem. 249: 5668-5676.
24. Ehrlich, H.A., PCR Technology, Stockton Press (1989).
25. Oliphant, A. R., Nussbaum, A. L., and Struhl, K. 1986. Cloning of random-sequence oligodeoxynucleotides. Gene 44: 177-183.
26. Hermes, J. D., Blacklow, S. C., and Knowles, J. R. 1990. Searching sequence space by definably random mutagenesis - improving the catalytic potency of an enzyme. Proc. Natl. Acad. Sci. USA 87: 696-700.
27. Leung, D. W., Chen, E., and Goeddel, D. V. 1989. A method for random mutagenesis of a defined DNA segment using a modified polymerase chain reaction. BioTechnique 1: 11-15.
28. Chen, K. and Arnold, F. H. 1993. Tuning the activity of an enzyme for unusual environments: sequential random mutagenesis of subtilisin E for catalysis in dimethylformamide. Proc. Natl. Acad. Sci. USA 90:5681-5622.
29. Sambrook, J., Fritsch, E. F. and Maniatis, T. 1989. Molecular cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
30. Hodgson, C. P. and Fisk R.Z. 1987. Hybridization probe size control: optimized 'oligolabeling'. Nucleic Acids Res. 15:6296.
31. Tabor, S. and Richardson, C. C. 1987. DNA sequence analysis with a modified bacteriophage T7 DNA polymerase. Proc. Natl. Acad. Sci., USA, 84:4767-4771.
32. Tabor, S. and Richardson, C. C. 1989. Selective inactivation of the exonuclease activity of bacteriophage-T7 DNA polymerase by *in vitro* mutagenesis. J.Biol.Chem. 264:6447-6458.



33. Zhao, H. and Arnold, F.H. 1997. Functional and non-functional mutations distinguished by random recombination of homologous genes. *Proc. Natl. Acad. Sci. USA* 94:7997-8000.
34. Zock, J., Cantwell, C., Swartling, J., Hodges, R., Pohl, T., Sutton, K., Rosteck Jr., P., McGilvray, D. & Queener, S. 1994. The *Bacillus subtilis* pnbA gene encoding p-nitrobenzyl esterase - cloning, sequence and high-level expression in *Escherichia coli*. *Gene*, 151, 37-43.
35. Zhao, H. and Arnold, F.H. 1997. Optimization of DNA shuffling for high fidelity recombination. *Nucleic Acids Research*, 25:1307-1308.
36. Lehman, I. R. and Richardson, C. C. 1964. The deoxyribonucleases of *Escherichia coli*. IV. An exonuclease activity present in purified preparations of deoxyribonucleic acid polymerase. *J. Biol. Chem.* 239:233.
37. Shafikhani, S., Siegel, R. A., Ferrari, E. & Schellenberger, V. 1997. Generation of large libraries of random mutants in *Bacillus subtilis* by PCR-based plasmid multimerization. *Biotechniques*, in press.
38. Ebel, T., Middleton, J. F. S., Frisch, A., and Lipp, J. 1997. Characterization of a secretory type *Theileria parva* glutaredoxin homologue identified by novel screening procedure. *J. Biol. Chem.* 272 (5): 3042-3048.
39. Messing, J. 1983. *Methods Enzymology* 101:20-78.
40. Innis, M. A. et al., 1988. *Proc. Natl. Acad. Sci.* 85:9436-9440.

## SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- (i) APPLICANTS: Frances H. Arnold  
Zhixin Shao  
Joseph A. Affholter  
Huimin Zhao  
Lorraine J. Giver
  - (ii) TITLE OF INVENTION: Recombination of Polynucleotide Sequences Using Defined or Random Primer Sequences
  - (iii) NUMBER OF SEQUENCES: 36
  - (iv) CORRESPONDENCE ADDRESS:
    - (A) ADDRESSEE: Oppenheimer Wolff & Donnelly LLP
    - (B) STREET: 2029 Century Park East, Suite 3800
    - (C) CITY: Los Angeles
    - (D) STATE: CA
    - (E) COUNTRY: USA
    - (F) ZIP: 90067
  - (v) COMPUTER READABLE FORM:
    - (A) MEDIUM TYPE: Floppy disk
    - (B) COMPUTER: IBM PC compatible
    - (C) OPERATING SYSTEM: Windows
    - (D) SOFTWARE: Microsoft Word 6.0
  - (vi) CURRENT APPLICATION DATA:
    - (A) APPLICATION NUMBER:
    - (B) FILING DATE:
    - (C) CLASSIFICATION:
  - (vii) PRIOR APPLICATION DATA:
    - (A) APPLICATION NUMBER: 60/041,666
    - (B) FILING DATE: March 25, 1997
    - (C) APPLICATION NUMBER: 60/045,211
    - (D) FILING DATE: April 30, 1997
    - (E) APPLICATION NUMBER: 60/046,256
    - (F) FILING DATE: May 12, 1997
    - (G) APPLICATION NUMBER: 08/905,359
    - (H) FILING DATE: August 4, 1997
  - (viii) ATTORNEY/AGENT INFORMATION:
    - (A) NAME: Oldenkamp, David J.
    - (B) REGISTRATION NUMBER: 29,421
    - (C) REFERENCE/DOCKET NUMBER: 330187-89
  - (ix) TELECOMMUNICATION INFORMATION:
    - (A) TELEPHONE: (310) 788-5000
    - (B) TELEFAX: (310) 277-1297
- (2) INFORMATION FOR SEQ ID NO: 1:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 22 nucleotides
    - (B) TYPE: nucleotide

- (C) TOPOLOGY: linear
- (ii) MOLECULE TYPE: oligonucleotide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
- CCG AGC GTT GCA TAT GTG GAA G 22
- (2) INFORMATION FOR SEQ ID NO: 2:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 nucleotides
- (B) TYPE: nucleotide
- (C) TOPOLOGY: linear
- (ii) MOLECULE TYPE: oligonucleotide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
- CGA CTC TAG AGG ATC CGA TTC 21
- (2) INFORMATION FOR SEQ ID NO: 3:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 nucleotides
- (B) TYPE: nucleotide
- (C) TOPOLOGY: linear
- (ii) MOLECULE TYPE: oligonucleotide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
- GAG CAC ATC AGA TCT ATT AAC 21
- (2) INFORMATION FOR SEQ ID NO: 4:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 nucleotides
- (B) TYPE: nucleotide
- (C) TOPOLOGY: linear
- (ii) MOLECULE TYPE: oligonucleotide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
- GGA GTG GCT CAC AGT CGG TGG 21
- (2) INFORMATION FOR SEQ ID NO: 5:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 nucleotides
- (B) TYPE: nucleotide
- (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TTG AAC TAT CGG CTG GGG CGG 21

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 nucleotides

(B) TYPE: nucleotide

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

TTA CTA GGG AAG CCG CTG GCA 21

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 nucleotides

(B) TYPE: nucleotide

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

TCA GAG ATT ACG ATC GAA AAC 21

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 nucleotides

(B) TYPE: nucleotide

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGA TTG TAT CGT GTG AGA AAG 21

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 nucleotides

(B) TYPE: nucleotide

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

AAT GCC GGA AGC AGC CCC TTC

21

(2) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

CAC GAC AGG AAG ATT TTG ACT

21

(2) INFORMATION FOR SEQ ID NO: 11:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

ACT TAA TCT AGA GGG TAT TA

20

(2) INFORMATION FOR SEQ ID NO: 12:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

AGC CTC GCG GGA TCC CCG GG

20

(2) INFORMATION FOR SEQ ID NO: 13:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 28 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GGT AGA GCG AGT CTC GAG GGG GAG ATG C

28

## (2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

- (ii) MOLECULE TYPE: oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

AGC CGG CGT GAC GTG GGT CAG C

22

## (2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

- (ii) MOLECULE TYPE: oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

CCG AGC GTT GCA TAT GTG GAA G

22

## (2) INFORMATION FOR SEQ ID NO: 16:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

- (ii) MOLECULE TYPE: oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

CGA CTC TAG AGG ATC CGA TTC

21

## (2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

- (ii) MOLECULE TYPE: oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

CGG TAC GCA TGT AGC CGG TAC G

22



## (2) INFORMATION FOR SEQ ID NO: 18:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

- (ii) MOLECULE TYPE: oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

CGG TAC GAT TGC CGC CGG TAC G

22

## (2) INFORMATION FOR SEQ ID NO: 19:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

- (ii) MOLECULE TYPE: oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

CCG AGC GTT GCA TAT GTG GAA G

22

## (2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

- (ii) MOLECULE TYPE: oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

CGA CTC TAG AGG ATC CGA TTC

21

## (2) INFORMATION FOR SEQ ID NO: 21:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 18 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

- (ii) MOLECULE TYPE: oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GGC GGA GCT AGC TTC GTA

18

## (2) INFORMATION FOR SEQ ID NO: 22:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 18 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GAT GTG ATG GCT CCT GGC

18

(2) INFORMATION FOR SEQ ID NO: 23:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 18 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

CAG AAC ACC GAT TGA GTT

18

(2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 18 nucleotides
  - (B) TYPE: nucleotide
  - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

AGT GCT TTC TAA ACG ATC

18

(2) INFORMATION FOR SEQ ID NO: 25:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH 4 amino acids
  - (B) TYPE: peptide
  - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Ala Ala Pro Phe

(2) INFORMATION FOR SEQ ID NO: 26:

- (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4050 nucleotides  
(B) TYPE: nucleotide  
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: polynucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

|  |      |
|--|------|
| GGGATCCTCT AAAGTCGACC TGCAGCGTGC CCAGCTGTTC GTGGTGGTGA TCGCGGCCGC  | 60   |
| GCTGGCCGCC GTCGCGGTCT CCGCCGCCGG GCCGATCGAG TTCGTCGCCT TCGTCGTGCC  | 120  |
| GCAGATCGCC CTGCGGCTCT GCGGCGGCAG CCGGCCGCCCT CTGCTCGCCT CGGCGATGCT | 180  |
| CGGCGCGCTG CTGGTGGTCT GCGCCGACCT GGTCTGCTCAG ATCGTGGTGG CGCCGAAGGA | 240  |
| GCTGCCGGTC GGCCTGCTCA CCGCGATGAT CGGCACCCCG TACCTGCTCT GGCTCCTGCT  | 300  |
| TCGGCGATCA AGAAAGGTGA GCGGATGAAC GCCCGCCTGC GTGGCGAGGG CCTGCACCTC  | 360  |
| GCGTACGGGG ACCTGACCGT GATCGACGGC CTCGACGTCG ACGTGCACGA CGGGCTGGTC  | 420  |
| ACCACCATCA TCGGGCCCAA CGGGTGCGGC AAGTCGACGC TGCTCAAGGC GCTCGGCCGG  | 480  |
| CTGCTGCGCC CGACCGGCGG GCAGGTGCTG CTGGACGGCC GCCGCATCGA CCGGACCCCC  | 540  |
| ACCCGTGACG TGGCCCGGGT GCTCGGCGTG CTGCCGCAGT CGCCCACCGC GCCCGAAGGG  | 600  |
| CTCACCGTCG CCGACCTGGT GATGCGCGGC CGGCACCCGC ACCAGACCTG GTTCCGGCAG  | 660  |
| TGGTCGCGCG ACGACGAGGA CCAGGTCGCC GACGCGCTGC GCTGGACCGA CATGCTGGCG  | 720  |
| TACGCGGACC GCCCGGTGGA CGCCCTCTCC GGCGGTCAGC GCCAGCGCGC CTGGATCAGC  | 780  |
| ATGGCGCTGG CCCAGGGCAC CGACCTGCTG CTGCTGGACG AGCCGACCAC CTTCTCTGAC  | 840  |
| CTGGCCCACC AGATCGACGT GCTGGACCTG GTCCGCCGGC TGCACGCCGA GATGGGCCGG  | 900  |
| ACCGTGGTGA TGGTGCTGCA CGACCTGAGC CTGGCCGCCC GGTACGCCGA CCGGCTGATC  | 960  |
| GCGATGAAGG ACGGCCGGAT CGTGCGGAGC GGGGCGCCGG ACGAGGTGCT CACCCCGGCG  | 1020 |
| CTGCTGGAGT CGGTCTTCGG GCTGCGCGCG ATGGTGGTGC CCGACCCGGC GACCGGCACC  | 1080 |
| CCGCTGGTGA TCCCCCTGCC GCGCACCGCC ACCTCGGTGC GGGCCTGAAA TCGATGAGCG  | 1140 |
| TGGTTGCTTC ATCGGCCTGC CGAGCGATGA GAGTATGTGG GCGGTAGAGC GAGTCCCGAG  | 1200 |
| GGGGAGATGC CGCCGTGACG TCCTCGTACA TGCGCCTGAA AGCAGCAGCG ATCGCCTTCG  | 1260 |
| GTGTGATCGT GGCGACCGCA ACCGTGCCGT CACCCGCTTC CGGCAGGGAA CATGACGGCG  | 1320 |
| GCTATGCGGC CCTGATCCGC CGGGCCTCGT ACGGCGTCCC GCACATCACC GCCGACGACT  | 1380 |
| TCGGGAGCCT CGGTTTCGGC GTCGGGTACG TGCAGGCCGA GGACAACATC TCGGTCATCG  | 1440 |
| CCGAGAGCGT GGTGACGGCC AACGGTGAGC GGTCGCGGTG GTTCGGTGCG ACCGGGCCGG  | 1500 |

ACGACGCCGA TGTGCGCAGC GACCTCTTCC ACCGCAAGGC GATCGACGAC CGCGTCGCCG 1560  
AGCGGCTCCT CGAAGGGCCC CGCGACGGCG TGCGGGCGCC GTCGGACGAC GTCCGGGACC 1620  
AGATGCGCGG CTTCGTGCCG GGCTACAACC ACTTCCTACG CCGCACCGGC GTGCACCGCC 1680  
TGACCGACCC GCGGTGCCGC GGCAAGGCCT GGGTGCGCCC GCTCTCCGAG ATCGATCTCT 1740  
GGCGTACATT GTGGGACAGC ATGGTCCGGG CCGGTTCCGG GCGCTGCTC GACGGCATCG 1800  
TCGCCGCGAC GCCACCGACA GCCGCCGGGC CCGCGTCAGC CCCGGAGGCA CCCGACGCCG 1860  
CCGCGATCGC CGCCGCCCTC GACGGGACGA GCGCGGGCAT CCGCAGCAAC GCGTACGGCC 1920  
TCGGCGCGCA GGCCACCGTG AACGGCAGCG GGATGGTGCT GGCCAACCCG CACTTCCCGT 1980  
GGCAGGGCGC CGCACGCTTC TACCGGATGC ACCTCAAGGT GCCCGGCCGC TACGACGTCG 2040  
AGGGCGCGGC GCTGGTCGGC GACCCGATCA TCGAGATCGG GCACAACCGC ACGGTCGCCT 2100  
GGAGCCACAC CGTCTCCACC GCCCGCCGGT TCGTGTGGCA CCGCCTGAGC CTCGTGCCCG 2160  
GCGACCCAC CTCCTATTAC GTCGACGGCC GGCCCGAGCG GATGCGCGCC CGCACGGTCA 2220  
CGGTCCAGAC CCGCAGCGGC CCGGTCAGCC GCACCTTCCA CGACACCCGC TACGGCCCGG 2280  
TGGCCGTGGT GCCGGGCACC TTCGACTGGA CGCCGGCCAC CGCGTACGCC ATCACCGACG 2340  
TCAACGCGGG CAACAACCGC GCCTTCGACG GGTGGCTGCG GATGGGCCAG GCCAAGGACG 2400  
TCCGGGCGCT CAAGGCGGTC CTCGACCGGC ACCAGTTCTT GCCCTGGGTC AACGTGATCG 2460  
CCGCCGACGC GCGGGGCGAG GCCCTCTACG GCGATCATTC GGTCGTCCCC CGGGTGACCG 2520  
GCGCGCTCGC TGCCGCCTGC ATCCCGGCGC CGTTCCAGCC GCTCTACGCC TCCAGCGGCC 2580  
AGGCGGTCCT GGACGGTTCC CGGTCCGACT GCGCGCTCGG CGCCGACCCC GACGCCGCGG 2640  
TCCCGGGCAT TCTCGGCCCC GCGAGCCTGC CCGTGCGGTT CCGCGACGAC TACGTCACCA 2700  
ACTCCAACGA CAGTCACTGG CTGGCCAGCC CGGCCGCCCC GCTGGAAGGC TTCCCGCGGA 2760  
TCCTCGGCAA CGAACGCACC CCGCGCAGCC TGCGCACCCG GCTCGGGCTG GACCAGATCC 2820  
AGCAGCGCCT CGCCGGCACG GACGGTCTGC CCGGCAAGGG CTTACCACC GCCCGGCTCT 2880  
GGCAGGTCAT GTTCGGCAAC CGGATGCAGC GCGCCGAACT CGTCCGCGAC GACCTGGTCG 2940  
CGCTCTGCCG CCGCCAGCCG ACCGCGACCG CCTCGAACGG CGCGATCGTC GACCTCACCG 3000  
CGGCCTGCAC GCGGCTGTCC CGCTTCGATG AGCGTGCCGA CCTGGACAGC CGGGGCGCGC 3060  
ACCTGTTTAC CGAGTTCGCC CTCGCGGGCG GAATCAGGTT CGCCGACACC TTCGAGGTGA 3120  
CCGATCCGGT ACGCACCCCG CGCCGTCTGA ACACCACGGA TCCGCGGGTA CGGACGGCGC 3180  
TCGCCGACGC CGTGCAACGG CTCGCCGGCA TCCCCCTCGA CGCGAAGCTG GGAGACATTC 3240

- 57 -

```

ACACCGACAG CCGCGGCGAA CGGCGCATCC CCATCCACGG TGGCCGCGGG GAAGCAGGCA 3300
CCTTCAACGT GATCACCAAC CCGCTCGTGC CGGGCGTGGG ATACCCGCAG GTCGTCCACG 3360
GAACATCGTT CGTGATGGCC GTCGAACTCG GCGCGCACGG CCCGTGCGGA CGGCAGATCC 3420
TCACCTATGC GCAGTCGACG AACCCGAACT CACCCTGGTA CGCCGACCAG ACCGTGCTCT 3480
ACTCGCGGAA GGGCTGGGAC ACCATCAAGT ACACCGAGGC GCAGATCGCG GCCGACCCGA 3540
ACCTGCGCGT CTACCGGGTG GCACAGCGGG GACGCTGACC CACGTCACGC CGGCTCGGCC 3600
CGTGCGGGGG CGCAGGGCGC CGATCGTCTC TGCATCGCCG GTCAGCCGGG GCCTGCGTCG 3660
ACCGGCGGCG GCCGGTCGAC GCGCGCTCC CGGCGCAGCG ACTGGCTGAA GCGCCAGGCG 3720
TCGGCGGCCC GGGGCAGGTT GTTGAACATC ACGTACGCCG GGCCGCCGTC GAGGATGCCG 3780
GCGAGGTGTG CCAGCTCGGC ATCCGTGTAC ACATGCCGGG CGCCGGTGAT GCCGTGCAGC 3840
CGGTAATAGG CCATCGGCGT CAGACTGCGG CGCAGGAACG GGTGCGCGGC GTGGGTCAGG 3900
TCCAGCTCCT GGCACAAGCC CTCGACCACC TCGTCCGGCC ACGGGCCGCG CGGCTCCCAC 3960
AACAGCCGGA CACCGGCCGG CCGGCGCGCT CGGGCGCAGA ACTCACGCAG TCGCGCGATG 4020
GCGGGTTCGG TCGGCCGGAA ACTCGCCGGG 4050

```

## (2) INFORMATION FOR SEQ ID NO: 27:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4101 nucleotides
- (B) TYPE: nucleotide
- (C) TOPOLOGY: linear

## (ii) MOLECULE TYPE: polynucleotide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

```

AAGCTTGCAT GCCTGCAGCG TGCCAGCTG TTCGTGGTGG TGATCGCGGC CGCGCTGGCC 60
GCCGTCGCGG TCGCCGCCGC CGGGCCGATC GAGTTCGTCG CCTTCGTCGT GCCGCAGATC 120
GCCCTGCGGC TCTGCGGCGG CAGCCGGCCG CCCCTGCTCG CCTCGGCGAT GCTCGGCGCG 180
CTGCTGGTGG TCGGCGCCGA CCTGGTCGCT CAGATCGTGG TGGCGCCGAA GGAGCTGCCG 240
GTCGGCCTGC TCACCGCGAT GATCGGCACC CCGTACCTGC TCTGGCTCCT GCTTCGGCGA 300
TCAAGAAAGG TGAGCGGATG AACGCCCCGC TCGTGCGGA GGGCCTGCAC CTCGCGTACG 360
GGGACCTGAC CGTGATCGAC GGCCTCGACG TCGACGTGCA CGACGGGCTG GTCACCACCA 420
TCATCGGGCC CAACGGGTGC GGCAAGTCGA CGCTGCTCAA GCGCTCGGC CGGCTGCTGC 480
GCCCGACCGG CGGGCAGGTG CTGCTGGACG GCCGCCGCAT CGACCGGACC CCCACCCGTG 540

```

ACGTGGCCCG GGTGCTCGGC GTGCTGCCGC AGTCGCCCAC CGCGCCCGAA GGGCTCACCG 600  
TCGCCGACCT GGTGATGCGC GGCCGGCACC CGCACCAGAC CTGGTTCCGG CAGTGGTCGC 660  
GCGACGACGA GGACCAGGTC GCCGACGCGC TCGCTGGAC CGACATGCTG GCGTACGCGG 720  
ACCGCCCGGT GGACGCCCTC TCCGGCGGTC AGCGCCAGCG CGCCTGGATC AGCATGGCGC 780  
TGGCCCAGGG CACCGACCTG CTGCTGCTGG ACGAGCCGAC CACCTTCCTC GACCTGGCCC 840  
ACCAGATCGA CGTGCTGGAC CTGGTCCGCC GGCTGCACGC CGAGATGGGC CGGACCGTGG 900  
TGATGGTGCT GCACGACCTG AGCCTGGCCG CCCGGTACGC CGACCGGCTG ATCGCGATGA 960  
AGGACGGCCG GATCGTGGCG AGCGGGGCGC CGGACGAGGT GCTCACCCCG GCGCTGCTGT 1020  
AGTCGGTCTT CGGGCTGCGC GCGATGGTGG TGCCCGACCC GGCGACCGGC ACCCCGCTGG 1080  
TGATCCCCCT GCCGCGCACC GCCACCTCGG TCGGGGCCTG AAATCGATGA GCGTGGTTGC 1140  
TTCATCGGCC TGCCGAGCGA TGAGAGTATG TGGGCGGTAG AGCGAGTCTC GAGGGGGAGA 1200  
TGCCGCCGTG ACGTCCTCGT ACATGCGCCT GAAAGCAGCA GCGATCGCCT TCGGTGTGAT 1260  
CGTGGCGACC GCAGCCGTGC CGTCACCCGC TTCCGGCAGG GAACATGACG GCGGCTATGC 1320  
GGCCCTGATC CGCCGGGCCT CGTACGGCGT CCCGCACATC ACCGCCGACG ACTTCGGGAG 1380  
CCTCGGTTTC GGCGTCGGGT ACGTGCAGGC CGAGGACAAC ATCTGCGTCA TCGCCGAGAG 1440  
CGTGGTAACG GCCAACGGTG AGCGGTCGCG GTGGTTCCGT GCGACCGGGC CGGACGACGC 1500  
CGATGTGCGC AGCGACCTCT TCCACCGCAA GGCGATCGAC GACCGCGTCG CCGAGCGGCT 1560  
CCTCGAAGGG CCCCGCGACG GCGTGCGGGC GCCGTCCGAC GACGTCCGGG ACCAGATGCG 1620  
CGGCTTCGTC GCCGGCTACA ACCACTTCCT ACGCCGCACC GCGTGCACC GCCTGACCGA 1680  
CCCGGCGTGC CGCGGCAAGG CCTGGGTGCG CCCGCTCTCC GAGATCGATC TCTGGCGTAC 1740  
GTCGTGGGAC AGCATGGTCC GGGCCGGTTC CGGGGCGCTG CTCGACGGCA TCGTCGCCGC 1800  
GACGCCACCT ACAGCCGCCG GGCCCGCGTC AGCCCCGGAG GCACCCGACG CCGCCGCGAT 1860  
CGCCGCCGCC CTCGACGGGA CGAGCGCGGG CATCGGCAGC AACCGGTACG GCCTCGGCGC 1920  
GCAGGCCACC GTGAACGGCA GCGGGATGGT GCTGGCCAAC CCGCACTTCC CGTGGCAGGG 1980  
CGCCGAACGC TTCTACCGGA TGCACCTCAA GGTGCCCCGC CGCTACGACG TCGAGGGCGC 2040  
GGCGCTGATC GGCGACCCGA TCATCGGGAT CGGGCACAAC CGCACGGTCG CCTGGAGCCA 2100  
CACCGTCTCC ACCGCCCGCC GGTTCGTGTG GCACCGCCTG AGCCTCGTGC CCGGCGACCC 2160  
CACCTCCTAT TACGTCGACG GCCGGCCCGA GCGGATGCGC GCCCGCACGG TCACGGTCCA 2220  
GACCGGCAGC GGCCCGGTCA GCCGCACCTT CCACGACACC CGCTACGGCC CCGTGGCCGT 2280



GATGCCGGGC ACCTTCGACT GGACGCCGGC CACCGCGTAC GCCATCACCG ACGTCAACGC 2340  
GGGCAACAAC CGCGCCTTCG ACGGGTGGCT GCGGATGGGC CAGGCCAAGG ACGTCCGGGC 2400  
GCTCAAGGCG GTCCTCGACC GGCACCAGTT CCTGCCCTGG GTCAACGTGA TCGCCGCCGA 2460  
CGCGCGGGGC GAGGCCCTCT ACGGCGATCA TTCGGTCGTC CCCCGGGTGA CCGGCGCGCT 2520  
CGCTGCCGCC TGCATCCCGG CGCCGTTCGA GCCGCTCTAC GCCTCCAGCG GCCAGGCGGT 2580  
CCTGGACGGT TCCCGGTCGG ACTGCGCGCT CGGCGCCGAC CCGACGCCG CCGTCCCGGG 2640  
CATTCCTGGC CCGGCGAGCC TGCCGGTGCG GTTCCGCGAC GACTACGTCA CCAACTCCAA 2700  
CGACAGTCAC TGGCTGGCCA GCCCGGCCGC CCCGCTGGAA GGCTTCCCGC GGATCCTCGG 2760  
CAACGAACGC ACCCGCGCA GCCTGCGCAC CCGGCTCGGG CTGGACCAGA TCCAGCAGCG 2820  
CCTCGCCGGC ACGGACGGTC TGCCCGGCAA GGGCTTCACC ACCGCCCGGC TCTGGCAGGT 2880  
CATGTTTCGGC AACCGGATGC ACGGCGCCGA ACTCGCCCGC GACGACCTGG TCGCGCTCTG 2940  
CCGCCGCCAG CCGACCGCGA CCGCCTCGAA CGGCGCGATC GTCGACCTCA CCGCGGCCTG 3000  
CACGGCGCTG TCCCGCTTCG ATGAGCGTGC CGACCTGGAC AGCCGGGGCG CGCACCTGTT 3060  
CACCGAGTTC GCCCTCGCGG GCGGAATCAG GTTCGCCGAC ACCTTCGAGG TGACCGATCC 3120  
GGTACGCACC CCGCGCCGTC TGAACACCAC GGATCCGCGG GTACGGACGG CGCTCGCCGA 3180  
CGCCGTGCAA CGGCTCGCCG GCATCCCCCT CGACGCGAAG CTGGGAGACA TCCACACCGA 3240  
CAGCCGCGGC GAACGGCGCA TCCCCATCCA CCGTGGCCGC GGGGAAGCAG GCACCTTCAA 3300  
CGTGATCACC AACCCGCTCG TGCCGGGCGT GGGATACCCG CAGGTCGTCC ACGGAACATC 3360  
GTTCTGTATG GCCGTGGAAC TCGGCCCGCA CGGCCCGTCG GGACGGCAGA TCCTCACCTA 3420  
TGCGCAGTCG ACGAACCCGA ACTCACCTG GTACGCCGAC CAGACCGTGC TCTACTCGCG 3480  
GAAGGGCTGG GACACCATCA AGTACACCGA GGCGCAGATC GCGGCCGACC CGAACCTGCG 3540  
CGTCTACCGG GTGGCACAGC GGGGACGCTG ACCCACGTCA CGCCGGCTCG GCCCGTGCGG 3600  
GGGCGCAGGG CGCCGATCGT CTCTGCATCG CCGGTCAGCC GGGGCTGCG TCGACCGGCG 3660  
GCGGCCGGTC GACGCCCGCG TCCCGGCGCA GCGACTGGCT GAAGCGCCAG GCGTCGGCGG 3720  
CCCGGGGCAG GTTGTTGAAC ATCACGTACG CCGGGCCGCC GTCGAGGATG CCGGCGAGGT 3780  
GTGCCAGCTC GGCATCCGTA TACACATGCC GGGCGCCGGT GATGCCGTGC AGCCGGTAAT 3840  
AGGCCATCGG CGTCAGACTG CGGCGCAGGA ACGGGTCGGC GCGGTGGGTC AGGTCCAGCT 3900  
CCTGGCACAA GCCCTCGACC ACCTCGTCCG GCCACGGGCC GCGCGGCTCC CACAACAGCC 3960  
GGACACCGGC CGGCCGGCGC GCTCGGGCGC AGAACTCACG CAGTCGCGCG ATGGCGGGTT 4020

CGGTCGGCCG GAAACTCGCC GGGCACTGCA GGTCGACTCT AGAGGATCCC CGGGTACCGA 4080  
GCTCGAATTC GTAATCATGT C 4101

(2) INFORMATION FOR SEQ ID NO: 28:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 4093 nucleotides  
(B) TYPE: nucleotide  
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: polynucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

AAGCTTGCAT GCCTGCAGCG TGCCCAGCTG TTCGTGGTGG TGATCGCGGC CGCGCTGGCC 60  
GCCGTCGCGG TCGCCGCCGC CGGGCCGATC GAGTTCGTGG CCTTCGTCTG GCCGCAGATC 120  
GCCCTGCGGC TCTGCGGCGG CAGCCGGCCG CCCCTGCTCG CCTCGGCGAT GCTCGGCGCG 180  
CTGCTGGTGG TCGGCGCCGA CCTGGTCGCT CAGATCGTGG TGGCGCCGAA GGAGCTGCCG 240  
GTCGGCCTGC TCACCGCGAT GATCGGCACC CCGTACCTGC TCTGGCTCCT GCTTCGGCGA 300  
TCAAGAAAGG TGAGCGGATG AACGCCCCGCC TGCCTGGCGA GGGCCTGCAC CTCGCGTACG 360  
GGGACCTGAC CGTGATCGAC GGCCTCGACG TCGACGTGCA CGACGGGCTG GTCACCACCA 420  
TCATCGGGCC CAACGGGTGC GGCAAGTCGA CGCTGCTCAA GCGCTCGGC CGGCTGCTGC 480  
GCCCCACCGG CGGGCAGGTG CTGCTGGACG GCCGCCGCAT CGACCGGACC CCCACCCGTG 540  
ACGTGGCCCCG GGTGCTCGGC GTGCTGCCGC AGTCGCCAC CGCGCCCGAA GGGCTCACCG 600  
TCGCCGACCT GGTGATGCGC GGCCGGCACC CGCACCAGAC CTGGTTCCGG CAGTGGTCGC 660  
GCGACGACGA GGACCAGGTC GCCGACGCGC TCGCTGGAC CGACATGCTG GCGTACGCGG 720  
ACCGCCCGGT GGACGCCCTC TCCGGCGGTC AGCGCCAGCG CGCCTGGATC AGCATGGCGC 780  
TGGCCCAGGG CACCGACCTG CTGCTGCTGG ACGAGCCGAC CACCTTCCTC GACCTGGCCC 840  
ACCAGATCGA CGTGCTGGAC CTGGTCCGCC GGCTGCACGC CGAGATGGGC CGGACCGTGG 900  
TGATGGTGCT GCACGACCTG AGCCTGGCCG CCCGGTACGC CGACCGGCTG ATCGCGATGA 960  
AGGACGGCCG GATCGTGGCG AGCGGGGCGC CGGACGAGGT GCTCACCCCG GCGCTGCTGG 1020  
AGTCGGTCTT CGGGCTGCGC GCGATGGTGG TGCCCGACCC GGCGACCGGC ACCCCGCTGG 1080  
TGATCCCCCT GCCGCGCACC GCCACCTCGG TGCGGGCCTG AAATCGATGA GCGTGGTTGC 1140  
TTCATCGGCC TGCCGAGCGA TGAGAGTATG TGGGCGGTAG AGCGAGTCCC GAGGGGGAGA 1200  
TGCCGCCGTG ACGTCCTCGT ACATGCGCCT GAAAGCAGCA GCGATCGCCT TCGGTGTGAT 1260

|            |            |            |            |            |            |      |
|------------|------------|------------|------------|------------|------------|------|
| CGTGGCGACC | GCAACCGTGC | CGTCACCCGC | TTCCGGCAGG | GAACATGACG | GCGGCTATGC | 1320 |
| GGCCCTGATC | CGCCGGGCCT | CGTACGGCGT | CCCGCACATC | ACCGCCGACG | ACTTCGGGAG | 1380 |
| CCTCGGTTTC | GGCGTCGGGT | ACGTGCAGGC | CGAGGACAAC | ATCTGCGTCA | TCGCCGAGAG | 1440 |
| CGTGGTGACG | GCCAACGGTG | AGCGGTCGCG | GTGGTTCGGT | GCGACCGGGC | CGGACGACGC | 1500 |
| CGATGTGCGC | AGCGACCTCT | TCCACCGCAA | GGCGATCGAC | GACCGCGTCG | CCGAGCGGCT | 1560 |
| CCTCGAAGGG | CCCCGCGACG | GCGTGCGGGC | GCCGTCGGAC | GACGTCCGGG | ACCAGATGCG | 1620 |
| CGGCTTCGTC | GCCGGCTACA | ACCACTTCCT | ACGCCGCACC | GGCGTGACCC | GCCTGACCGA | 1680 |
| CCCGGCGTGC | CGCGGCAAGG | CCTGGGTGCG | CCCGCTCTCC | GAGATCGATC | TCTGGCGTAC | 1740 |
| ATTGTGGGAC | AGCATGGTCC | GGGCCGGTTC | CGGGGCGCTG | CTCGACGGCA | TCGTGCGCCG | 1800 |
| GACGCCACCG | ACAGCCGCCG | GGCCCGCGTC | AGCCCCGGAG | GCACCCGACG | CCGCCGCGAT | 1860 |
| CGCCGCCGCC | CTCGACGGGA | CGAGCGCGGG | CATCGGCAGC | AACGCGTACG | GCCTCGGCGC | 1920 |
| GCAGGCCACC | GTGAACGGCA | GCGGGATGGT | GCTGGCCAAC | CCGCACCTTC | CGTGGCAGGG | 1980 |
| CGCCGCACGC | TTCTACCGGA | TGCACCTCAA | GGTGCCCGGC | CGCTACGACG | TCGAGGGCGC | 2040 |
| GGCGCTGGTC | GGCGACCCGA | TCATCGAGAT | CGGGCACAAC | CGCACGGTCG | CCTGGAGCCA | 2100 |
| CACCGTCTCC | ACCGCCCGCC | GGTTCGTGTG | GCACCGCCTG | AGCCTCGTGC | CCGGCGACCC | 2160 |
| CACCTCCTAT | TACGTCGACG | GCCGGCCCGA | GCGGATGCGC | GCCCGCACGG | TCACGGTCCA | 2220 |
| GACCGGCAGC | GGCCCGGTCA | GCCGCACCTT | CCACGACACC | CGCTACGGCC | CGGTGGCCGT | 2280 |
| GGTGCCGGGC | ACCTTCGACT | GGACGCCGGC | CACCGCGTAC | GCCATCACCG | ACGTCAACGC | 2340 |
| GGGCAACAAC | CGCGCCTTCG | ACGGGTGGCT | GCGGATGGGC | CAGGCCAAGG | ACGTCCGGGC | 2400 |
| GCTCAAGGCG | GTCCTCGACC | GGCACCAGTT | CCTGCCCTGG | GTCAACGTGA | TCGCCGCCGA | 2460 |
| CGCGCGGGGC | GAGGCCCTCT | ACGGCGATCA | TTCGGTCGTC | CCCCGGGTGA | CCGGCGCGCT | 2520 |
| CGCTGCCGCC | TGCATCCCGG | CGCCGTTCCT | GCCGCTCTAC | GCCTCCAGCG | GCCAGGCGGT | 2580 |
| CCTGGACGGT | TCCCGGTCGG | ACTGCGCGCT | CGGCGCCGAC | CCCGACGCCG | CGGTCCCGGG | 2640 |
| CATTCTCGGC | CCGGCGAGCC | TGCCGGTGCG | GTTCCGCGAC | GACTACGTCA | CCAACTCCAA | 2700 |
| CGACAGTCAC | TGGCTGGCCA | GCCCGGCCGC | CCCGCTGGAA | GGCTTCCCGC | GGATCCTCGG | 2760 |
| CAACGAACGC | ACCCCGCGCA | GCCTGCGCAC | CCGGCTCGGG | CTGGACCAGA | TCCAGCAGCG | 2820 |
| CCTCGCCGGC | ACGGACGGTC | TGCCCCGGCA | GGGCTTCACC | ACCGCCCGGC | TCTGGCAGGT | 2880 |
| CATGTTCTGG | AACCGGATGC | ACGGCGCCGA | ACTCGTCCGC | GACGACCTGG | TCGCGCTCTG | 2940 |
| CCGCCGCCAG | CCGACCGCGA | CCGCCTCGAA | CGGCGCGATC | GTCGACCTCA | CCGCGGCCTG | 3000 |

CACGGCGCTG TCCCGCTTCG ATGAGCGTGC CGACCTGGAC AGCCGGGGCG CGCACCTGTT 3060  
CACCGAGTTC GCCCTCGCGG GCGGAATCAG GTTCGCCGAC ACCTTCGAGG TGACCGATCC 3120  
GGTACGCACC CCGCGCCGTC TGAACACCAC GGATCCGCGG GTACGGACGG CGCTCGCCGA 3180  
CGCCGTGCAA CGGCTCGCCG GCATCCCCCT CGACGCGAAG CTGGGAGACA TTCACACCGA 3240  
CAGCCGCGGC GAACGGCGCA TCCCCATCCA CGGTGGCCGC GGGGAAGCAG GCACCTTCAA 3300  
CGTGATCACC AACCCGCTCG TGCCGGGCGT GGGATACCCG CAGGTCGTCC ACGGAACATC 3360  
GTTCGTGATG GCCGTGGAAC TCGGCCCCGA CGGCCCGTCG GGACGGCAGA TCCTCACCTA 3420  
TGCGCAGTCG ACGAACCCGA ACTCACCTG GTACGCCGAC CAGACCGTGC TCTACTCGCG 3480  
GAAGGGCTGG GACACCATCA AGTACACCGA GGCGCAGATC GCGGCCGACC CGAACCTGCG 3540  
CGTCTACCGG GTGGCACAGC GGGGACGCTG ACCCACGTCA CGCCGGCTCG GCCCGTGCGG 3600  
GGGCGCAGGG CGCCGATCGT CTCTGCATCG CCGGTCAGCC GGGGCCTGCG TCGACCGGCG 3660  
GCGGCCGGTC GACGCCCGCG TCCCGGCGCA GCGACTGGCT GAAGCGCCAG GCGTCGGCGG 3720  
CCCGGGGCAG GTTGTTGAAC ATCACGTACG CCGGGCCGCC GTCGAGGATG CCGGCGAGGT 3780  
GTGCCAGCTC GGCATCCGTG TACACATGCC GGGCGCCGGT GATGCCGTGC AGCCGGTAAT 3840  
AGGCCATCGG CGTCAGACTG CGGCGCAGGA ACGGGTCGGC GGCCTGGGTC AGGTCCAGCT 3900  
CCTGGCACAA GCCCTCGACC ACCTCGTCCG GCCACGGGCC GCGCGGCTCC CACAACAGCC 3960  
GGACACCGGC CGGCCGGCGC GCTCGGGCGC AGAACTCACG CAGTCGCGCG ATGGCGGGTT 4020  
CGGTCGGCCG GAAACTCGCC GGGCACTGCA GGTGACTCT AGAGGATCCC CCGGGTACCG 4080  
AGCTCGAATT CGT 4093

## (2) INFORMATION FOR SEQ ID NO: 29:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3222 nucleotides
- (B) TYPE: nucleotide
- (C) TOPOLOGY: linear

## (ii) MOLECULE TYPE: polynucleotide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

GCCGGCTGCA CGCCGAGATG GGCCGGACCG TGGTGATGGT GCTGCACGAC CTGAGCCTGG 60  
CCGCCCCGTA CGCCGACCGG CTGATCGCGA TGAAGGACGG CCGGATCGTG GCGAGCGGGG 120  
CGCCGGACGA GGTGCTCACC CCGGCGCTGC TGGAGTCGGT CTTGGGGCTG CGCGCGATGG 180  
TGGTGCCCGA CCCGGCGACC GGCACCCCGC TGGTGATCCC CCTGCCGCGC ACCGCCACCT 240

CGGTGCGGGC CTGAAATCGA TGAGCGTGGT TGCTTCATCG GCCTGCCGAG CGATGAGAGT 300  
ATGTGGGCGG TAGAGCGAGT CCCGAGGGGG AGATGCCGCC GTGACGTCCT CGTACATGCG 360  
CCTGAAAGCA GCAGCGATCG CCTTCGGTGT GATCGTGGCG ACCGCAACCG TGCCGTCACC 420  
CGCTTCCGGC AGGGAACATG ACGGCGGCTA TGCGGCCCTG ATCCGCCGGG CCTCGTACGG 480  
CGTCCCGCAC ATCACCGCCG ACGACTTCGG GAGCCTCGGT TTCGGCGTCG GGTACGTGCA 540  
GGCCGAGGAC AACATCTGCG TCATCGCCGA GAGCGTGGTG ACGGCCAACG GTGAGCGGTC 600  
GCGGTGGTTC GGTGCGACCG GGCCGGACGA CGCCGATGTG CGCAGCGACC TCTTCCACCG 660  
CAAGGCGATC GACGACCGCG TCGCCGAGCG GCTCCTCGAA GGGCCCCGCG ACGGCGTGCG 720  
GGCGCCGTCG GACGACGTCC GGGACCAGAT GCGCGGCTTC GTCGCCGGCT ACAACCACTT 780  
CCTACGCCGC ACCGGCGTGC ACCGCCTGAC CGACCCGGCG TGCCGCGGCA AGGCCTGGGT 840  
GCGCCCGCTC TCCGAGATCG ATCTCTGGCG TACATTGTGG GACAGCATGG TCCGGGCCGG 900  
TTCCGGGGCG CTGCTCGACG GCATCGTCGC CGCGACGCCA CCGACAGCCG CCGGGCCCGC 960  
GTCAGCCCCG GAGGCACCCG ACGCCGCCGC GATCGCCGCC GCCCTCGACG GGACGAGCGC 1020  
GGGCATCGGC AGCAACGCGT ACGGCCTCGG CGCGCAGGCC ACCGTGAACG GCAGCGGGAT 1080  
GGTGCTGGCC AACCCGCACT TCCCGTGGCA GGGCGCCGCA CGCTTCTACC GGATGCACCT 1140  
CAAGGTGCCC GGCCGCTACG ACGTCGAGGG CGCGGCGCTG GTCGGCGACC CGATCATCGA 1200  
GATCGGGCAC AACCGCACGG TCGCCTGGAG CCACACCGTC TCCACCGCCC GCCGGTTCGT 1260  
GTGGCACCGC CTGAGCCTCG TGCCCGGCGA CCCCACCTCC TATTACGTCG ACGGCCGGCC 1320  
CGAGCGGATG CGCGCCCGCA CGGTCACGGT CCAGACCGGC AGCGGCCCGG TCAGCCGCAC 1380  
CTTCCACGAC ACCCGCTACG GCCCGGTGGC CGTGATGCCG GGCACCTTCG ACTGGACGCC 1440  
GGCCACCGCG TACGCCATCA CCGACGTCAA CGCGGGCAAC AACCGCGCCT TCGACGGGTG 1500  
GCTGCGGATG GGCCAGGCCA AGGACGTCCG GGCGCTCAAG GCGGTCCTCG ACCGGCACCA 1560  
GTTCTGCCC TGGGTCAACG TGATCGCCGC CGACGCGCGG GGCGAGGCC TCTACGGCGA 1620  
TCATTGGTC GTCCCCCGGG TGACCGGCGC GCTCGCTGCC GCCTGCATCC CGGCGCCGTT 1680  
CCAGCCGCTC TACGCCTCCA GCGGCCAGGC GGTCTTGGAC GGTTCCTGGT CGGACTGCGC 1740  
GCTCGGCGCC GACCCCGACG CCGCGGTCCC GGGCATTCTC GGCCCGGCGA GCCTGCCGGT 1800  
GCGGTTCCGC GACGACTACG TCACCAACTC CAACGACAGT CACTGGCTGG CCAGCCCGGC 1860  
CGCCCCGCTG GAAGGCTTCC CGCGGATCCT CGGCAACGAA CGCACCCCGC GCAGCCTGCG 1920  
CACCCGGCTC GGGCTGGACC AGATCCAGCA GCGCCTCGCC GGCACGGACG GTCTGCCCGG 1980

CAAGGGCTTC ACCACCGCCC GGCTCTGGCA GGTCATGTTT GGCAACCGGA TGCACGGCGC 2040  
CGAACTCGCC CGCGACGACC TGGTCGCGCT CTGCCGCCGC CAGCCGACCG CGACCGCCTC 2100  
GAACGGCGCG ATCGTCGACC TCACCGCGGC CTGCACGGCG CTGTCCCGCT TCGATGAGCG 2160  
TGCCGACCTG GACAGCCGGG GCGCGCACCT GTTCACCGAG TTCGCCCTCG CGGGCGGAAT 2220  
CAGGTTTCGCC GACACCTTCG AGGTGACCGA TCCGGTACGC ACCCCGCGCC GTCTGAACAC 2280  
CACGGATCCG CCGGTACGGA CGGCGCTCGC CGACGCCGTG CAACGGCTCG CCGGCATCCC 2340  
CCTCGACGCG AAGCTGGGAG ACATCCACAC CGACAGCCGC GCGGAACGGC GCATCCCCAT 2400  
CCACGGTGGC CGCGGGGAAG CAGGCACCTT CAACGTGATC ACCAACCCGC TCGTGCCGGG 2460  
CGTGGGATAC CCGCAGGTCG TCCACGGAAC ATCGTTCTGT ATGGCCGTCT AACTCGGCCC 2520  
GCACGGCCCG TCGGGACGGC AGATCCTCAC CTATGCGCAG TCGACGAACC CGAACTCACC 2580  
CTGGTACGCC GACCAGACCG TGCTCTACTC GCGGAAGGGC TGGGACACCA TCAAGTACAC 2640  
CGAGGCGCAG ATCGCGGCCG ACCCGAACCT GCGCGTCTAC CGGGTGGCAC AGCGGGGACG 2700  
CTGACCCACG TCACGCCGGC TCGGCCCGTG CGGGGGCGCA GGGCGCCGAT CGTCTCTGCA 2760  
TCGCCGGTCA GCCGGGGCCT GCGTCGACCG GCGGCGGCCG GTCGACGCCC GCGTCCCGGC 2820  
GCAGCGACTG GCTGAAGCGC CAGGCGTCGG CGGCCCCGGG CAGGTTGTTG AACATCACGT 2880  
ACGCCGGGCC GCCGTCGAGG ATGCCGGCGA GGTGTGCCAG CTCGGCATCC GTATACACAT 2940  
GCCGGGCGCC GGTGATGCCG TGCAGCCGGT AATAGGCCAT CGGCGTCAGA CTGCGGCGCA 3000  
GGAACGGGTC GCGGGCGTGG GTCAGGTCCA GTCCTGGCA CAAGCCCTCG ACCACCTCGT 3060  
CCGGCCACGG GCCGCGCGGC TCCCACAACA GCCGGACACC GGCCGGCCGG CGCGCTCGGG 3120  
CGCAGAACTC ACGCAGTCGC GCGATGGCGG GTTCGGTTCG CCGGAAACTC GCCGGGCACT 3180  
GCAGGTCGAC TCTAGAGGAT CCCCGGGTAC CGAGCTCGAA TT 3222

## (2) INFORMATION FOR SEQ ID NO: 30:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3193 nucleotides
- (B) TYPE: nucleotide
- (C) TOPOLOGY: linear

## (ii) MOLECULE TYPE: polynucleotide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

GATGGTGCTG CACGACCTGA GCCTGGCCGC CCGGTACGCC GACCGGCTGA TCGCGATGAA 60  
GGACGGCCGG ATCGTGGCGA GCGGGGCGCC GGACGAGGTG CTCACCCCGG CGCTGCTGTA 120

- 65 -

|  |      |
|--|------|
| GTCGGTCTTC GGGCTGCGCG CGATGGTGGT GCGGACCCG GCGACCGGCA CCCCCTGGT    | 180  |
| GATCCCCCTG CCGCGCACCG CCACCTCGGT GCGGGCCTGA AATCGATGAG CGTGGTTGCT  | 240  |
| TCATCGGCCT GCCGAGCGAT GAGAGTATGT GGGCGGTAGA GCGAGTCTCG AGGGGGAGAT  | 300  |
| GCCGCCGTGA CGTCCTCGTA CATGCGCCTG AAAGCAGCAG CGATCGCCTT CCGTGTGATC  | 360  |
| GTGGCGACCG CAGCCGTGCC GTCACCCGCT TCCGGCAGGG AACATGACGG CGGCTATGCG  | 420  |
| GCCCTGATCC GCCGGGCCTC GTACGGCGTC CCGCACATCA CCGCCGACGA CTCGGGAGC   | 480  |
| CTCGGTTTCG GCGTCGGGTA CGTGCAGGCC GAGGACAACA TCTGCGTCAT CGCCGAGAGC  | 540  |
| GTGGTAACGG CCAACGGTGA GCGGTCGCGG TGGTTCGGTG CGACCGGGCC GGACGACGCC  | 600  |
| GATGTGCGCA GCGACCTCTT CCACCGCAAG GCGATCGACG ACCGCGTCGC CGAGCGGCTC  | 660  |
| CTCGAAGGGC CCCGCGACGG CGTGCGGGCG CCGTCGGACG ACGTCCGGGA CCAGATGCGC  | 720  |
| GGCTTCGTCTG CCGGCTACAA CCACTTCCTA CGCCGCACCG GCGTGCACCG CCTGACCGAC | 780  |
| CCGGCGTGCC GCGGCAAGGC CTGGGTGCGC CCGCTCTCCG AGATCGATCT CTGGCGTACG  | 840  |
| TCGTGGGACA GCATGGTCCG GGCCGGTTCC GGGGCGCTGC TCGACGGCAT CGTCGCCGCG  | 900  |
| ACGCCACCTA CAGCCGCCGG GCCCGCGTCA GCGCCGGAGG CACCCGACGC CGCCGCGATC  | 960  |
| GCCGCCGCC TCGACGGGAC GAGCGCGGGC ATCGGCAGCA ACGCGTACGG CCTCGGCGCG   | 1020 |
| CAGGCCACCG TGAACGGCAG CCGGATGGTG CTGGCCAACC CGCACTTCCC GTGGCAGGGC  | 1080 |
| GCCGAACGCT TCTACCGGAT GCACCTCAAG GTGCCCCGCC GCTACGACGT CGAGGGCGCG  | 1140 |
| GCGCTGATCG GCGACCCGAT CATCGGGATC GGGCACAACC GCACGGTCGC CTGGAGCCAC  | 1200 |
| ACCGTCTCCA CCGCCCGCCG GTTCGTGTGG CACCGCCTGA GCCTCGTGCC CGGCGACCCC  | 1260 |
| ACCTCCTATT ACGTCGACGG CCGGCCCGAG CGGATGCGCG CCCGCACGGT CACGGTCCAG  | 1320 |
| ACCGGCAGCG GCGCGGTCAG CCGCACCTTC CACGACACCC GCTACGGCCC GGTGGCCGTG  | 1380 |
| ATGCCGGGCA CCTTCGACTG GACGCCGGCC ACCGCGTACG CCATCACCGA CGTCAACGCG  | 1440 |
| GGCAACAACC GCGCCTTCGA CGGGTGGCTG CGGATGGGCC AGGCCAAGGA CGTCCGGGCG  | 1500 |
| CTCAAGGCGG TCCTCGACCG GCACCACTTC CTGCCCTGGG TCAACGTGAT CGCCGCCGAC  | 1560 |
| GCGCGGGGCG AGGCCCTCTA CGGCGATCAT TCGGTCGTCC CCCGGGTGAC CGGCGCGCTC  | 1620 |
| GCTGCCGCTT GCATCCCGGC GCCGTTCCAG CCGCTCTACG CCTCCAGCGG CCAGGCGGTC  | 1680 |
| CTGGACGGTT CCCGGTCGGA CTGCGCGCTC GCGCCGACC CCGACGCCGC GGTCCCGGGC   | 1740 |
| ATTCTCGGCC CGGCGAGCCT GCCGGTGCGG TTCCGCGACG ACTACGTCAC CAACTCCAAC  | 1800 |
| GACAGTCACT GGCTGGCCAG CCCGGCCGCC CCGCTGGAAG GCTTCCCGCG GATCCTCGGC  | 1860 |



|  |      |
|--|------|
| AACGAACGCA CCCC GCGCAG CCTGCGCACC CGGCTCGGGC TGGACCAGAT CCAGCAGCGC | 1920 |
| CTCGCCGGCA CGGACGGTCT GCCCGGCAAG GGCTTCACCA CCGCCCGGCT CTGGCAGGTC  | 1980 |
| ATGTTTCGGCA ACCGGATGCA CGGCGCCGAA CTCGCCCGCG ACGACCTGGT CGCGCTCTGC | 2040 |
| CGCCGCCAGC CGACCGCGAC CGCCTCGAAC GGC GCGATCG TCGACCTCAC CGCGGCCTGC | 2100 |
| ACGGCGCTGT CCCGCTTCGA TGAGCGTGCC GACCTGGACA GCCGGGGCGC GCACCTGTTC  | 2160 |
| ACCGAGTTCG CCCTCGCGGG CGGAATCAGG TTCGCCGACA CCTTCGAGGT GACCGATCCG  | 2220 |
| GTACGCACCC CGCGCCGTCT GAACACCACG GATCCGCGGG TACGGACGGC GCTCGCCGAC  | 2280 |
| GCCGTGCAAC GGCTCGCCGG CATCCCCCTC GACGCGAAGC TGGGAGACAT CCACACCGAC  | 2340 |
| AGCCGCGGCG AACGGCGCAT CCCCATCCAC GGTGGCCGCG GGG AAGCAGG CACCTTCAAC | 2400 |
| GTGATCACCA ACCCGCTCGT GCCGGGCGTG GGATACCCGC AGGTCGTCCA CGGAACATCG  | 2460 |
| TTCGTGATGG CCGTCGAACT CGGCCCCGAC GGCCCGTCGG GACGGCAGAT CCTCACCTAT  | 2520 |
| GCGCAGTCGA CGAACCCGAA CTCACCCTGG TACGCCGACC AGACCGTGCT CTACTCGCGG  | 2580 |
| AAGGGCTGGG ACACCATCAA GTACACCGAG GCGCAGATCG CGGCCGACCC GAACCTGCGC  | 2640 |
| GTCTACCGGG TGGCACAGCG GGGACGCTGA CCCACGTCAC GCCGGCTCGG CCCGTGCGGG  | 2700 |
| GGCGCAGGGC GCCGATCGTC TCTGCATCGC CGGTCAGCCG GGGCCTGCGT CGACCGGCGG  | 2760 |
| CGGCCGGTCG ACGCCCGCGT CCCGGCGCAG CGACTGGCTG AAGCGCCAGG CGTCGGCGGC  | 2820 |
| CCGGGGCAGG TTGTTGAACA TCACGTACGC CGGGCCGCCG TCGAGGATGC CGGCGAGGTG  | 2880 |
| TGCCAGCTCG GCATCCGTAT ACACATGCCG GGC GCCGGTG ATGCCGTGCA GCCGGTAATA | 2940 |
| GGCCATCGGC GTCAGACTGC GGCGCAGGAA CGGGTCGGCG GCGTGGGTCA GGTCCAGCTC  | 3000 |
| CTGGCACAAG CCCTCGACCA CCTCGTCCGG CCACGGGCCG CGCGGCTCCC ACAACAGCCG  | 3060 |
| GACACCGGCC GGCCGGCGCG CTCGGGCGCA GAACTCACGC AGTCGCGCGA TGGCGGGTTC  | 3120 |
| GGTCGGCCGG AAACTCGCCG GGC ACTGCAG GTCGACTCTA GAGGATCCCC GGGTACCGAG | 3180 |
| CTCGAATTCG TTA   | 3193 |

## (2) INFORMATION FOR SEQ ID NO: 31:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3193 nucleotides
- (B) TYPE: nucleotide
- (C) TOPOLOGY: linear

## (ii) MOLECULE TYPE: polynucleotide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

- 67 -

|  |      |
|--|------|
| ATCGATGAGC GTGGTTGCTT CATCGGCCTG CCGAGCGATG AGAGTATGTG GGCGGTAGAG  | 60   |
| CGAGTCTCGA GGGGGAGATG CCGCCGTGAC GTCCTCGTAC ATGCGCCTGA AAGCAGCAGC  | 120  |
| GATCGCCTTC GGTGTGATCG TGGCGACCGC AGCCGTGCCG TCACCCGCTT CCGGCAGGGA  | 180  |
| ACATGACGGC GGCTATGCGG CCCTGATCCG CCGGGCCTCG TACGGCGTCC CGCACATCAC  | 240  |
| CGCCGACGAC TTCGGGAGCC TCGGTTTCGG CGTCGGGTAC GTGCAGGCCG AGGACAACAT  | 300  |
| CTGCGTCATC GCCGAGAGCG TGGTGACGGC CAACGGTGAG CGGTCGCGGT GGTTCGGTGC  | 360  |
| GACCGGGCCG GACGACGCCG ATGTGCGCAG CGACCTCTTC CACCGCAAGG CGATCGACGA  | 420  |
| CCGCGTCGCC GAGCGGCTCC TCGAAGGGCC CCGCGACGGC GTGCGGGCGC CGTCGGACGA  | 480  |
| CGTCCGGGAC CAGATGCGCG GCTTCGTGCG CGGCTACAAC CACTTCCTAC GCCGCACCGG  | 540  |
| CGTGCAACCGC CTGACCGACC CGGCGTGCCG CGGCAAGGCC TGGGTGCGCC CGCTCTCCGA | 600  |
| GATCGATCTC TGGCGTACGT CGTGGGACAG CATGGTCCGG GCCGGTTCCG GGGCGCTGCT  | 660  |
| CGACGGCATC GTCGCCGCGA CGCCACCGAC AGCCGCCGGG CCCGCGTCAG CCCCAGAGGC  | 720  |
| ACCCGACGCC GCCGCGATCG CCGCCGCCCT CGACGGGACG AGCGCGGGCA TCGGCAGCAA  | 780  |
| CGCGTACGGC CTCGGCGCGC AGGCCACCGT GAACGGCAGC GGGATGGTGC TGGCCAACCC  | 840  |
| GCACTTCCCG TGGCAGGGCG CCGAACGCTT CTACCGGATG CACCTCAAGG TGCCCGGCCG  | 900  |
| CTACGACGTC GAGGGCGCGG CGCTGATCGG CGACCCGATC ATCGAGATCG GGCACAACCG  | 960  |
| CACGGTCGCC TGGAGCCACA CCGTCTCCAC CGCCCGCCGG TTCGTGTGGC ACCGCCTGAG  | 1020 |
| CCTCGTGCCC GGCGACCCCA CCTCCTATTA CGTCGACGGC CGGCCCGAGC GGATGCGCGC  | 1080 |
| CCGCACGGTC ACGGTCCAGA CCGGCAGCGG CCCGGTCAGC CGCACCTTCC ACGACACCCG  | 1140 |
| CTACGGCCCG GTGGCCGTGG TGCCGGGCAC CTTCGACTGG ACGCCGGCCA CCGCGTACGC  | 1200 |
| CATCACCGAC GTCAACGCGG GCAACAACCG CGCCTTCGAC GGGTGGCTGC GGATGGGCCA  | 1260 |
| GGCCAAGGAC GTCCGGGCGC TCAAGGCGGT CCTCGACCGG CACCAGTTCC TGCCCTGGGT  | 1320 |
| CAACGTGATC GCCGCCGACG CGCGGGGCGA GGCCCTCTAC GGCATCATT CCGTCGTCCC   | 1380 |
| CCGGGTGACC GGCGCGCTCG CTGCCGCCTG CATCCCGGCG CCGTTCCAGC CGCTCTACGC  | 1440 |
| CTCCAGCGGC CAGGCGGTCC TGGACGGTTC CCGGTCGGAC TGCGCGCTCG GCGCCGACCC  | 1500 |
| CGACGCCGCG GTCCCGGGCA TTCTCGGCCC GGCGAGCCTG CCGGTGCGGT TCCGCGACGA  | 1560 |
| CTACGTCACC AACTCCAACG ACAGTCACTG GCTGGCCAGC CCGGCCGCCC CGCTGGAAGG  | 1620 |
| CTTCCCGCGG ATCCTCGGCA ACGAACGCAC CCCGCGCAGC CTGCGCACCC GGCTCGGGCT  | 1680 |
| GGACCAGATC CAGCAGCGCC TCGCCGGCAC GGACGGTCTG CCCGGCAAGG GCTTCACCAC  | 1740 |

- 68 -

|             |            |            |            |            |             |      |
|-------------|------------|------------|------------|------------|-------------|------|
| CGCCCCGGCTC | TGGCAGGTCA | TGTTCGGCAA | CCGGATGCAC | GGCGCCGAAC | TCGTCCGCGA  | 1800 |
| CGACCTGGTC  | GCGCTCTGCC | GCCGCCAGCC | GACCGCGACC | GCCTCGAACG | GCGCGATCGT  | 1860 |
| CGACCTCACC  | GCGGCCTGCA | CGGCGCTGTC | CCGCTTCGAT | GAGCGTGCCG | ACCTGGACAG  | 1920 |
| CCGGGGCGCG  | CACCTGTTCA | CCGAGTTCGC | CCTCGCGGGC | GGAATCAGGT | TCGCCGACAC  | 1980 |
| CTTCGAGGTG  | ACCGATCCGG | TACGCACCCC | GCGCCGTCTG | AACACCACGG | ATCCGCGGGT  | 2040 |
| ACGGACGGCG  | CTCGCCGACG | CCGTGCAACG | GCTCGCCGGC | ATCCCCCTCG | ACGCGAAGCT  | 2100 |
| GGGAGACATC  | CACACCGACA | GCCGCGGCGA | ACGGCGCATC | CCCATCCACG | GTGGCCGCGG  | 2160 |
| GGAAGCAGGC  | ACCTTCAACG | TGATCACCAA | CCCGCTCGTG | CCGGGCGTGG | GATACCCGCA  | 2220 |
| GGTCGTCCAC  | GGAACATCGT | TCGTGATGGC | CGTCGAACTC | GGCCCGCACG | GCCCGTCGGG  | 2280 |
| ACGGCAGATC  | CTCACCTATG | CGCAGTCGAC | GAACCCGAAC | TCACCCTGGT | ACGCCGACCA  | 2340 |
| GACCGTGCTC  | TACTCGCGGA | AGGGCTGGGA | CACCATCAAG | TACACCGAGG | CGCAGATCGC  | 2400 |
| GGCCGACCCG  | AACCTGCGCG | TCTACCGGGT | GGCACAGCGG | GGACGCTGAC | CCACGTCACG  | 2460 |
| CCGGCTCGGC  | CCGTGCGGGG | GCGCAGGGCG | CCGATCGTCT | CTGCATCGCC | GGTCAGCCGG  | 2520 |
| GGCCTGCGTC  | GACCGGCGGC | GGCCGGTCGA | CGCCCGCGTC | CCGGCGCAGC | GA CTGGCTGA | 2580 |
| AGCGCCAGGC  | GTCGGCGGCC | CGGGGCAGGT | TGTTGAACAT | CACGTACGCC | GGGCCGCCGT  | 2640 |
| CGAGGATGCC  | GGCGAGGTGT | GCCAGCTCGG | CATCCGTGTA | CACATGCCGG | GCGCCGGTGA  | 2700 |
| TGCCGTGCAG  | CCGGTAATAG | GCCATCGGCG | TCAGACTGCG | GCGCAGGAAC | GGGTCGGCGG  | 2760 |
| CGTGGGTCAG  | GTCCAGCTCC | TGGCACAAGC | CCTCGACCAC | CTCGTCCGGC | CACGGGCCGC  | 2820 |
| GCGGCTCCCA  | CAACAGCCGG | ACACCGGCCG | GCCGGCGCGC | TCGGGCGCAG | AACTCACGCA  | 2880 |
| GTCGCGCGAT  | GGCGGGTTCG | GTCGGCCGGA | AACTCGCCGG | GCACTGCAG  |             | 2929 |

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 782 amino acids  
(B) TYPE: amino acid  
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEO ID NO: 32:

Met Arg Leu Lys Ala Ala Ala Ile Ala Phe Gly Val Ile Val Ala Thr  
5 10 15

Ala Thr Val Pro Ser Pro Ala Ser Gly Arg Glu His Asp Gly Gly Tyr  
20 25 30

- 69 -

Ala Ala Leu Ile Arg Arg Ala Ser Tyr Gly Val Pro His Ile Thr Ala  
 35 40 45  
 Asp Asp Phe Gly Ser Leu Gly Phe Gly Val Gly Tyr Val Gln Ala Glu  
 50 55 60  
 Asp Asn Ile Cys Val Ile Ala Glu Ser Val Val Thr Ala Asn Gly Glu  
 65 70 75 80  
 Arg Ser Arg Trp Phe Gly Ala Thr Gly Pro Asp Asp Ala Asp Val Arg  
 85 90 95  
 Ser Asp Leu Phe His Arg Lys Ala Ile Asp Asp Arg Val Ala Glu Arg  
 100 105 110  
 Leu Leu Glu Gly Pro Arg Asp Gly Val Arg Ala Pro Ser Asp Asp Val  
 115 120 125  
 Arg Asp Gln Met Arg Gly Phe Val Ala Gly Tyr Asn His Phe Leu Arg  
 130 135 140  
 Arg Thr Gly Val His Arg Leu Thr Asp Pro Ala Cys Arg Gly Lys Ala  
 145 150 155 160  
 Trp Val Arg Pro Leu Ser Glu Ile Asp Leu Trp Arg Thr Leu Trp Asp  
 165 170 175  
 Ser Met Val Arg Ala Gly Ser Gly Ala Leu Leu Asp Gly Ile Val Ala  
 180 185 190  
 Ala Thr Pro Pro Thr Ala Ala Gly Pro Ala Ser Ala Pro Glu Ala Pro  
 195 200 205  
 Asp Ala Ala Ala Ile Ala Ala Ala Leu Asp Gly Thr Ser Ala Gly Ile  
 210 215 220  
 Gly Ser Asn Ala Tyr Gly Leu Gly Ala Gln Ala Thr Val Asn Gly Ser  
 225 230 235 240  
 Gly Met Val Leu Ala Asn Pro His Phe Pro Trp Gln Gly Ala Ala Arg  
 245 250 255  
 Phe Tyr Arg Met His Leu Lys Val Pro Gly Arg Tyr Asp Val Glu Gly  
 260 265 270  
 Ala Ala Leu Val Gly Asp Pro Ile Ile Glu Ile Gly His Asn Arg Thr  
 275 280 285  
 Val Ala Trp Ser His Thr Val Ser Thr Ala Arg Arg Phe Val Trp His  
 290 295 300  
 Arg Leu Ser Leu Val Pro Gly Asp Pro Thr Ser Tyr Tyr Val Asp Gly  
 305 310 315 320  
 Arg Pro Glu Arg Met Arg Ala Arg Thr Val Thr Val Gln Thr Gly Ser  
 325 330 335  
 Gly Pro Val Ser Arg Thr Phe His Asp Thr Arg Tyr Gly Pro Val Ala

- 70 -

| 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Met | Pro | Gly | Thr | Phe | Asp | Trp | Thr | Pro | Ala | Thr | Ala | Tyr | Ala | Ile |
| 355 |     |     |     |     | 360 |     |     |     |     | 365 |     |     |     |     |     |
| Thr | Asp | Val | Asn | Ala | Gly | Asn | Asn | Arg | Ala | Phe | Asp | Gly | Trp | Leu | Arg |
| 370 |     |     |     |     | 375 |     |     |     |     | 380 |     |     |     |     |     |
| Met | Gly | Gln | Ala | Lys | Asp | Val | Arg | Ala | Leu | Lys | Ala | Val | Leu | Asp | Arg |
| 385 |     |     |     |     | 390 |     |     |     |     | 395 |     |     |     |     | 400 |
| His | Gln | Phe | Leu | Pro | Trp | Val | Asn | Val | Ile | Ala | Ala | Asp | Ala | Arg | Gly |
| 405 |     |     |     |     | 410 |     |     |     |     | 415 |     |     |     |     |     |
| Glu | Ala | Leu | Tyr | Gly | Asp | His | Ser | Val | Val | Pro | Arg | Val | Thr | Gly | Ala |
| 420 |     |     |     |     | 425 |     |     |     |     | 430 |     |     |     |     |     |
| Leu | Ala | Ala | Ala | Cys | Ile | Pro | Ala | Pro | Phe | Gln | Pro | Leu | Tyr | Ala | Ser |
| 435 |     |     |     |     | 440 |     |     |     |     | 445 |     |     |     |     |     |
| Ser | Gly | Gln | Ala | Val | Leu | Asp | Gly | Ser | Arg | Ser | Asp | Cys | Ala | Leu | Gly |
| 450 |     |     |     |     | 455 |     |     |     |     | 460 |     |     |     |     |     |
| Ala | Asp | Pro | Asp | Ala | Ala | Val | Pro | Gly | Ile | Leu | Gly | Pro | Ala | Ser | Leu |
| 465 |     |     |     |     | 470 |     |     |     |     | 475 |     |     |     |     | 480 |
| Pro | Val | Arg | Phe | Arg | Asp | Asp | Tyr | Val | Thr | Asn | Ser | Asn | Asp | Ser | His |
| 485 |     |     |     |     | 490 |     |     |     |     | 495 |     |     |     |     |     |
| Trp | Leu | Ala | Ser | Pro | Ala | Ala | Pro | Leu | Glu | Gly | Phe | Pro | Arg | Ile | Leu |
| 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |     |     |     |
| Gly | Asn | Glu | Arg | Thr | Pro | Arg | Ser | Leu | Arg | Thr | Arg | Leu | Gly | Leu | Asp |
| 515 |     |     |     |     | 520 |     |     |     |     | 525 |     |     |     |     |     |
| Gln | Ile | Gln | Gln | Arg | Leu | Ala | Gly | Thr | Asp | Gly | Leu | Pro | Gly | Lys | Gly |
| 530 |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |     |
| Phe | Thr | Thr | Ala | Arg | Leu | Trp | Gln | Val | Met | Phe | Gly | Asn | Arg | Met | His |
| 545 |     |     |     |     | 550 |     |     |     |     | 555 |     |     |     |     | 560 |
| Gly | Ala | Glu | Leu | Ala | Arg | Asp | Asp | Leu | Val | Ala | Leu | Cys | Arg | Arg | Gln |
| 565 |     |     |     |     | 570 |     |     |     |     | 575 |     |     |     |     |     |
| Pro | Thr | Ala | Thr | Ala | Ser | Asn | Gly | Ala | Ile | Val | Asp | Leu | Thr | Ala | Ala |
| 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |     |     |     |
| Cys | Thr | Ala | Leu | Ser | Arg | Phe | Asp | Glu | Arg | Ala | Asp | Leu | Asp | Ser | Arg |
| 595 |     |     |     |     | 600 |     |     |     |     | 605 |     |     |     |     |     |
| Gly | Ala | His | Leu | Phe | Thr | Glu | Phe | Ala | Leu | Ala | Gly | Gly | Ile | Arg | Phe |
| 610 |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |     |     |
| Ala | Asp | Thr | Phe | Glu | Val | Thr | Asp | Pro | Val | Arg | Thr | Pro | Arg | Arg | Leu |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     |     | 640 |
| Asn | Thr | Thr | Asp | Pro | Arg | Val | Arg | Thr | Ala | Leu | Ala | Asp | Ala | Val | Gln |
| 645 |     |     |     |     | 650 |     |     |     |     | 655 |     |     |     |     |     |

Arg Leu Ala Gly Ile Pro Leu Asp Ala Lys Leu Gly Asp Ile His Thr  
 660 665 670  
 Asp Ser Arg Gly Glu Arg Arg Ile Pro Ile His Gly Gly Arg Gly Glu  
 675 680 685  
 Ala Gly Thr Phe Asn Val Ile Thr Asn Pro Leu Val Pro Gly Val Gly  
 690 695 700  
 Tyr Pro Gln Val Val His Gly Thr Ser Phe Val Met Ala Val Glu Leu  
 705 715 715 720  
 Gly Pro His Gly Pro Ser Gly Arg Gln Ile Leu Thr Tyr Ala Gln Ser  
 725 730 735  
 Thr Asn Pro Asn Ser Pro Trp Tyr Ala Asp Gln Thr Val Leu Tyr Ser  
 740 745 750  
 Arg Lys Gly Trp Asp Thr Ile Lys Tyr Thr Glu Ala Gln Ile Ala Ala  
 755 760 765  
 Asp Pro Asn Leu Arg Val Tyr Arg Val Ala Gln Arg Gly Arg  
 770 775 780 782

## (2) INFORMATION FOR SEQ ID NO: 33:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 782 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

Met Arg Leu Lys Ala Ala Ala Ile Ala Phe Gly Val Ile Val Ala Thr  
 5 10 15  
 Ala Ala Val Pro Ser Pro Ala Ser Gly Arg Glu His Asp Gly Gly Tyr  
 20 25 30  
 Ala Ala Leu Ile Arg Arg Ala Ser Tyr Gly Val Pro His Ile Thr Ala  
 35 40 45  
 Asp Asp Phe Gly Ser Leu Gly Phe Gly Val Gly Tyr Val Gln Ala Glu  
 50 55 60  
 Asp Asn Ile Cys Val Ile Ala Glu Ser Val Val Thr Ala Asn Gly Glu  
 65 70 75 80  
 Arg Ser Arg Trp Phe Gly Ala Thr Gly Pro Asp Asp Ala Asp Val Arg  
 85 90 95  
 Ser Asp Leu Phe His Arg Lys Ala Ile Asp Asp Arg Val Ala Glu Arg  
 100 105 110

Leu Leu Glu Gly Pro Arg Asp Gly Val Arg Ala Pro Ser Asp Asp Val  
 115 120 125  
 Arg Asp Gln Met Arg Gly Phe Val Ala Gly Tyr Asn His Phe Leu Arg  
 130 135 140  
 Arg Thr Gly Val His Arg Leu Thr Asp Pro Ala Cys Arg Gly Lys Ala  
 145 150 155 160  
 Trp Val Arg Pro Leu Ser Glu Ile Asp Leu Trp Arg Thr Ser Trp Asp  
 165 170 175  
 Ser Met Val Arg Ala Gly Ser Gly Ala Leu Leu Asp Gly Ile Val Ala  
 180 185 190  
 Ala Thr Pro Pro Thr Ala Ala Gly Pro Ala Ser Ala Pro Glu Ala Pro  
 195 200 205  
 Asp Ala Ala Ala Ile Ala Ala Ala Leu Asp Gly Thr Ser Ala Gly Ile  
 210 215 220  
 Gly Ser Asn Ala Tyr Gly Leu Gly Ala Gln Ala Thr Val Asn Gly Ser  
 225 230 235 240  
 Gly Met Val Leu Ala Asn Pro His Phe Pro Trp Gln Gly Ala Glu Arg  
 245 250 255  
 Phe Tyr Arg Met His Leu Lys Val Pro Gly Arg Tyr Asp Val Glu Gly  
 260 265 270  
 Ala Ala Leu Ile Gly Asp Pro Ile Ile Gly Ile Gly His Asn Arg Thr  
 275 280 285  
 Val Ala Trp Ser His Thr Val Ser Thr Ala Arg Arg Phe Val Trp His  
 290 295 300  
 Arg Leu Ser Leu Val Pro Gly Asp Pro Thr Ser Tyr Tyr Val Asp Gly  
 305 310 315 320  
 Arg Pro Glu Arg Met Arg Ala Arg Thr Val Thr Val Gln Thr Gly Ser  
 325 330 335  
 Gly Pro Val Ser Arg Thr Phe His Asp Thr Arg Tyr Gly Pro Val Ala  
 340 345 350  
 Val Met Pro Gly Thr Phe Asp Trp Thr Pro Ala Thr Ala Tyr Ala Ile  
 355 360 365  
 Thr Asp Val Asn Ala Gly Asn Asn Arg Ala Phe Asp Gly Trp Leu Arg  
 370 375 380  
 Met Gly Gln Ala Lys Asp Val Arg Ala Leu Lys Ala Val Leu Asp Arg  
 385 390 395 400  
 His Gln Phe Leu Pro Trp Val Asn Val Ile Ala Ala Asp Ala Arg Gly  
 405 410 415  
 Glu Ala Leu Tyr Gly Asp His Ser Val Val Pro Arg Val Thr Gly Ala



|   |     |     |
|---|-----|-----|
| 420   | 425 | 430 |
| Leu Ala Ala Ala Cys Ile Pro Ala Pro Phe Gln Pro Leu Tyr Ala Ser |     |     |
| 435   | 440 | 445 |
| Ser Gly Gln Ala Val Leu Asp Gly Ser Arg Ser Asp Cys Ala Leu Gly |     |     |
| 450   | 455 | 460 |
| Ala Asp Pro Asp Ala Ala Val Pro Gly Ile Leu Gly Pro Ala Ser Leu |     |     |
| 465   | 470 | 475 |
| Pro Val Arg Phe Arg Asp Asp Tyr Val Thr Asn Ser Asn Asp Ser His |     |     |
| 485   | 490 | 495 |
| Trp Leu Ala Ser Pro Ala Ala Pro Leu Glu Gly Phe Pro Arg Ile Leu |     |     |
| 500   | 505 | 510 |
| Gly Asn Glu Arg Thr Pro Arg Ser Leu Arg Thr Arg Leu Gly Leu Asp |     |     |
| 515   | 520 | 525 |
| Gln Ile Gln Gln Arg Leu Ala Gly Thr Asp Gly Leu Pro Gly Lys Gly |     |     |
| 530   | 535 | 540 |
| Phe Thr Thr Ala Arg Leu Trp Gln Val Met Phe Gly Asn Arg Met His |     |     |
| 545   | 550 | 555 |
| Gly Ala Glu Leu Ala Arg Asp Asp Leu Val Ala Leu Cys Arg Arg Gln |     |     |
| 565   | 570 | 575 |
| Pro Thr Ala Thr Ala Ser Asn Gly Ala Ile Val Asp Leu Thr Ala Ala |     |     |
| 580   | 585 | 590 |
| Cys Thr Ala Leu Ser Arg Phe Asp Glu Arg Ala Asp Leu Asp Ser Arg |     |     |
| 595   | 600 | 605 |
| Gly Ala His Leu Phe Thr Glu Phe Ala Leu Ala Gly Gly Ile Arg Phe |     |     |
| 610   | 615 | 620 |
| Ala Asp Thr Phe Glu Val Thr Asp Pro Val Arg Thr Pro Arg Arg Leu |     |     |
| 625   | 630 | 635 |
| Asn Thr Thr Asp Pro Arg Val Arg Thr Ala Leu Ala Asp Ala Val Gln |     |     |
| 645   | 650 | 655 |
| Arg Leu Ala Gly Ile Pro Leu Asp Ala Lys Leu Gly Asp Ile His Thr |     |     |
| 660   | 665 | 670 |
| Asp Ser Arg Gly Glu Arg Arg Ile Pro Ile His Gly Gly Arg Gly Glu |     |     |
| 675   | 680 | 685 |
| Ala Gly Thr Phe Asn Val Ile Thr Asn Pro Leu Val Pro Gly Val Gly |     |     |
| 690   | 695 | 700 |
| Tyr Pro Gln Val Val His Gly Thr Ser Phe Val Met Ala Val Glu Leu |     |     |
| 705   | 715 | 720 |
| Gly Pro His Gly Pro Ser Gly Arg Gln Ile Leu Thr Tyr Ala Gln Ser |     |     |
| 725   | 730 | 735 |

Thr Asn Pro Asn Ser Pro Trp Tyr Ala Asp Gln Thr Val Leu Tyr Ser  
                     740                    745                    750

Arg Lys Gly Trp Asp Thr Ile Lys Tyr Thr Glu Ala Gln Ile Ala Ala  
                     755                    760                    765

Asp Pro Asn Leu Arg Val Tyr Arg Val Ala Gln Arg Gly Arg  
                     770                    775                    780                    782

## (2) INFORMATION FOR SEQ ID NO: 34:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 782 amino acids  
 (B) TYPE: amino acid  
 (C) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

Met Arg Leu Lys Ala Ala Ala Ile Ala Phe Gly Val Ile Val Ala Thr  
                     5                    10                    15

Ala Thr Val Pro Ser Pro Ala Ser Gly Arg Glu His Asp Gly Gly Tyr  
                     20                    25                    30

Ala Ala Leu Ile Arg Arg Ala Ser Tyr Gly Val Pro His Ile Thr Ala  
                     35                    40                    45

Asp Asp Phe Gly Ser Leu Gly Phe Gly Val Gly Tyr Val Gln Ala Glu  
                     50                    55                    60

Asp Asn Ile Cys Val Ile Ala Glu Ser Val Val Thr Ala Asn Gly Glu  
                     65                    70                    75                    80

Arg Ser Arg Trp Phe Gly Ala Thr Gly Pro Asp Asp Ala Asp Val Arg  
                     85                    90                    95

Ser Asp Leu Phe His Arg Lys Ala Ile Asp Asp Arg Val Ala Glu Arg  
                     100                    105                    110

Leu Leu Glu Gly Pro Arg Asp Gly Val Arg Ala Pro Ser Asp Asp Val  
                     115                    120                    125

Arg Asp Gln Met Arg Gly Phe Val Ala Gly Tyr Asn His Phe Leu Arg  
                     130                    135                    140

Arg Thr Gly Val His Arg Leu Thr Asp Pro Ala Cys Arg Gly Lys Ala  
                     145                    150                    155                    160

Trp Val Arg Pro Leu Ser Glu Ile Asp Leu Trp Arg Thr Leu Trp Asp  
                     165                    170                    175

Ser Met Val Arg Ala Gly Ser Gly Ala Leu L u Asp Gly Ile Val Ala  
                     180                    185                    190

Ala Thr Pro Pro Thr Ala Ala Gly Pro Ala Ser Ala Pro Glu Ala Pro  
 195 200 205  
 Asp Ala Ala Ala Ile Ala Ala Ala Leu Asp Gly Thr Ser Ala Gly Ile  
 210 215 220  
 Gly Ser Asn Ala Tyr Gly Leu Gly Ala Gln Ala Thr Val Asn Gly Ser  
 225 230 235 240  
 Gly Met Val Leu Ala Asn Pro His Phe Pro Trp Gln Gly Ala Ala Arg  
 245 250 255  
 Phe Tyr Arg Met His Leu Lys Val Pro Gly Arg Tyr Asp Val Glu Gly  
 260 265 270  
 Ala Ala Leu Val Gly Asp Pro Ile Ile Glu Ile Gly His Asn Arg Thr  
 275 280 285  
 Val Ala Trp Ser His Thr Val Ser Thr Ala Arg Arg Phe Val Trp His  
 290 295 300  
 Arg Leu Ser Leu Val Pro Gly Asp Pro Thr Ser Tyr Tyr Val Asp Gly  
 305 310 315 320  
 Arg Pro Glu Arg Met Arg Ala Arg Thr Val Thr Val Gln Thr Gly Ser  
 325 330 335  
 Gly Pro Val Ser Arg Thr Phe His Asp Thr Arg Tyr Gly Pro Val Ala  
 340 345 350  
 Val Val Pro Gly Thr Phe Asp Trp Thr Pro Ala Thr Ala Tyr Ala Ile  
 355 360 365  
 Thr Asp Val Asn Ala Gly Asn Asn Arg Ala Phe Asp Gly Trp Leu Arg  
 370 375 380  
 Met Gly Gln Ala Lys Asp Val Arg Ala Leu Lys Ala Val Leu Asp Arg  
 385 390 395 400  
 His Gln Phe Leu Pro Trp Val Asn Val Ile Ala Ala Asp Ala Arg Gly  
 405 410 415  
 Glu Ala Leu Tyr Gly Asp His Ser Val Val Pro Arg Val Thr Gly Ala  
 420 425 430  
 Leu Ala Ala Ala Cys Ile Pro Ala Pro Phe Gln Pro Leu Tyr Ala Ser  
 435 440 445  
 Ser Gly Gln Ala Val Leu Asp Gly Ser Arg Ser Asp Cys Ala Leu Gly  
 450 455 460  
 Ala Asp Pro Asp Ala Ala Val Pro Gly Ile Leu Gly Pro Ala Ser Leu  
 465 470 475 480  
 Pro Val Arg Phe Arg Asp Asp Tyr Val Thr Asn Ser Asn Asp Ser His  
 485 490 495  
 Trp Leu Ala Ser Pro Ala Ala Pro Leu Glu Gly Phe Pro Arg Ile Leu

| 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |     |     |     |  |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Gly | Asn | Glu | Arg | Thr | Pro | Arg | Ser | Leu | Arg | Thr | Arg | Leu | Gly | Leu | Asp |  |
| 515 |     |     |     |     | 520 |     |     |     |     | 525 |     |     |     |     |     |  |
| Gln | Ile | Gln | Gln | Arg | Leu | Ala | Gly | Thr | Asp | Gly | Leu | Pro | Gly | Lys | Gly |  |
| 530 |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |     |  |
| Phe | Thr | Thr | Ala | Arg | Leu | Trp | Gln | Val | Met | Phe | Gly | Asn | Arg | Met | His |  |
| 545 |     |     |     |     | 550 |     |     |     |     | 555 |     |     |     |     | 560 |  |
| Gly | Ala | Glu | Leu | Val | Arg | Asp | Asp | Leu | Val | Ala | Leu | Cys | Arg | Arg | Gln |  |
| 565 |     |     |     |     | 570 |     |     |     |     | 575 |     |     |     |     |     |  |
| Pro | Thr | Ala | Thr | Ala | Ser | Asn | Gly | Ala | Ile | Val | Asp | Leu | Thr | Ala | Ala |  |
| 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |     |     |     |  |
| Cys | Thr | Ala | Leu | Ser | Arg | Phe | Asp | Glu | Arg | Ala | Asp | Leu | Asp | Ser | Arg |  |
| 595 |     |     |     |     | 600 |     |     |     |     | 605 |     |     |     |     |     |  |
| Gly | Ala | His | Leu | Phe | Thr | Glu | Phe | Ala | Leu | Ala | Gly | Gly | Ile | Arg | Phe |  |
| 610 |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |     |     |  |
| Ala | Asp | Thr | Phe | Glu | Val | Thr | Asp | Pro | Val | Arg | Thr | Pro | Arg | Arg | Leu |  |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     |     | 640 |  |
| Asn | Thr | Thr | Asp | Pro | Arg | Val | Arg | Thr | Ala | Leu | Ala | Asp | Ala | Val | Gln |  |
| 645 |     |     |     |     | 650 |     |     |     |     | 655 |     |     |     |     |     |  |
| Arg | Leu | Ala | Gly | Ile | Pro | Leu | Asp | Ala | Lys | Leu | Gly | Asp | Ile | His | Thr |  |
| 660 |     |     |     |     | 665 |     |     |     |     | 670 |     |     |     |     |     |  |
| Asp | Ser | Arg | Gly | Glu | Arg | Arg | Ile | Pro | Ile | His | Gly | Gly | Arg | Gly | Glu |  |
| 675 |     |     |     |     | 680 |     |     |     |     | 685 |     |     |     |     |     |  |
| Ala | Gly | Thr | Phe | Asn | Val | Ile | Thr | Asn | Pro | Leu | Val | Pro | Gly | Val | Gly |  |
| 690 |     |     |     |     | 695 |     |     |     |     | 700 |     |     |     |     |     |  |
| Tyr | Pro | Gln | Val | Val | His | Gly | Thr | Ser | Phe | Val | Met | Ala | Val | Glu | Leu |  |
| 705 |     |     |     |     | 715 |     |     |     |     | 715 |     |     |     |     | 720 |  |
| Gly | Pro | His | Gly | Pro | Ser | Gly | Arg | Gln | Ile | Leu | Thr | Tyr | Ala | Gln | Ser |  |
| 725 |     |     |     |     | 730 |     |     |     |     | 735 |     |     |     |     |     |  |
| Thr | Asn | Pro | Asn | Ser | Pro | Trp | Tyr | Ala | Asp | Gln | Thr | Val | Leu | Tyr | Ser |  |
| 740 |     |     |     |     | 745 |     |     |     |     | 750 |     |     |     |     |     |  |
| Arg | Lys | Gly | Trp | Asp | Thr | Ile | Lys | Tyr | Thr | Glu | Ala | Gln | Ile | Ala | Ala |  |
| 755 |     |     |     |     | 760 |     |     |     |     | 765 |     |     |     |     |     |  |
| Asp | Pro | Asn | Leu | Arg | Val | Tyr | Arg | Val | Ala | Gln | Arg | Gly | Arg |     |     |  |
| 770 |     |     |     |     | 775 |     |     |     |     | 780 |     |     |     |     | 782 |  |

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 782 amino acids

(B) TYPE: amino acid

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

```

Met Arg Leu Lys Ala Ala Ala Ile Ala Phe Gly Val Ile Val Ala Thr
      5              10              15

Ala Thr Val Pro Ser Pro Ala Ser Gly Arg Glu His Asp Gly Gly Tyr
      20              25              30

Ala Ala Leu Ile Arg Arg Ala Ser Tyr Gly Val Pro His Ile Thr Ala
      35              40              45

Asp Asp Phe Gly Ser Leu Gly Phe Gly Val Gly Tyr Val Gln Ala Glu
      50              55              60

Asp Asn Ile Cys Val Ile Ala Glu Ser Val Val Thr Ala Asn Gly Glu
      65              70              75              80

Arg Ser Arg Trp Phe Gly Ala Thr Gly Pro Asp Asp Ala Asp Val Arg
      85              90              95

Ser Asp Leu Phe His Arg Lys Ala Ile Asp Asp Arg Val Ala Glu Arg
      100             105             110

Leu Leu Glu Gly Pro Arg Asp Gly Val Arg Ala Pro Ser Asp Asp Val
      115             120             125

Arg Asp Gln Met Arg Gly Phe Val Ala Gly Tyr Asn His Phe Leu Arg
      130             135             140

Arg Thr Gly Val His Arg Leu Thr Asp Pro Ala Cys Arg Gly Lys Ala
      145             150             155             160

Trp Val Arg Pro Leu Ser Glu Ile Asp Leu Trp Arg Thr Leu Trp Asp
      165             170             175

Ser Met Val Arg Ala Gly Ser Gly Ala Leu Leu Asp Gly Ile Val Ala
      180             185             190

Ala Thr Pro Pro Thr Ala Ala Gly Pro Ala Ser Ala Pro Glu Ala Pro
      195             200             205

Asp Ala Ala Ala Ile Ala Ala Ala Leu Asp Gly Thr Ser Ala Gly Ile
      210             215             220

Gly Ser Asn Ala Tyr Gly Leu Gly Ala Gln Ala Thr Val Asn Gly Ser
      225             230             235             240

Gly Met Val Leu Ala Asn Pro His Phe Pro Trp Gln Gly Ala Ala Arg
      245             250             255

Phe Tyr Arg Met His Leu Lys Val Pro Gly Arg Tyr Asp Val Glu Gly
      260             265             270

```

Ala Ala Leu Val Gly Asp Pro Ile Ile Glu Ile Gly His Asn Arg Thr  
 275 280 285  
 Val Ala Trp Ser His Thr Val Ser Thr Ala Arg Arg Phe Val Trp His  
 290 295 300  
 Arg Leu Ser Leu Val Pro Gly Asp Pro Thr Ser Tyr Tyr Val Asp Gly  
 305 310 315 320  
 Arg Pro Glu Arg Met Arg Ala Arg Thr Val Thr Val Gln Thr Gly Ser  
 325 330 335  
 Gly Pro Val Ser Arg Thr Phe His Asp Thr Arg Tyr Gly Pro Val Ala  
 340 345 350  
 Val Val Pro Gly Thr Phe Asp Trp Thr Pro Ala Thr Ala Tyr Ala Ile  
 355 360 365  
 Thr Asp Val Asn Ala Gly Asn Asn Arg Ala Phe Asp Gly Trp Leu Arg  
 370 375 380  
 Met Gly Gln Ala Lys Asp Val Arg Ala Leu Lys Ala Val Leu Asp Arg  
 385 390 395 400  
 His Gln Phe Leu Pro Trp Val Asn Val Ile Ala Ala Asp Ala Arg Gly  
 405 410 415  
 Glu Ala Leu Tyr Gly Asp His Ser Val Val Pro Arg Val Thr Gly Ala  
 420 425 430  
 Leu Ala Ala Ala Cys Ile Pro Ala Pro Phe Gln Pro Leu Tyr Ala Ser  
 435 440 445  
 Ser Gly Gln Ala Val Leu Asp Gly Ser Arg Ser Asp Cys Ala Leu Gly  
 450 455 460  
 Ala Asp Pro Asp Ala Ala Val Pro Gly Ile Leu Gly Pro Ala Ser Leu  
 465 470 475 480  
 Pro Val Arg Phe Arg Asp Asp Tyr Val Thr Asn Ser Asn Asp Ser His  
 485 490 495  
 Trp Leu Ala Ser Pro Ala Ala Pro Leu Glu Gly Phe Pro Arg Ile Leu  
 500 505 510  
 Gly Asn Glu Arg Thr Pro Arg Ser Leu Arg Thr Arg Leu Gly Leu Asp  
 515 520 525  
 Gln Ile Gln Gln Arg Leu Ala Gly Thr Asp Gly Leu Pro Gly Lys Gly  
 530 535 540  
 Phe Thr Thr Ala Arg Leu Trp Gln Val Met Phe Gly Asn Arg Met His  
 545 550 555 560  
 Gly Ala Glu Leu Val Arg Asp Asp Leu Val Ala Leu Cys Arg Arg Gln  
 565 570 575  
 Pro Thr Ala Thr Ala Ser Asn Gly Ala Ile Val Asp Leu Thr Ala Ala

| 580 |     |     |     |     |     | 585 |     |     |     |     |     | 590 |     |     |     |  |  |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|
| Cys | Thr | Ala | Leu | Ser | Arg | Phe | Asp | Glu | Arg | Ala | Asp | Leu | Asp | Ser | Arg |  |  |
|     |     | 595 |     |     |     |     | 600 |     |     |     |     | 605 |     |     |     |  |  |
| Gly | Ala | His | Leu | Phe | Thr | Glu | Phe | Ala | Leu | Ala | Gly | Gly | Ile | Arg | Phe |  |  |
|     | 610 |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |     |  |  |
| Ala | Asp | Thr | Phe | Glu | Val | Thr | Asp | Pro | Val | Arg | Thr | Pro | Arg | Arg | Leu |  |  |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     |     | 640 |  |  |
| Asn | Thr | Thr | Asp | Pro | Arg | Val | Arg | Thr | Ala | Leu | Ala | Asp | Ala | Val | Gln |  |  |
|     |     |     |     | 645 |     |     |     |     | 650 |     |     |     |     | 655 |     |  |  |
| Arg | Leu | Ala | Gly | Ile | Pro | Leu | Asp | Ala | Lys | Leu | Gly | Asp | Ile | His | Thr |  |  |
|     |     |     | 660 |     |     |     | 665 |     |     |     |     |     | 670 |     |     |  |  |
| Asp | Ser | Arg | Gly | Glu | Arg | Arg | Ile | Pro | Ile | His | Gly | Gly | Arg | Gly | Glu |  |  |
|     |     | 675 |     |     |     |     | 680 |     |     |     |     |     | 685 |     |     |  |  |
| Ala | Gly | Thr | Phe | Asn | Val | Ile | Thr | Asn | Pro | Leu | Val | Pro | Gly | Val | Gly |  |  |
|     | 690 |     |     |     |     |     | 695 |     |     |     |     |     | 700 |     |     |  |  |
| Tyr | Pro | Gln | Val | Val | His | Gly | Thr | Ser | Phe | Val | Met | Ala | Val | Glu | Leu |  |  |
| 705 |     |     |     |     | 715 |     |     |     |     | 715 |     |     |     |     | 720 |  |  |
| Gly | Pro | His | Gly | Pro | Ser | Gly | Arg | Gln | Ile | Leu | Thr | Tyr | Ala | Gln | Ser |  |  |
|     |     |     |     | 725 |     |     |     |     | 730 |     |     |     |     | 735 |     |  |  |
| Thr | Asn | Pro | Asn | Ser | Pro | Trp | Tyr | Ala | Asp | Gln | Thr | Val | Leu | Tyr | Ser |  |  |
|     |     |     | 740 |     |     |     |     | 745 |     |     |     |     | 750 |     |     |  |  |
| Arg | Lys | Gly | Trp | Asp | Thr | Ile | Lys | Tyr | Thr | Glu | Ala | Gln | Ile | Ala | Ala |  |  |
|     |     | 755 |     |     |     |     | 760 |     |     |     |     |     | 765 |     |     |  |  |
| Asp | Pro | Asn | Leu | Arg | Val | Tyr | Arg | Val | Ala | Gln | Arg | Gly | Arg |     |     |  |  |
|     | 770 |     |     |     |     |     | 775 |     |     |     |     |     | 780 |     | 782 |  |  |

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 782 amino acids  
(B) TYPE: amino acid  
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

Met Arg Leu Lys Ala Ala Ala Ile Ala Phe Gly Val Ile Val Ala Thr  
5 10 15

Ala Ala Val Pro Ser Pro Ala Ser Gly Arg Glu His Asp Gly Gly Tyr  
20 25 30

Ala Ala Leu Ile Arg Arg Ala Ser Tyr Gly Val Pro His Ile Thr Ala



| 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Asp | Phe | Gly | Ser | Leu | Gly | Phe | Gly | Val | Gly | Tyr | Val | Gln | Ala | Glu |
| 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |     |
| Asp | Asn | Ile | Cys | Val | Ile | Ala | Glu | Ser | Val | Val | Thr | Ala | Asn | Gly | Glu |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Arg | Ser | Arg | Trp | Phe | Gly | Ala | Thr | Gly | Pro | Asp | Asp | Ala | Asp | Val | Arg |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Ser | Asp | Leu | Phe | His | Arg | Lys | Ala | Ile | Asp | Asp | Arg | Val | Ala | Glu | Arg |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Leu | Leu | Glu | Gly | Pro | Arg | Asp | Gly | Val | Arg | Ala | Pro | Ser | Asp | Asp | Val |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Arg | Asp | Gln | Met | Arg | Gly | Phe | Val | Ala | Gly | Tyr | Asn | His | Phe | Leu | Arg |
|     |     | 130 |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Arg | Thr | Gly | Val | His | Arg | Leu | Thr | Asp | Pro | Ala | Cys | Arg | Gly | Lys | Ala |
| 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |
| Trp | Val | Arg | Pro | Leu | Ser | Glu | Ile | Asp | Leu | Trp | Arg | Thr | Ser | Trp | Asp |
|     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |
| Ser | Met | Val | Arg | Ala | Gly | Ser | Gly | Ala | Leu | Leu | Asp | Gly | Ile | Val | Ala |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Ala | Thr | Pro | Pro | Thr | Ala | Ala | Gly | Pro | Ala | Ser | Ala | Pro | Glu | Ala | Pro |
|     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |
| Asp | Ala | Ala | Ala | Ile | Ala | Ala | Ala | Leu | Asp | Gly | Thr | Ser | Ala | Gly | Ile |
|     |     | 210 |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Gly | Ser | Asn | Ala | Tyr | Gly | Leu | Gly | Ala | Gln | Ala | Thr | Val | Asn | Gly | Ser |
| 225 |     |     |     |     | 230 |     |     |     | 235 |     |     |     |     | 240 |     |
| Gly | Met | Val | Leu | Ala | Asn | Pro | His | Phe | Pro | Trp | Gln | Gly | Ala | Glu | Arg |
|     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |
| Phe | Tyr | Arg | Met | His | Leu | Lys | Val | Pro | Gly | Arg | Tyr | Asp | Val | Glu | Gly |
|     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |     |
| Ala | Ala | Leu | Ile | Gly | Asp | Pro | Ile | Ile | Gly | Ile | Gly | His | Asn | Arg | Thr |
|     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |
| Val | Ala | Trp | Ser | His | Thr | Val | Ser | Thr | Ala | Arg | Arg | Phe | Val | Trp | His |
|     |     | 290 |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |
| Arg | Leu | Ser | Leu | Val | Pro | Gly | Asp | Pro | Thr | Ser | Tyr | Tyr | Val | Asp | Gly |
| 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |     |     | 320 |     |
| Arg | Pro | Glu | Arg | Met | Arg | Ala | Arg | Thr | Val | Thr | Val | Gln | Thr | Gly | Ser |
|     |     |     |     | 325 |     |     |     |     | 330 |     |     |     |     | 335 |     |
| Gly | Pro | Val | Ser | Arg | Thr | Phe | His | Asp | Thr | Arg | Tyr | Gly | Pro | Val | Ala |
|     |     |     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |     |

Val Met Pro Gly Thr Phe Asp Trp Thr Pro Ala Thr Ala Tyr Ala Ile  
 355 360 365  
 Thr Asp Val Asn Ala Gly Asn Asn Arg Ala Phe Asp Gly Trp Leu Arg  
 370 375 380  
 Met Gly Gln Ala Lys Asp Val Arg Ala Leu Lys Ala Val Leu Asp Arg  
 385 390 395 400  
 His Gln Phe Leu Pro Trp Val Asn Val Ile Ala Ala Asp Ala Arg Gly  
 405 410 415  
 Glu Ala Leu Tyr Gly Asp His Ser Val Val Pro Arg Val Thr Gly Ala  
 420 425 430  
 Leu Ala Ala Ala Cys Ile Pro Ala Pro Phe Gln Pro Leu Tyr Ala Ser  
 435 440 445  
 Ser Gly Gln Ala Val Leu Asp Gly Ser Arg Ser Asp Cys Ala Leu Gly  
 450 455 460  
 Ala Asp Pro Asp Ala Ala Val Pro Gly Ile Leu Gly Pro Ala Ser Leu  
 465 470 475 480  
 Pro Val Arg Phe Arg Asp Asp Tyr Val Thr Asn Ser Asn Asp Ser His  
 485 490 495  
 Trp Leu Ala Ser Pro Ala Ala Pro Leu Glu Gly Phe Pro Arg Ile Leu  
 500 505 510  
 Gly Asn Glu Arg Thr Pro Arg Ser Leu Arg Thr Arg Leu Gly Leu Asp  
 515 520 525  
 Gln Ile Gln Gln Arg Leu Ala Gly Thr Asp Gly Leu Pro Gly Lys Gly  
 530 535 540  
 Phe Thr Thr Ala Arg Leu Trp Gln Val Met Phe Gly Asn Arg Met His  
 545 550 555 560  
 Gly Ala Glu Leu Ala Arg Asp Asp Leu Val Ala Leu Cys Arg Arg Gln  
 565 570 575  
 Pro Thr Ala Thr Ala Ser Asn Gly Ala Ile Val Asp Leu Thr Ala Ala  
 580 585 590  
 Cys Thr Ala Leu Ser Arg Phe Asp Glu Arg Ala Asp Leu Asp Ser Arg  
 595 600 605  
 Gly Ala His Leu Phe Thr Glu Phe Ala Leu Ala Gly Gly Ile Arg Phe  
 610 615 620  
 Ala Asp Thr Phe Glu Val Thr Asp Pro Val Arg Thr Pro Arg Arg Leu  
 625 630 635 640  
 Asn Thr Thr Asp Pro Arg Val Arg Thr Ala Leu Ala Asp Ala Val Gln  
 645 650 655

Arg Leu Ala Gly Ile Pro Leu Asp Ala Lys Leu Gly Asp Ile His Thr  
660 665 670

Asp Ser Arg Gly Glu Arg Arg Ile Pro Ile His Gly Gly Arg Gly Glu  
675 680 685

Ala Gly Thr Phe Asn Val Ile Thr Asn Pro Leu Val Pro Gly Val Gly  
690 695 700

Tyr Pro Gln Val Val His Gly Thr Ser Phe Val Met Ala Val Glu Leu  
705 715 715 720

Gly Pro His Gly Pro Ser Gly Arg Gln Ile Leu Thr Tyr Ala Gln Ser  
725 730 735

Thr Asn Pro Asn Ser Pro Trp Tyr Ala Asp Gln Thr Val Leu Tyr Ser  
740 745 750

Arg Lys Gly Trp Asp Thr Ile Lys Tyr Thr Glu Ala Gln Ile Ala Ala  
755 760 765

Asp Pro Asn Leu Arg Val Tyr Arg Val Ala Gln Arg Gly Arg  
770 775 780 782

CLAIMSWhat is claimed is:

1. A gene which encodes an enzyme having ECB deacylase activity, said gene comprising a nucleotide sequence which is selected from the group consisting of SEQ. ID. NOS: 26, 27, 28, 29 and 30.

2. An enzyme which exhibits ECB deacylase activity, said enzyme having an amino acid sequence which is selected from the group consisting of SEQ. ID. NOS: 32, 33, 34, 35 and 36.


3. An enzyme which exhibits ECB deacylase activity, said enzyme being made by the method comprising the steps of:

- 5 a) inserting into a vector a double-stranded mutagenized polynucleotide having the SEQ. ID. NOS: 26, 27, 28, 29 or 30 to form an expression vector, said mutagenized polynucleotide encoding an enzyme;
- b) transforming a host cell with said expression vector; and
- c) expressing the enzyme encoded by said mutagenized polynucleotide.

4. A method for producing an enzyme comprising the steps of:

- 5 a) inserting into a vector a double-stranded mutagenized polynucleotide having the SEQ. ID. NOS: 26, 27, 28, 29 or 30 to form an expression vector, said mutagenized polynucleotide encoding an enzyme;
- b) transforming a host cell with said expression vector; and
- c) expressing the enzyme encoded by said mutagenized polynucleotide.

1/14






FIG. 2




FIG. 3






FIG. 4





FIG. 5

6/14



forward primers: P50F: 5'-GGCGGAGCTAGCTTCGTA-3' (SEQ. ID. NO: 21)  
 (mutagenic primer, underlined base is the mutagenized base at position 598)  
 P200F: 5'-GATGTGATGGCTCCTGGC-3' (SEQ. ID. NO: 22)

reverse primers: P80R: 5'-CAGAACACCGATTGAGTT-3' (SEQ. ID. NO: 23)  
 P250R: AGTGCTTTCTAACGATC-3' (SEQ. ID. NO: 24)

FIG. 6

7/14




FIG. 7

8/14




FIG. 8




FIG. 9




FIG. 10






FIG. 11







FIG.12

13/14



14/14




FIG. 13d




FIG. 13e

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/05814

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 21/04; C12N 9/18, 15/31, 15/55

US CL : 435/69.1, 320.1; 530/350; 536/23.2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 172.3, 196, 320.1; 530/350; 536/23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|-----------|--|-----------------------|
| A         | US 5,573,936 A (A. J. KREUZMAN et al.) 12 November 1996.   | 1-4                   |
| A         | BOECK et al. Deacylation of Echinocandin B by Actinoplanes Utahensis. The Journal of Antibiotics. March 1989, Vol. XLII, No. 3, pages 382-388. See entire document.  | 1-4                   |
| A         | DEBONO et al. Synthesis of New Analogs of Echinocandin B by Enzymatic Deacylation and Chemical Reacylation of the Echinocandin B Peptide: Synthesis of the Antifungal Agent Cilofungin (LY121019). The Journal of Antibiotics. March 1989, Vol. XLII, No. 3, pages 389-397. See entire document. | 1-4                   |

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

|   |     |  |
|---|-----|--|
| * Special categories of cited documents:  | *T* | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| *A* document defining the general state of the art which is not considered to be of particular relevance  | *X* | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| *B* earlier document published on or after the international filing date  | *Y* | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *A* | document member of the same patent family  |
| *O* document referring to an oral disclosure, use, exhibition or other means  |     |  |
| *P* document published prior to the international filing date but later than the priority date claimed  |     |  |

Date of the actual completion of the international search

14 MAY 1998

Date of mailing of the international search report

30 JUL 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

THOMAS G. LARSON, PH.D.

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/05814

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN (Agricola, Biosis, CAPlus, INPADOC, LifeSci, Medline, WPIDS)

Search Terms: ECB, echinocandin, deacylase, Actinoplanes, utahensis.

The computer readable format (CRF) of the sequence listing was found to be defective and could not be processed.

Therefore, a sequence search for SEQ. ID. NOS. 26-30 could not be performed